

Tetrahydroisoquinoline Heterobifunctional BCL-X_L

Degraders

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims priority to U.S. Provisional Application Serial Nos. 63/547,657, filed November 7, 2023; and 63/641,269, filed May 1, 2024; each of which is incorporated by reference in its entirety herein.

TECHNICAL FIELD

10 This disclosure provides compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, that induce degradation of a BCL-X_L protein. These compounds are useful, for example, for treating cancer in a subject (e.g., a human). This disclosure also provides compositions comprising the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.

15

BACKGROUND

20 The BCL-2 family of proteins is involved in the regulation of cell apoptosis and includes proteins that are pro-apoptosis, pro-survival, and BH3-only. At a high level, the balance of binding of BH3-only proteins to the pro-apoptosis and pro-survival members of the BCL-2 family can determine whether a cell will undergo apoptosis. The protein BCL-X_L, encoded by the *BCL2L1* gene, is a pro-survival member of the BCL-2 family. In many cancers, it can be desirable to initiate apoptosis of tumor cells, which may be achieved by decreasing the amount of pro-survival protein (e.g., BCL-X_L) available to compete for BH3-only protein binding.


25

SUMMARY

This disclosure provides compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, that induce degradation of a BCL-X_L protein. These compounds are useful, e.g., for treating a cancer in a subject (e.g., a human). This disclosure also provides compositions comprising the compounds of Formula

(I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.

Provided herein are compounds of Formula (I):



Formula (I)

or pharmaceutically acceptable salts thereof, wherein:

5 **R¹, R², m2, R³, m3, R⁴, m4, R⁵, m5, R⁶, m6, Ring A, L², L¹, Ring C, L^C, and X** are
each as defined herein.

Also provided herein is a pharmaceutical composition comprising a compound of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Provided herein is a method for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein.

Also provided herein is a BCL-X_L protein non-covalently bound with a compound of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof.

Also provided herein is a ternary complex comprising a BCL-X_L protein, a compound of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, and a CRBN protein, or a portion thereof.

To facilitate understanding of the disclosure set forth herein, a number of additional terms are provided. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms

used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Each of the patents, applications, published applications, and other publications that are mentioned throughout the specification and the attached appendices are incorporated herein by reference in their entireties. In the case of
5 conflict between the present disclosure and any content incorporated by reference, the present disclosure controls.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features and advantages of the invention will be apparent from the description and drawings, and from the claims.

10

DETAILED DESCRIPTION

This disclosure provides compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, that induce degradation of a BCL-X_L (also referred to as Bcl-xL herein) protein. These compounds are useful, e.g., for treating a cancer. This disclosure also provides compositions comprising the compounds of
15 Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.

Without being bound by any particular theory, it is believed that in healthy cells, pro-apoptotic effectors such as BAX and BAK can move between the cytosol and the mitochondrial outer membrane (MOM), on which Voltage Dependent Anion Channel 2 (VDAC2) can act as
20 a receptor. Pro-survival BCL-2 family members (e.g., BCL-2, BCL-X_L, and Mcl-1) can retrotranslocate BAX back to the cytosol. A BH3-only protein (e.g., BIM) can engage a rear site on a pro-apoptotic effector (e.g., BAX or BAK) and release the C-terminal transmembrane domain (α 9) of the effector, enabling binding to the MOM. Binding of BIM to the canonical BH3 binding groove of BAX or BAK releases the N-terminus and α 1 of BAX or BAK, and
25 subsequent unfolding of the “latch” domain releases BIM from the BH3 binding groove. If a pro-survival BCL-2 family member then binds to BAX or BAK, apoptotic signaling is generally halted. However, if BAX or BAK are allowed to dimerize, then oligomerize, the MOM can be permeabilized, leading to apoptosis.

An abundance of pro-survival BCL-2 family members is sometimes thought to “prime”
30 cells for death (e.g., via cytotoxic therapies, including BH3 mimetics). It is believed that oncogenic mutations and stresses can cause an upregulation in BH3-only proteins, thus placing a selective pressure on cancer cells for upregulation of the pro-survival BCL-2 family proteins. Thus, with more BH3-only proteins around, the cells are believed to be more sensitive to further

manipulations of the BCL-2 family balance. See, e.g., Adams and Cory, *Cell Death & Differentiation* 25.1 (2018): 27-36, doi: 10.1038/cdd.2017.161.

Compounds that induce degradation of a target protein are sometimes referred to as heterobifunctional compounds, PROTACs, or degraders. Such compounds generally include a moiety that binds to the target protein and a moiety that binds to a ubiquitin E3 ligase (sometimes referred to as an E3 ligase or simply an E3), these two moieties being optionally separated by a linker. To induce degradation, heterobifunctional compounds are believed to induce formation of a ternary complex between the target protein, the compound, and an E3 ligase. Formation of the ternary complex is then followed by ubiquitination of the target protein and degradation of the ubiquitinated target protein by a proteasome. Several E3 ligases have been used as the partner E3 ligase for heterobifunctional degraders. Herein, the cereblon (CRBN) E3 ligase (also referred to herein as a CRBN protein) is used.


A degradation approach for a target protein can have potential advantages compared to, e.g., small molecule inhibition of the target protein. One potential advantage is that the duration of effect of a heterobifunctional compound is generally based on the resynthesis rate of the target protein. Another potential advantage is that many heterobifunctional compounds are believed to be released from the ubiquitinated target protein-E3 ligase complex and made available for formation of further ternary complexes; this is sometimes referred to as “catalytic” turnover of the heterobifunctional compound. Degradation of a target protein can also be advantageous over small molecule inhibition in some cases, as degradation can impair a scaffolding function of a target protein, whereas a small molecule might not. It is also generally believed that for formation of a ternary complex, high affinity to the target protein is not always required.

Heterobifunctional compounds are further described in, for example, International Publication Nos. WO 2017/184995; WO 2019/144117; WO 2020/163823; WO 2021/078301; WO 2021/146536; WO 2021/007307; WO 2021/222114; WO 2022/169780; WO 2023/044046; WO 2023/185986; WO 2024/027706; WO 2024/179577; WO 2024/169976; WO 2024/078581; WO 2024/077023; WO 2024/067818; WO 2024/051741; WO 2024/012449; WO 2024/012557; Chamberlain and Hamann, *Nature Chemical Biology* 15.10 (2019): 937-944, doi: 10.1038/s41589-019-0362-y; Li and Song, *Journal of Hematology & Oncology* 13 (2020): 1-14, doi: 10.1186/s13045-020-00885-3; Wu, et al. *Nature Structural & Molecular Biology* 27.7 (2020): 605-614, doi: 10.1038/s41594-020-0438-0; Dong, et al., *Journal of Medicinal Chemistry* 64.15 (2021): 10606-10620, doi:

10.1021/acs.jmedchem.1c00895; Yang, et al., *Targeted Oncology* 16.1 (2021): 1-12, doi:
 10.1007/s11523-020-00782-2; Lv, et al., *Nature Communications* 12.1 (2021): 6896, doi:
 10.1038/s41467-021-27210-x.

5 Compound Embodiments

Provided herein are compounds of Formula (I):



Formula (I)

or pharmaceutically acceptable salts thereof, wherein:

R¹ is selected from the group consisting of:

- (a) C(O)OH,
- (b) C(O)NR^dR^e, and
- (c) C(O)OC₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 **R^c**;

each **R²**, **R³**, **R⁴**, and **R⁵** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, OH, and NR^dR^e;

m₂ is 0, 1, or 2;

m₃ and **m₄** are independently 0, 1, 2, or 3;

m₅ is 0, 1, 2, 3, or 4;

each **R⁶** is independently selected from the group consisting of: **R^a**, -(C₀₋₃ alkylene)-C₃₋₆ cycloalkyl, and -(C₀₋₃ alkylene)-(4-6 membered heterocyclyl);

m₆ is 0, 1, 2, 3, or 4;

L¹ is -(L^A)_{n1}-, wherein **n1** is an integer from 2 to 12, and each **L^A** is selected from the group consisting of **L^{A1}**, **L^{A3}**, and **L^{A4}**, wherein 1-3 occurrence of **L^A** is **L^{A4}**;

L^2 is $-(L^B)_{n2}-$, wherein $n2$ is an integer from 1 to 5, and each L^B is selected from the group consisting of L^{B1} and L^{B3} ;

each L^{A1} and L^{B1} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;

each L^{A3} and L^{B3} is independently selected from the group consisting of: $-N(R^d)-$, $-N(R^b)-$, $-O-$, $-S(O)_{0-2}-$, and $C(=O)-$;


each L^{A4} is independently selected from the group consisting of:

(a) C_{3-15} cycloalkylene or 3-15 membered heterocyclylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ; and

(b) C_{6-15} arylene or 5-15 membered heteroarylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ;

wherein each R^L is independently selected from the group consisting of: halo, cyano, $-OH$, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NR^dR^e$, $C(=O)N(R^f)_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), $S(O)_{0-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(R^f)_2$, $-R^b$, and C_{1-6} alkyl optionally substituted with 1-6 R^c ;

20



$c1$ is 0, 1, 2, or 3;

each R^Y is independently selected from the group consisting of: R^a and R^b ;

R^{aN} is H or C_{1-6} alkyl optionally substituted with 1-3 R^c ;

Y^1 and Y^2 are independently N, CH, or CR^Y ;

yy represents the point of attachment to L^1 ;

L^c is selected from the group consisting of: a bond, $-CH_2-$, $-CHR^a-$, $-C(R^a)_2-$, $-N(R^d)-$, and O;

each R^a is independently selected from the group consisting of:

- (a) halo;
- 5 (b) cyano;
- (c) $-OH$;
- (d) oxo;
- (e) $-C_{1-6}$ alkoxy;
- (f) $-C_{1-6}$ haloalkoxy;
- 10 (g) $-NR^dR^e$;
- (h) $C(=O)C_{1-6}$ alkyl;
- (i) $C(=O)C_{1-6}$ haloalkyl;
- (j) $C(=O)OH$;
- (k) $C(=O)OC_{1-6}$ alkyl;
- 15 (l) $C(=O)OC_{1-6}$ haloalkyl;
- (m) $C(=O)N(R^f)_2$;
- (n) $S(O)_{0-2}(C_{1-6}$ alkyl);
- (o) $S(O)_{0-2}(C_{1-6}$ haloalkyl);
- (p) $S(O)_{1-2}N(R^f)_2$; and
- 20 (q) C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, each optionally substituted with 1-6 R^e ;

each R^b is independently selected from the group consisting of: $-(L^b)_b-R^{b1}$ and $-R^{b1}$, wherein:

each b is independently 1, 2, or 3;

25 each $-L^b$ is independently selected from the group consisting of: $-O-$, $-N(H)-$, $-N(C_{1-3}$ alkyl)-, $-S(O)_{0-2}-$, $C(=O)$, and C_{1-3} alkylene; and

each R^{b1} is independently selected from the group consisting of: C_{3-10} cycloalkyl, 4-10 membered heterocyclyl, C_{6-10} aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 R^g ;

30

each R^e is independently selected from the group consisting of: halo, cyano, $-OH$, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NR^dR^e$, $C(=O)C_{1-6}$ alkyl, $C(=O)C_{1-6}$ haloalkyl, $C(=O)OC_{1-6}$ alkyl,

C(=O)OC₁₋₆ haloalkyl, C(=O)OH, C(=O)N(**R^f**)₂, S(O)₀₋₂(C₁₋₆ alkyl), S(O)₀₋₂(C₁₋₆ haloalkyl), and S(O)₁₋₂N(**R^f**)₂;

5 each **R^d** and **R^e** is independently selected from the group consisting of: H, C(=O)C₁₋₆ alkyl, C(=O)C₁₋₆ haloalkyl, C(=O)OC₁₋₆ alkyl, C(=O)OC₁₋₆ haloalkyl, C(=O)N(**R^f**)₂, S(O)₁₋₂(C₁₋₆ alkyl), S(O)₁₋₂(C₁₋₆ haloalkyl), S(O)₁₋₂N(**R^f**)₂, and C₁₋₆ alkyl optionally substituted with 1-3 **R^h**;

each **R^f** is independently selected from the group consisting of: H and C₁₋₆ alkyl optionally substituted with 1-3 **R^h**;

10 each **R^g** is independently selected from the group consisting of: **R^h**, C₁₋₃ alkyl, and C₁₋₃ haloalkyl; and

each **R^h** is independently selected from the group consisting of: halo, cyano, -OH, -C₁₋₆ alkoxy, -C₁₋₆ haloalkoxy, -NH₂, -N(H)(C₁₋₃ alkyl), and -N(C₁₋₃ alkyl)₂;

15 provided that the compound does not contain any N-O, N-N, N-S(O)₀, or O-S(O)₀₋₂ bonds.

In some embodiments, **R¹** is C(O)OH.

In some embodiments, **R¹** is C(O)NHR^e.

20 In some embodiments, **m2** is 0.


In some embodiments, **m3** is 0.

In some embodiments, **m4** is 0.

In some embodiments, **m5** is 0.


25 In some embodiments, 3-4 of **m2**, **m3**, **m4**, and **m5** are 0. In some embodiments, **m2**, **m3**, **m4**, and **m5** are 0.

In some embodiments, **R¹** is C(O)OH or C(O)NHR^e; and 3-4 of **m2**, **m3**, **m4**, and **m5** are 0. In some embodiments, **R¹** is C(O)OH; and 3-4 of **m2**, **m3**, **m4**, and **m5** are 0.




In some embodiments, **Ring C** is


. In some embodiments, **Ring C** is



. In some embodiments, **Ring C** is



. In some




embodiments, **Ring C** is

. In some embodiments, **R^{aN}** is C₁₋₃ alkyl. For example,


R^{aN} can be methyl. In some embodiments, **c1** is 0. In some embodiments, **c1** is 1; and **R^Y** is -

5 F.




In some embodiments, **Ring C** is

, or



. In some




embodiments, **Ring C** is

. In some embodiments, **c1** is 1; and **R^Y** is -F.



In some embodiments, **R^{aN}** is C₁₋₃ alkyl. For example, **R^{aN}** can be methyl.

10 In some embodiments, **L^C** is a bond.



In some embodiments, the

moiety is



5

In some embodiments, $n1 + n2$ is 4 to 12.

In some embodiments, $n1 + n2$ is 5 to 10.

In some embodiments, $n2$ is an integer from 2 to 5. In some embodiments, $n2$ is an integer from 2 to 4.

10

In some embodiments, L^2 is $-(L^{B1})_{1-3}-L^{B3}-aa$, wherein aa represents the point of attachment to **Ring A**. In some embodiments, each L^{B1} is CH_2 .

In some embodiments, L^2 is $-(L^{B1})_{1-3}-O-aa$, wherein aa represents the point of attachment to **Ring A**. In some embodiments, each L^{B1} is CH_2 .

15

In some embodiments, L^2 is $-CH_2-O-aa$ or $-CH_2CH_2CH_2O-aa$, wherein aa represents the point of attachment to **Ring A**.

In some embodiments, $m6$ is 0.

In some embodiments, $m6$ is 1.

20

In some embodiments, L^1 is *para* to L^2 . For avoidance of doubt, when L^1 is *para* to L^2 , the **Ring A** ring carbon to which L^1 is attached is in a *para* relationship to the **Ring A** ring carbon to which L^2 is attached.

In some embodiments, L^1 is *meta* to L^2 . For avoidance of doubt, when L^1 is *meta* to L^2 , the **Ring A** ring carbon to which L^1 is attached is in a *meta* relationship to the **Ring A** ring carbon to which L^2 is attached.

5 In some embodiments, **n1** is an integer from 3 to 10.

In some embodiments, **n1** is an integer from 4 to 7.

In some embodiments, L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-(L^{A3})_{1-2}-bb$, wherein *bb* represents the point of attachment to **Ring C**.

10 In some embodiments, L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)NH-bb$, wherein *bb* represents the point of attachment to **Ring C**.


In some embodiments, L^{A4} is C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

In some embodiments, L^{A4} is a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, L^{A4} is a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, L^{A4} is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

20 In some embodiments, each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

In some embodiments, each L^{A1} is CH_2 .

In some embodiments, L^1 is selected from the group consisting of:



25 attachment to **Ring C**. , wherein *bb* represents the point of

In some embodiments, L^1 is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-L^{A3}-L^{A4}-bb$;

$-(L^{A1})_{0-2}-L^{A4}-L^{A3}-(L^{A1})_{0-2}-L^{A4}-bb$; and

30 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-3}-L^{A4}-bb$;

wherein *bb* represents the point of attachment to **Ring C**.

In some embodiments, L^1 is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-L^{A3}-L^{A4}-bb$; and

$-(L^{A1})_{0-2}-L^{A4}-L^{A3}-(L^{A1})_{0-2}-L^{A4}-bb$,

wherein bb represents the point of attachment to **Ring C**.

In some embodiments, L^1 is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$; and

$-(L^{A1})_{0-2}-L^{A4}-C(=O)-(L^{A1})_{0-2}-L^{A4}-bb$,

wherein bb represents the point of attachment to **Ring C**.

In some embodiments, L^1 is:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-3}-L^{A4}-bb$;

wherein bb represents the point of attachment to **Ring C**.


In some embodiments, each L^{A4} is independently C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

In some embodiments, each L^{A4} is independently a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, each L^{A4} is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, each L^{A4} is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, each L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.


In some embodiments, each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

In some embodiments, each L^{A1} is CH_2 .

In some embodiments, L^1 is selected from the group consisting of:




and



, wherein bb represents the


point of attachment to **Ring C**.

In some embodiments, L^1 is selected from the group consisting of:



5 wherein *bb* represents the point of attachment to **Ring C**. In some embodiments, each L^{A4} is independently a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, each L^{A4} is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, each L^{A4} is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, each L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms. In some embodiments, each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F. In some embodiments, each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

In some embodiments, the compounds of Formula (I) are compounds of Formula (I-a):



Formula (I-a)

20 or pharmaceutically acceptable salts thereof, wherein:

$m6$ is 0, 1, or 2;

each R^6 is independently selected from the group consisting of: halo, CN, C_{1-3} alkoxy, C_{1-3} haloalkoxy, and C_{1-3} alkyl optionally substituted with 1-3 F;

25 L^2 is $-(L^{B1})_{1-3}-O-aa$, wherein *aa* represents the point of attachment to **Ring A**;

L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)NH-bb$, wherein *bb* represents the point of attachment to **Ring C**; and


L^{A4} is C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

In some embodiments of Formula (I-a), L^{A4} is a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments of Formula (I-a), L^{A4} is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments, L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

In some embodiments of Formula (I-a), each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

In some embodiments of Formula (I-a), each L^{A1} is CH_2 .

In some embodiments, the compounds of Formula (I) are compounds of Formula (I-b):



Formula (I-b)

or pharmaceutically acceptable salts thereof, wherein:

$m6$ is 0, 1, or 2;

each R^6 is independently selected from the group consisting of: halo, CN, C_{1-3} alkoxy, C_{1-3} haloalkoxy, and C_{1-3} alkyl optionally substituted with 1-3 F;

L^2 is $-(L^{B1})_{1-3}-O-aa$, wherein aa represents the point of attachment to **Ring A**;

L^{A1} is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$; and

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-3}-L^{A4}-bb$ wherein bb represents the point of attachment to **Ring C**;

and

each L^{A4} is independently C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

In some embodiments of Formula (I-b), L^2 is $-(L^{B1})_{1-3}-O-aa$, wherein aa represents the point of attachment to **Ring A**;

L^{A1} is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$; and

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-2}-L^{A4}-bb$ wherein bb represents the point of attachment to **Ring C**;

and

each L^{A4} is independently C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

In some embodiments of Formula (I-b), L^2 is $-(L^{B1})_{1-3}-O-aa$, wherein aa represents the point of attachment to **Ring A**;

L^{A1} is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$, wherein bb represents the point of attachment to **Ring C**; and



each L^{A4} is independently C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

In some embodiments of Formula (I-b), each L^{A4} is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a . In some embodiments of Formula (I-b), each L^{A4} is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

In some embodiments of Formula (I-b), each L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

In some embodiments of Formula (I-b), each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

In some embodiments of Formula (I-b), each L^{A1} is CH_2 .




5

In some embodiments of Formula (I-a) or (I-b), m_6 is 0.


In some embodiments of Formula (I-a) or (I-b), each L^{B1} is CH_2 .

In some embodiments, the compounds of Formula (I) are compounds of Formula (I-b1), (I-b2), (I-b3), or (I-b4):

10




Formula (I-b1)




Formula (I-b2)

15




Formula (I-b3)



Formula (I-b4)

5

or pharmaceutically acceptable salts thereof, wherein:



Ring C is selected from the group consisting of:

, wherein:

c1 is 0, 1, or 2;

10 each **R^Y** is independently -F, C₁₋₃ alkoxy, or C₁₋₃ alkyl optionally substituted with 1-3 F; and

R^{aN} is C₁₋₃ alkyl optionally substituted with 1-3 F;

15 **L^{A4a}** and **L^{A4b}** are independently selected 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 substituents each independently selected from the group consisting of: -F, CN, C₁₋₃ alkoxy, OH, and C₁₋₃ alkyl optionally substituted with 1-3 F;

20 each **L^{A1a}**, **L^{A1b}**, and **L^{A1c}** is independently selected from the group consisting of: -CH₂-, -CHR^L-, and -C(R^L)₂-;

a1a is 0, 1, or 2;

a1b is 1, 2, or 3;

a1c is 1 or 2;

5 each **L^{B1}** is independently selected from the group consisting of: -CH₂-, -CHR^L-, and -C(**R^L**)₂-;

b1 is 1, 2, or 3;

10 each **R^L** is independently selected from the group consisting of: -F and C₁₋₃ alkyl optionally substituted with 1-3 F;

m6 is 0 or 1; and

each **R⁶** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl optionally substituted with 1-3 F.

15

In some embodiments of Formula (**I-b1**), (**I-b2**), (**I-b3**), or (**I-b4**), each **L^{A1a}**, **L^{A1b}**, and **L^{A1c}** is CH₂.

In some embodiments of Formula (**I-b1**), (**I-b2**), (**I-b3**), or (**I-b4**), each **L^{B1}** is CH₂.

20 In some embodiments of Formula (**I-b1**), (**I-b2**), (**I-b3**), or (**I-b4**), **L^{A4a}** and **L^{A4b}** are each an independently selected 4-6 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 substituents each independently selected from the group consisting of: -F, CN, C₁₋₃ alkoxy, OH, and C₁₋₃ alkyl optionally substituted with 1-3 F, wherein:

L^{A4a} and **L^{A4b}** independently contain 1-2 ring nitrogen atoms and no additional ring heteroatoms.

25

In some embodiments of Formula (**I-b1**), (**I-b2**), (**I-b3**), or (**I-b4**), **L^{A4a}** and **L^{A4b}** are each an independently selected 4-6 (e.g., 5-6) membered nitrogen-containing heterocyclylene, wherein:

L^{A4a} and **L^{A4b}** independently contain 1-2 ring nitrogen atoms and no additional ring heteroatoms.

30

In some embodiments of Formula (**I-b1**), (**I-b2**), (**I-b3**), or (**I-b4**), **m6** is 0.





In some embodiments of Formula (**I-b1**), (**I-b2**), (**I-b3**), or (**I-b4**), **c1** is 0; and **R^{aN}** is methyl.







In some embodiments, the compounds of Formula (I) are selected from the group consisting of the compounds in **Table C1**, or pharmaceutically acceptable salts thereof.






Table C1







No.	Compound Structure
101	
102	
104	
105	
107	






No.	Compound Structure
108	
109	
111	
112	
113	
114	






No.	Compound Structure
115	 Chemical structure of compound 115: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a propyl chain connected to a p-phenylene ring. This p-phenylene ring is further linked via a propyl chain to a piperidine ring, which is connected to a carbonyl group. The carbonyl group is linked to a piperazine ring, which is connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 4-oxo-4,5,6,7-tetrahydro-1H-benzothiazine-2-yl group.
116	 Chemical structure of compound 116: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a propyl chain connected to a p-phenylene ring. This p-phenylene ring is further linked via a propyl chain to a piperidine ring, which is connected to a carbonyl group. The carbonyl group is linked to a piperazine ring, which is connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 4-oxo-4,5,6,7-tetrahydro-1H-benzothiazine-2-yl group.
117	 Chemical structure of compound 117: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a propyl chain connected to a p-phenylene ring. This p-phenylene ring is further linked via a propyl chain to a piperidine ring, which is connected to a carbonyl group. The carbonyl group is linked to a piperazine ring, which is connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 4-oxo-4,5,6,7-tetrahydro-1H-benzothiazine-2-yl group.
118	 Chemical structure of compound 118: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a propyl chain connected to a p-phenylene ring. This p-phenylene ring is further linked via a propyl chain to a piperidine ring, which is connected to a carbonyl group. The carbonyl group is linked to a piperazine ring, which is connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 4-oxo-4,5,6,7-tetrahydro-1H-benzothiazine-2-yl group.






No.	Compound Structure
124	
125	
126	
127	
128	
129	





No.	Compound Structure
130	
131	
132	
133	
134	






No.	Compound Structure
135	 Chemical structure of compound 135: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a side chain containing a p-phenylene ring, a piperidine ring, and a morpholine ring. The morpholine ring is further connected to a pyrazole ring, which is substituted with a carboxylic acid group.
136	 Chemical structure of compound 136: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a side chain containing a p-phenylene ring, a piperidine ring, and a morpholine ring. The morpholine ring is further connected to a pyrazole ring, which is substituted with a carboxylic acid group.
137	 Chemical structure of compound 137: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a side chain containing a p-phenylene ring, a piperidine ring, and a morpholine ring. The morpholine ring is further connected to a pyrazole ring, which is substituted with a carboxylic acid group.
138	 Chemical structure of compound 138: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a side chain containing a p-phenylene ring, a piperidine ring, and a morpholine ring. The morpholine ring is further connected to a pyrazole ring, which is substituted with a carboxylic acid group.
139	 Chemical structure of compound 139: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a side chain containing a p-phenylene ring, a piperidine ring, and a morpholine ring. The morpholine ring is further connected to a pyrazole ring, which is substituted with a carboxylic acid group.
140	 Chemical structure of compound 140: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a side chain containing a p-phenylene ring, a piperidine ring, and a morpholine ring. The morpholine ring is further connected to a pyrazole ring, which is substituted with a carboxylic acid group.






No.	Compound Structure
141	
142	
143	
144	
145	






No.	Compound Structure
146	 Chemical structure of compound 146: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is further substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 2,6-dioxo-3,4-dihydro-1H-pyrimidin-5-yl group.
147	 Chemical structure of compound 147: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is further substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 2,6-dioxo-3,4-dihydro-1H-pyrimidin-5-yl group.
148	 Chemical structure of compound 148: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is further substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 2,6-dioxo-3,4-dihydro-1H-pyrimidin-5-yl group.
149	 Chemical structure of compound 149: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is further substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 2,6-dioxo-3,4-dihydro-1H-pyrimidin-5-yl group.
150	 Chemical structure of compound 150: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is further substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a 2,6-dioxo-3,4-dihydro-1H-pyrimidin-5-yl group.







No.	Compound Structure
155	 Chemical structure of compound 155: A complex molecule featuring a thiazole ring substituted with a benzamide group and a morpholine ring. This is linked via a pyridine ring to a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a morpholine ring, which is then linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a succinimide ring.
156	 Chemical structure of compound 156: A complex molecule featuring a thiazole ring substituted with a benzamide group and a morpholine ring. This is linked via a pyridine ring to a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a morpholine ring, which is then linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a succinimide ring.
157	 Chemical structure of compound 157: A complex molecule featuring a thiazole ring substituted with a benzamide group and a morpholine ring. This is linked via a pyridine ring to a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a morpholine ring, which is then linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a succinimide ring.
158	 Chemical structure of compound 158: A complex molecule featuring a thiazole ring substituted with a benzamide group and a morpholine ring. This is linked via a pyridine ring to a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a morpholine ring, which is then linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a succinimide ring.
159	 Chemical structure of compound 159: A complex molecule featuring a thiazole ring substituted with a benzamide group and a morpholine ring. This is linked via a pyridine ring to a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a morpholine ring, which is then linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a succinimide ring.







No.	Compound Structure
160	 Chemical structure of compound 160: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a long chain containing another piperidine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.
161	 Chemical structure of compound 161: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a long chain containing another piperidine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.
162	 Chemical structure of compound 162: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a long chain containing another piperidine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.
163	 Chemical structure of compound 163: A complex molecule featuring a benzothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a biphenyl system, which is further linked to a piperidine ring. The piperidine ring is connected to a long chain containing another piperidine ring, which is linked to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.



No.	Compound Structure
164	 Chemical structure of compound 164: A complex molecule featuring a thienothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is in turn connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.
165	 Chemical structure of compound 165: A complex molecule featuring a thienothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is in turn connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.
166	 Chemical structure of compound 166: A complex molecule featuring a thienothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is in turn connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.
167	 Chemical structure of compound 167: A complex molecule featuring a thienothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is in turn connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.
168	 Chemical structure of compound 168: A complex molecule featuring a thienothiazine core linked via a carboxamide group to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a dimethylpiperazine ring, which is in turn connected to a pyrazole ring. The pyrazole ring is substituted with a methyl group and a carboxamide group.

No.	Compound Structure
168a	 Chemical structure of compound 168a: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a pyrrolidine ring, which is linked to a benzimidazole group. The benzimidazole group is substituted with a methyl group and a carboxamide group.
168b	 Chemical structure of compound 168b: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a pyrrolidine ring, which is linked to a benzimidazole group. The benzimidazole group is substituted with a methyl group and a carboxamide group.
169	 Chemical structure of compound 169: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a pyrrolidine ring, which is linked to a benzimidazole group. The benzimidazole group is substituted with a methyl group and a carboxamide group.
169a	 Chemical structure of compound 169a: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a pyrrolidine ring, which is linked to a benzimidazole group. The benzimidazole group is substituted with a methyl group and a carboxamide group.
169b	 Chemical structure of compound 169b: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is connected to a phenyl ring, which is further linked to a piperidine ring. The piperidine ring is connected to a pyrrolidine ring, which is linked to a benzimidazole group. The benzimidazole group is substituted with a methyl group and a carboxamide group.


No.	Compound Structure
171b	 Chemical structure of compound 171b. It features a thienothiazine core substituted with a carboxamide group, a carboxylic acid group, and a pyridine ring. The pyridine ring is linked via a methoxy group to a phenyl ring, which is further connected to a piperidine ring. The piperidine ring is linked via a methylene group to a pyrrolidine ring, which is substituted with a 1-methyl-1H-benzotriazole-4-yl group and a 2,6-pyridinedione group.
172	 Chemical structure of compound 172. It features a thienothiazine core substituted with a carboxamide group, a carboxylic acid group, and a pyridine ring. The pyridine ring is linked via a methoxy group to a phenyl ring, which is further connected to a piperidine ring. The piperidine ring is linked via a methylene group to a pyrrolidine ring, which is substituted with a 1-methyl-1H-benzotriazole-4-yl group and a 2,6-pyridinedione group.
172a	 Chemical structure of compound 172a. It features a thienothiazine core substituted with a carboxamide group, a carboxylic acid group, and a pyridine ring. The pyridine ring is linked via a methoxy group to a phenyl ring, which is further connected to a piperidine ring. The piperidine ring is linked via a methylene group to a pyrrolidine ring, which is substituted with a 1-methyl-1H-benzotriazole-4-yl group and a 2,6-pyridinedione group.
172b	 Chemical structure of compound 172b. It features a thienothiazine core substituted with a carboxamide group, a carboxylic acid group, and a pyridine ring. The pyridine ring is linked via a methoxy group to a phenyl ring, which is further connected to a piperidine ring. The piperidine ring is linked via a methylene group to a pyrrolidine ring, which is substituted with a 1-methyl-1H-benzotriazole-4-yl group and a 2,6-pyridinedione group.
173	 Chemical structure of compound 173. It features a thienothiazine core substituted with a carboxamide group, a carboxylic acid group, and a pyridine ring. The pyridine ring is linked via a methoxy group to a phenyl ring, which is further connected to a piperidine ring. The piperidine ring is linked via a methylene group to a pyrrolidine ring, which is substituted with a 1-methyl-1H-benzotriazole-4-yl group and a 2,6-pyridinedione group.


No.	Compound Structure
173a	 Chemical structure of compound 173a: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is linked to a p-phenylene ring, which is further connected to a piperidine ring. The piperidine ring is linked to a pyrrolidine ring, which is connected to a benzimidazole ring system. The benzimidazole ring is substituted with a carboxylic acid group and a methyl group.
173b	 Chemical structure of compound 173b: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is linked to a p-phenylene ring, which is further connected to a piperidine ring. The piperidine ring is linked to a pyrrolidine ring, which is connected to a benzimidazole ring system. The benzimidazole ring is substituted with a carboxylic acid group and a methyl group.
174	 Chemical structure of compound 174: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is linked to a p-phenylene ring, which is further connected to a piperidine ring. The piperidine ring is linked to a pyrrolidine ring, which is connected to a benzimidazole ring system. The benzimidazole ring is substituted with a carboxylic acid group and a methyl group.
174a	 Chemical structure of compound 174a: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is linked to a p-phenylene ring, which is further connected to a piperidine ring. The piperidine ring is linked to a pyrrolidine ring, which is connected to a benzimidazole ring system. The benzimidazole ring is substituted with a carboxylic acid group and a methyl group.
174b	 Chemical structure of compound 174b: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is linked to a p-phenylene ring, which is further connected to a piperidine ring. The piperidine ring is linked to a pyrrolidine ring, which is connected to a benzimidazole ring system. The benzimidazole ring is substituted with a carboxylic acid group and a methyl group.
175	 Chemical structure of compound 175: A complex molecule featuring a benzothiazole ring system connected via an amide bond to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a methoxy group. The methoxy group is linked to a p-phenylene ring, which is further connected to a piperidine ring. The piperidine ring is linked to a pyrrolidine ring, which is connected to a benzimidazole ring system. The benzimidazole ring is substituted with a carboxylic acid group and a methyl group.

No.	Compound Structure
175a	 Chemical structure of compound 175a: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a 3-(4-(4-(1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidin-2-yl)phenyl)propyl ether group.
175b	 Chemical structure of compound 175b: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a 3-(4-(4-(1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidin-2-yl)phenyl)propyl ether group.
176	 Chemical structure of compound 176: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a 3-(4-(4-(1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidin-2-yl)phenyl)propyl ether group.
176a	 Chemical structure of compound 176a: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a 3-(4-(4-(1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidin-2-yl)phenyl)propyl ether group.
176b	 Chemical structure of compound 176b: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a 3-(4-(4-(1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidin-2-yl)phenyl)propyl ether group.
177	 Chemical structure of compound 177: A complex molecule featuring a benzothiazine-2-carboxamide group linked to a pyridine ring. The pyridine ring is substituted with a carboxylic acid group and a 3-(4-(4-(1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)pyrrolidin-2-yl)phenyl)propyl ether group.

No.	Compound Structure
177a	
177b	

Note: for compounds in **Table C1**, when a stereogenic center is denoted with “*or1*” in a structural formula, the stereogenic center has been resolved but the configuration at the

stereogenic center has not been determined. For example, the structure  represents (*R*)-2-methyl-3-(1-methylpiperidin-4-yl)propan-1-ol or (*S*)-2-methyl-3-(1-




5 methylpiperidin-4-yl)propan-1-ol. For example, the structure  represents (*R*)-2-methyl-3-(1-methylpiperidin-4-yl)propan-1-ol or (*S*)-2-methyl-3-(1-methylpiperidin-4-yl)propan-1-ol..

In some embodiments, the compounds of Formula (**I**) are selected from the group
 10 consisting of the compounds depicted in **Table C1** of U.S. Provisional Application Serial No. 63/547,657, filed November 7, 2023; and **Table C1** of U.S. Provisional Application Serial No. 63/641,269, filed May 1, 2024; each of the **Table C1**s is incorporated by reference in its entirety herein.

Certain examples of Formula (**I**) compounds were synthesized using methods involving
 15 resolution of stereoisomeric mixture(s) (e.g., SFC separation of stereoisomers). In **Table C1**, the resolved stereogenic centers in these compounds are labelled with the “*or1*” or “*or2*” enhanced stereochemical notations. In some instances, the stereoisomeric resolutions were performed during the last step of the synthesis, thereby providing the individual stereoisomers of the Formula (**I**) compounds. Alternatively, in some other instances, the resolutions were
 20 performed on an intermediate or starting material, wherein each of the constituent

stereoisomers of the intermediate or starting material could be separately subjected to the subsequent steps of the synthesis to provide the respective Formula (I) compounds as separate stereoisomers. Methods of resolution and correlation between resolved intermediates and Formula (I) compounds are disclosed in the examples herein. A person of ordinary skill in the art would understand that, under either approach for stereoisomeric resolution, stereoisomers having both (*R*)- and (*S*)-configurations at a resolved stereogenic center are provided. See Table C2, wherein Table C1 compounds whose stereoisomers contain the *or*/*I* notations are provided in non-stereogenic form, followed by the respective stereoisomers having the (*R*)- and (*S*)-configurations.

Table C2

No.	Compound Structure
177	
	
	

In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, reduce cell viability in a cell line expressing a BCL-X_L protein with an EC₅₀ of less than 1 μM (e.g., less than 750 nM, less than 500 nM, or less than 200 nM). In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)) reduce cell viability in a cell line expressing the BCL-X_L protein with an EC₅₀ of less than 200 nM (e.g., less than 150 nM, less than 200 nM, less than 100 nM, less than 10 nM, less than 1 nM). For example, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)) can reduce cell viability in a cell line expressing the BCL-X_L protein with an EC₅₀ of between 0.1 nM to 100

nM, between 0.1 nM to 50 nM, between 1 nM to 50 nM, between 1 nM to 20 nM, or between 0.1 nM to 1 nM.

In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with a DC₅₀ of less than 1 μM (e.g., less than 750 nM, less than 500 nM, or less than 200 nM). In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with a DC₅₀ of less than 200 nM (e.g., less than 150 nM, less than 200 nM, less than 100 nM, less than 10 nM, less than 1 nM). For example, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)) can induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with a DC₅₀ of between 0.1 nM to 100 nM, between 0.1 nM to 50 nM, between 1 nM to 50 nM, between 1 nM to 20 nM, or between 0.1 nM to 1 nM.

In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with an EC₅₀ of less than 1 μM (e.g., less than 750 nM, less than 500 nM, or less than 200 nM). In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with an EC₅₀ of less than 200 nM (e.g., less than 150 nM, less than 200 nM, less than 100 nM, less than 10 nM, less than 1 nM). For example, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)) can induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with an EC₅₀ of between 0.1 nM to 100 nM, between 0.1 nM to 50 nM, between 1 nM to 50 nM, between 1 nM to 20 nM, or between 0.1 nM to 1 nM.

In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or pharmaceutically acceptable salts thereof, induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with a Y_{min} of less than 70% (e.g., less than 50%, less than 30%, less than 20%, or less than 10%). In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with a Y_{min} of less than 50% (e.g., less than 40%, less than

30%, less than 20%, less than 10%, or less than 5%). In some embodiments, the compounds of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with a Y_{min} of less than 30% (e.g., less than 25%, less than 20%, less than 15%, less than 10%, or less than 5%). For example, the compounds of Formula (I) (e.g.,
5 Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)) can induce degradation of a BCL-X_L protein in a cell line expressing the BCL-X_L protein with a Y_{min} of about 1% to about 70% (e.g., about 5% to about 50% or about 10% to about 30%).

Also provided herein is a BCL-X_L protein non-covalently bound with a compound of
10 Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof.

Also provided herein is a ternary complex comprising a BCL-X_L protein, a compound of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)), or a pharmaceutically acceptable salt thereof, and a CRBN protein, or a portion thereof.

15

Chemical definitions

The term “halo” refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).

The term “oxo” refers to a divalent doubly bonded oxygen atom (i.e., “=O”). As used herein, oxo groups are attached to carbon atoms to form carbonyls.





20 The term “alkyl” refers to a saturated acyclic hydrocarbon radical that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C₁₋₁₀ indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. Alkyl groups can either be unsubstituted or substituted with one or more substituents. Non-limiting examples include methyl, ethyl, *iso*-propyl, *tert*-butyl, *n*-hexyl. The term “saturated” as used in this
25 context means only single bonds present between constituent carbon atoms and other available valences occupied by hydrogen and/or other substituents as defined herein.

The term “haloalkyl” refers to an alkyl, in which one or more hydrogen atoms is/are replaced with an independently selected halo (e.g., -CF₃, -CHF₂, or -CH₂F).

The term “alkoxy” refers to an -O-alkyl radical (e.g., -OCH₃).

30 The term “alkylene” refers to a divalent alkyl (e.g., -CH₂-). Similarly, terms such as “cycloalkylene” and “heterocyclylene” refer to divalent cycloalkyl and heterocyclyl respectively. For avoidance of doubt, in “cycloalkylene” and “heterocyclylene”, the two

radicals can be on the same ring carbon atom (e.g., a geminal diradical such as  or ) or on different ring atoms (e.g., ring carbon and/or nitrogen atoms (e.g., vicinal ring

carbon and/or nitrogen atoms)) (e.g., , , , .

The term “alkenyl” refers to an acyclic hydrocarbon chain that may be a straight chain
 5 or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C₂₋₆ indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it. Alkenyl groups can either be unsubstituted or substituted with one or more substituents.

The term “alkynyl” refers to an acyclic hydrocarbon chain that may be a straight chain
 10 or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C₂₋₆ indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it. Alkynyl groups can either be unsubstituted or substituted with one or more substituents.

The term “aryl” refers to a 6-20 carbon mono-, bi-, tri- or polycyclic group wherein at
 15 least one ring in the system is aromatic (e.g., 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system); and wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, tetrahydronaphthyl, and the like.

The term “cycloalkyl” as used herein refers to mono-, bi-, tri-, or polycyclic saturated
 20 or partially unsaturated hydrocarbon groups having, e.g., 3 to 20 ring carbons, preferably 3 to 15 ring carbons, and more preferably 3 to 12 ring carbons or 3-10 ring carbons or 3-6 ring carbons, wherein the cycloalkyl group may be optionally substituted. The term “saturated” as used in this context means only single bonds present between constituent carbon atoms. Examples of saturated cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Partially unsaturated cycloalkyl may
 25 have any degree of unsaturation provided that one or more double bonds is present in the cycloalkyl, none of the rings in the ring system are aromatic, and the partially unsaturated cycloalkyl group is not fully saturated overall. Examples of partially unsaturated cycloalkyl

include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Cycloalkyl may include multiple fused and/or bridged rings. Non-limiting examples of fused/bridged cycloalkyl includes: bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[1.1.1]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.1.1]hexyl, bicyclo[3.2.0]heptyl, bicyclo[4.1.0]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[4.2.0]octyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, and the like. Cycloalkyl also includes spirocyclic rings (e.g., spirocyclic bicycle wherein two rings are connected through just one atom). Non-limiting examples of spirocyclic cycloalkyls include spiro[2.2]pentyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[2.6]nonyl, spiro[4.5]decyl, spiro[3.6]decyl, spiro[5.5]undecyl, and the like.


The term “heteroaryl”, as used herein, means a mono-, bi-, tri- or polycyclic group having 5 to 20 ring atoms, alternatively 5, 6, 9, 10, or 15 ring atoms; wherein at least one ring in the system contains one or more heteroatoms independently selected from the group

consisting of N, O, S (inclusive of oxidized forms such as:  or ) and P (inclusive of oxidized forms such as: ) (e.g., N, O, and S (inclusive of oxidized forms such as:

 or )) and at least one ring in the system is aromatic (but does not have to be a ring which contains a heteroatom, e.g. tetrahydroisoquinoliny, e.g., tetrahydroquinoliny). In some embodiments, heteroaryl groups contain 1-4 (e.g., 1, 2, or 3) ring heteroatoms each independently selected from the group consisting of N, O, and S (inclusive of oxidized forms

such as:  or ). Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnoliny, indazolyl, indolyl, isoquinoliny, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-*d*]pyrimidinyl, pyrrolo[2,3-*b*]pyridinyl, quinazolinyl, quinoliny, thieno[2,3-*c*]pyridinyl, pyrazolo[3,4-*b*]pyridinyl, pyrazolo[3,4-*c*]pyridinyl, pyrazolo[4,3-*c*]pyridinyl, pyrazolo[4,3-*b*]pyridinyl, tetrazolyl, chromanyl, 2,3-dihydrobenzo[*b*][1,4]dioxinyl, benzo[*d*][1,3]dioxolyl, 2,3-dihydrobenzofuranyl, tetrahydroquinoliny, 2,3-dihydrobenzo[*b*][1,4]oxathiinyl, isoindoliny,

and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, isoindolyl, pyranyl, pyrazinyl, and pyrimidinyl. For purposes of clarification, heteroaryl also includes aromatic lactams, aromatic cyclic ureas, or vinylogous analogs thereof, in which each ring nitrogen adjacent to a carbonyl is tertiary (i.e., all three valences are occupied by non-hydrogen substituents), such as one or more of pyridone (e.g.,



10 The term “heterocyclyl” refers to a mono-, bi-, tri-, or polycyclic saturated or partially unsaturated ring system with 3-15 ring atoms (e.g., 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-15 membered tricyclic ring system) having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic or polycyclic, the heteroatoms selected

from O, N, S (inclusive of oxidized forms such as:  or ), and P (inclusive of

15 oxidized forms such as:  (e.g., N, O, and S (inclusive of oxidized forms such as: 

or )) (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, S, or P if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent. The term “saturated” as used in this context means only single bonds present between constituent ring atoms and other available valences occupied by hydrogen and/or other substituents as defined herein. Examples of saturated heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like. Partially unsaturated heterocyclyl groups may have any degree of unsaturation provided that one or more double bonds is present in the heterocyclyl, none of the rings in the ring system are aromatic, and the partially unsaturated heterocyclyl group is not fully saturated overall. Examples of partially

unsaturated heterocyclyl groups include, without limitation, tetrahydropyridyl, dihydropyrazinyl, dihydropyridyl, dihydropyrrolyl, dihydrofuranyl, dihydrothiophenyl.

Heterocyclyl may include multiple fused and/or bridged rings. Non-limiting examples of fused/bridged heterocyclyl includes: 2-azabicyclo[1.1.0]butyl, 2-azabicyclo[2.1.0]pentyl, 5 2-azabicyclo[1.1.1]pentyl, 3-azabicyclo[3.1.0]hexyl, 5-azabicyclo[2.1.1]hexyl, 3-azabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrole, 3-azabicyclo[4.1.0]heptyl, 7-azabicyclo[2.2.1]heptyl, 6-azabicyclo[3.1.1]heptyl, 7-azabicyclo[4.2.0]octyl, 2-azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, 2-oxabicyclo[1.1.0]butyl, 2-oxabicyclo[2.1.0]pentyl, 2-oxabicyclo[1.1.1]pentyl, 3-oxabicyclo[3.1.0]hexyl, 5-oxabicyclo[2.1.1]hexyl, 3-oxabicyclo[3.2.0]heptyl, 3-oxabicyclo[4.1.0]heptyl, 7-oxabicyclo[2.2.1]heptyl, 6-oxabicyclo[3.1.1]heptyl, 7-oxabicyclo[4.2.0]octyl, 2-oxabicyclo[2.2.2]octyl, 3-oxabicyclo[3.2.1]octyl, and the like. Heterocyclyl also includes spirocyclic rings (e.g., spirocyclic bicycle wherein two rings are connected through just one atom). Non-limiting examples of spirocyclic heterocyclyls include 2-azaspiro[2.2]pentyl, 4-azaspiro[2.5]octyl, 1-azaspiro[3.5]nonyl, 2-azaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 2-azaspiro[4.4]nonyl, 6-azaspiro[2.6]nonyl, 1,7-diazaspiro[4.5]decyl, 7-azaspiro[4.5]decyl, 2,5-diazaspiro[3.6]decyl, 3-azaspiro[5.5]undecyl, 2-oxaspiro[2.2]pentyl, 4-oxaspiro[2.5]octyl, 1-oxaspiro[3.5]nonyl, 2-oxaspiro[3.5]nonyl, 7-oxaspiro[3.5]nonyl, 2-oxaspiro[4.4]nonyl, 6-oxaspiro[2.6]nonyl, 1,7-dioxaspiro[4.5]decyl, 2,5-dioxaspiro[3.6]decyl, 1-oxaspiro[5.5]undecyl, 3-oxaspiro[5.5]undecyl, 3-oxa-9-azaspiro[5.5]undecyl and the like.





A nitrogen-containing heterocyclyl as used herein refers to a heterocyclyl having 1-2 ring nitrogen atoms and 0-2 additional ring heteroatoms selected from the group consisting of

O and S (inclusive of oxidized such as:  or ). The nitrogen-containing heterocyclyl can be monocyclic, bicyclic, or polycyclic as defined elsewhere herein. Examples of monocyclic nitrogen-containing heterocyclyl include azetidiny, pyrrolidiny, piperidiny, piperazinyl, morpholinyl, and the like. Examples of bicyclic nitrogen-containing heterocyclyl include 7-azaspiro[3.5]nonyl, 1,7-diazaspiro[4.5]decyl, 3-oxa-7,9-diazabicyclo[3.3.1]nonanyl, 2,6-diazaspiro[3.3]heptanyl, and the like.

As used herein, when a ring is described as being “partially unsaturated”, it means the ring has one or more additional degrees of unsaturation (in addition to the degree of unsaturation attributed to the ring itself; e.g., one or more double or triple bonds between constituent ring atoms), provided that the ring is not aromatic. Examples of such rings include:



cyclopentene, cyclohexene, cycloheptene, dihydropyridine, tetrahydropyridine, dihydrofuran, dihydrothiophene, and the like.

For the avoidance of doubt, and unless otherwise specified, for rings and cyclic groups (e.g., aryl, heteroaryl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, cycloalkyl, and the like described herein) containing a sufficient number of ring atoms to form bicyclic or higher order ring systems (e.g., tricyclic, polycyclic ring systems), it is understood that such rings and cyclic groups encompass those having fused rings, including those in which the points of fusion are located (i) on adjacent ring atoms (e.g., [x.x.0] ring systems, in which 0 represents a zero atom

bridge (e.g., )); (ii) a single ring atom (spiro-fused ring systems) (e.g., , , or , or (iii) a contiguous array of ring atoms (bridged ring systems having all bridge lengths > 0) (e.g., , , or .

In addition, atoms making up the compounds of the present embodiments are intended to include all isotopic forms of such atoms. Isotopes, as used herein, include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include ^{13}C and ^{14}C .

In addition, the compounds generically or specifically disclosed herein are intended to include all tautomeric forms. Thus, by way of example, a compound containing the moiety:

 encompasses the tautomeric form containing the moiety: . Similarly, a pyridinyl or pyrimidinyl moiety that is described to be optionally substituted with hydroxyl encompasses pyridone or pyrimidone tautomeric forms.

The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying

the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.

Methods of Treatment

Indications

Provided herein are methods for inducing degradation of a BCL-X_L protein. For example, provided herein are compounds capable of inducing degradation of a BCL-X_L protein useful for treating or preventing cancers. See, e.g., Guo, et al. *Aging (Albany NY)* 13.15 (2021): 19750, doi: 10.18632/aging.203386; Park, et al. *Proceedings of the National Academy of Sciences* 112.40 (2015): 12492-12497, doi: 10.1073/pnas.1507491112; Zhang, et al. *Molecular Cancer* 14.1 (2015): 1-9, doi: 10.1186/s12943-015-0397-y; Beroukhi, et al. *Nature* 463.7283 (2010): 899-905, doi: 10.1038/nature08822.

The term “compound(s) provided herein” refers to compound(s) of Formula (I) (e.g., Formula (I-a), (I-b), (I-b1), (I-b2), (I-b3), or (I-b4)) as disclosed herein.

The effect of protein degradation typically increases over time, and the appearance of degradation (e.g., as expressed by the percentage degradation compared to a control, or the parameters Y_{min}, DC₅₀, EC₅₀, and/or D_{max}) is affected by the resynthesis rate of the protein. Accordingly, degradation can be examined after a specified period of time, such as 6 hours, 12 hours, 18 hours, 1 day, 2 days, 3 days, or more. For example, degradation can be expressed as the percent degradation after 24 hours.

Exemplary assays for validating the degradation-inducing mechanism of a compound as provided herein are known in the art and are described, for example, in International Publication No. WO 2019/144117 and Wu, et al. *Nature Structural & Molecular Biology* 27.7 (2020): 605-614, doi: 10.1038/s41594-020-0438-0.

Degradation assays can be used to quantify both on- and off-target degradation-inducing effects of compounds, such as those compounds provided herein. Exemplary assays include quantitative immunoblotting, other immunoassays (e.g., MesoScale Discovery (MSD) immunoassays), homogenous time resolved fluorescence (HTRF), and HiBiT. In some embodiments, cells can be contacted with a compound provided herein, or a pharmaceutically acceptable salt thereof, incubated, and then the lysate can be prepared for gel electrophoresis (e.g., SDS-PAGE), followed by immunoblotting and quantification compared to a control (e.g., a DMSO-treated control). As another example, a cell line can be engineered to express a HiBiT-tagged BCL-X_L protein, and the amount of fluorescence observed when the complementary

LgBiT peptide is added can be compared between cells treated with a compound provided herein, or a pharmaceutically acceptable salt thereof, and a control (e.g., a DMSO-treated control). See, for instance, **Example B1** and **Example B2**. See also, e.g., International Publication Nos. WO 2020/163823 and WO 2019/144117. In some embodiments, off-target degradation inducing effects can be assessed for the proteins Eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1), Ikaros (IKZF1), Helios (IKZF2), Aiolos (IKZF3), and/or casein kinase I isoform alpha (CK1 α).

See also the assays described in International Publication Nos. WO 2023/044046; WO 2022/169780; WO 2021/222114; WO 2021/146536; WO 2021/078301; WO 2021/007307; WO 2020/163823; WO 2019/144117; WO 2017/184995, and Khan, et al. *Nature Medicine* 25.12 (2019): 1938-1947, doi: 10.1038/s41591-019-0668-z; Balachander, et al. *Clinical Cancer Research* 26.24 (2020): 6535-6549, doi: 10.1158/1078-0432.CCR-20-0863.

Binding affinity of a compound provided herein, or a pharmaceutically acceptable salt thereof to BCL-X_L can be determined by, for example, a binding IC₅₀ or K_i value (e.g., using a competition assay), or by a K_D value (e.g., using a biophysical assay). A compound with a lower binding IC₅₀ value, as determined under substantially similar conditions, is a more potent binder relative to a compound with a higher binding IC₅₀ value. A compound with a lower binding K_i value, as determined under substantially similar conditions, is a more potent binder relative to a compound with a higher binding K_i value. Similarly, a compound with a lower K_D value, as determined under substantially similar conditions, is a more potent binder relative to a compound with a higher K_D value. For example, a binding IC₅₀ value can be determined in a fluorescence polarization assay using a fluorescently labeled BH3-only peptide (e.g., BAD or BAX) as the competitor. As another example, a binding K_i value can be determined using a time resolved-fluorescence resonance energy transfer (TR-FRET) assay using a fluorescently labeled BH3-only peptide (e.g., BAK) and a fluorescently labeled antibody that binds to BCL-X_L, where the fluorophores are a FRET pair, and using a compound provided herein, or a pharmaceutically acceptable salt thereof, as provided herein as a competitor for the BH3-only peptide. See, e.g., U.S. Patent Publication Nos. US 2007/0027135, US 2010/305122, and US 2013/096120.

Another exemplary assay for evaluating the affinity of a compound provided herein, or a pharmaceutically acceptable salt thereof, includes using a competition assay with recombinant BCL-X_L protein. For example, purified recombinant affinity-tagged (e.g., His-tagged) BCL-X_L protein can be incubated with various concentrations of a compound provided

herein, or a pharmaceutically acceptable salt thereof, and a fixed concentration of affinity-tagged (e.g., biotin-tagged) BAD protein. After a period of incubation, FRET acceptor beads with a complementary affinity tag (e.g., His-acceptor beads) and FRET donor beads (e.g., streptavidin-tagged donor beads) can be added to the mixture, and a FRET reaction can be used to determine an inhibition constant of the compound provided herein, or pharmaceutically acceptable salt thereof. For example, an AlphaLISA competitive assay can be performed. See, e.g., International Publication No. WO 2019/144117.

The ability of a compound provided herein, or a pharmaceutically acceptable salt thereof, to inhibit BCL-X_L can be determined using an IC₅₀ value. A compound with a lower IC₅₀ value, as determined under substantially similar conditions, is a more potent inhibitor relative to a compound with a higher IC₅₀ value. One way that inhibition of BCL-X_L can be measured is measuring the interruption of the formation of a complex of BCL-X_L with a BH3-only peptide (e.g., BIM). For example, an electrochemiluminescence-based sandwich ELISA assay (e.g., a Meso Scale Discovery (MSD)-ELISA assay) can be used. See, for example, Phillips, D. C., et al. *Blood Cancer Journal* 5.11 (2015): e368-e368, doi: 10.1038/bcj.2015.88 and Xiao, Yu, et al. *Molecular Cancer Therapeutics* 14.8 (2015): 1837-1847, doi: 10.1158/1535-7163.MCT-14-0928. In such assays, cells expressing BCL-X_L can be incubated with a compound provided herein, or a pharmaceutically acceptable salt thereof for a period of time, lysed, and then evaluated in the assay. A tagged anti-BCL-X_L antibody (e.g., a biotin-tagged anti-BCL-X_L antibody) can be immobilized on an assay plate (e.g., a streptavidin assay plate), and then the lysate can be applied to pull down BCL-X_L. An anti-BIM antibody (e.g., a rabbit anti-BIM antibody) can be introduced, followed by addition of a detection antibody (e.g., a sulfo-tagged goat anti-rabbit antibody) and measurement of the detection antibody. As another example, interruption of the formation of a complex of BCL-X_L with a BH3-only peptide (e.g., BIM) can be measured using a mammalian two-hybrid assay. In such assays, a plasmid encoding the 'bait' and 'prey' fusion proteins (e.g., the DNA binding domain of GAL4 fused to BCL-X_L and the transcriptional activation domain of VP16 fused to BIM) can be introduced to cells (e.g., HeLa cells) stably expressing a GAL4-luciferase reporter. A compound provided herein, or a pharmaceutically acceptable salt thereof, can be added to the cells in culture, incubated, and the luciferase activity can be measured. See, for example, Souers, Andrew J., et al. *Nature Medicine* 19.2 (2013): 202-208, doi: 10.1038/nm.3048.

Additional methods of evaluating the binding of a compound to BCL-X_L protein or the inhibition of a BCL-X_L protein are described in, for example, U.S. Patent Publication Nos. US

2007/027135; US 2010/305122, and US 2013/096120.

Potency of degradation by a compound provided herein, or a pharmaceutically acceptable salt thereof, as provided herein can be determined by DC_{50} value. As used herein, DC_{50} refers to the concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, that results in a 50% decrease in the concentration of a protein (e.g., BCL- X_L protein) in a cell compared to the concentration of the protein before the cell is contacted with the compound provided herein, or a pharmaceutically acceptable salt thereof, or compared to the concentration of the protein in a cell not contacted with the compound provided herein, or a pharmaceutically acceptable salt thereof. A compound with a lower DC_{50} value, as determined under substantially similar conditions, is a more efficient inducer of degradation relative to a compound with a higher DC_{50} value. In some embodiments, a DC_{50} value can be determined (e.g., using HiBiT detection) in vitro or in vivo (e.g., in tumor cells (e.g., cell lines such as MOLT4, RS4;11, NCI-H146, EJM, HEK293T, HT1080, and/or H929) expressing a BCL- X_L protein).

Potency of degradation by a compound provided herein, or a pharmaceutically acceptable salt thereof, as provided herein can be determined by EC_{50} value. As used herein, EC_{50} refers to the concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof that results in a 50% decrease in the concentration of a protein (e.g., BCL- X_L protein) relative to the trough concentration of the protein in a cell, when compared to the concentration of the protein before the cell is contacted with the compound provided herein, or a pharmaceutically acceptable salt thereof, or compared to the concentration of the protein in a cell not contacted with the compound provided herein, or a pharmaceutically acceptable salt thereof. A compound with a lower EC_{50} value, as determined under substantially similar conditions, is a more potent compound relative to a compound with a higher EC_{50} value. In some embodiments, an EC_{50} value can be determined (e.g., using HiBiT detection) in vitro or in vivo (e.g., in tumor cells (e.g., cell lines such as MOLT4, RS4;11, NCI-H146, EJM, HEK293T, HT1080, and/or H929) expressing a BCL- X_L protein).

Potency of degradation by a compound provided herein, or a pharmaceutically acceptable salt thereof, as provided herein can be determined by Y_{min} value. As used herein, Y_{min} refers to the ratio of trough concentration of a protein (e.g., BCL- X_L protein) in a cell compared to the concentration of the protein before the cell is contacted with the compound provided herein, or a pharmaceutically acceptable salt thereof, or compared to the concentration of the protein in a cell not contacted with the compound provided herein, or a

pharmaceutically acceptable salt thereof, expressed as a percentage. As used herein, $D_{\max}$ is $1 - Y_{\min}$. $Y_{\min}$ can be measured by a HiBiT assay (e.g., as described in **Example B1**). A compound with a lower $Y_{\min}$ value, as determined under substantially similar conditions, is a more potent inducer of degradation relative to a compound with a higher $Y_{\min}$ value. In some embodiments, a $Y_{\min}$ value can be determined (e.g., using HiBiT detection) in vitro or in vivo (e.g., in tumor cells (e.g., cell lines such as MOLT4, RS4;11, NCI-H146, EJM, HEK293T, HT1080, and/or H929) expressing a BCL-X_L protein).

An exemplary assay for determining the potency of a compound provided herein, or a pharmaceutically acceptable salt thereof, includes measuring the effect of the compound provided herein, or a pharmaceutically acceptable salt thereof, on cell proliferation and/or viability. Cell proliferation assays can be performed in a number of formats, including 2D and 3D. Similarly, a cell proliferation assay can be performed with any appropriate cell line, including, for example, MOLT4, RS4;11, NCI-H146, EJM, HEK293T, HT1080, and/or H929. As an illustrative example, a 3D cell proliferation assay can include growing cells in a 3D medium, contacting the cells with a compound provided herein, or a pharmaceutically acceptable salt thereof, measuring the cellular proliferation using an appropriate reagent (e.g., CELLTITER-GLO® 3D), and then comparing the signal from an experiment with a compound provided herein, or a pharmaceutically acceptable salt thereof, to the signal from a control experiment (e.g., lacking the compound provided herein, or a pharmaceutically acceptable salt thereof). As another illustrative example, a 2D cell proliferation assay can include plating cells onto a growth surface, optionally letting the cells grow for a period of time, contacting the cells with a compound provided herein, or a pharmaceutically acceptable salt thereof, measuring the cellular proliferation using an appropriate reagent (e.g., CELLTITER-GLO®), and then comparing the signal from an experiment with a compound provided herein, or a pharmaceutically acceptable salt thereof, to the signal from a control experiment (e.g., lacking a compound provided herein, or a pharmaceutically acceptable salt thereof). In some embodiments, assessment degradation-mediated antiproliferation effects from compounds provided herein, CRBN knockout cells can be used in a similar cell viability assay. The CRBN knockout cells can be generated from parental cells (e.g., MOLT-4 cells) using Crispr gene editing technology. CRBN-targeted single guide RNA (sgRNA) and Cas9 protein can be purchased from commercial suppliers, and Cas9-sgRNA ribonucleoproteins (RNPs) can be electroporated into parental cells (e.g., MOLT-4 cells) using a kit (e.g., a Neon NxT Electroporation Kit (Invitrogen)). Cell viability can be assessed for the CRBN knockout cells

in the same way as for parental cells (e.g., MOLT-4 cells). Additional cell viability assays include MTT assays, which are colorimetric assays based on the reduction of the tetrazolium dye MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to the insoluble purple formazan, and other similar assays based on related tetrazolium salts. See, for instance,

5 **Example B3.**

A cell viability assay can be used to measure the effect of a compound provided herein, or a pharmaceutically acceptable salt thereof, on cell death. For example, cells expressing BCL-X_L protein (e.g., MOLT-4 cells) can be incubated with various concentrations of a compound provided herein, or a pharmaceutically acceptable salt thereof, then exposed to a detection
10 reagent (e.g., a CELLTITER-GLO® Cell Viability Assay kit) to determine cell viability.

An exemplary assay for determining the mechanism of cell death using of a compound provided herein, or a pharmaceutically acceptable salt thereof, includes measuring the effect of the compound provided herein, or a pharmaceutically acceptable salt thereof, on one or more markers of a mechanism of cell death (e.g., apoptosis). Exemplary markers of apoptosis include
15 caspase induction (e.g., caspase 3/7 induction) and annexin V staining. Such assays may also be used as determinants of cell viability. For example, cells expressing BCL-X_L protein (e.g., MOLT-4 cells) can be incubated with various concentrations of a compound provided herein, or a pharmaceutically acceptable salt thereof, and relative caspase activity can be assessed using a luciferase substrate that is activated by caspase 3/7 (e.g., using the CASPASE-GLO®
20 3/7 assay). As another example, cells expressing BCL-X_L protein (e.g., MOLT-4 cells) can be incubated with various concentrations of a compound provided herein, or a pharmaceutically acceptable salt thereof, and relative caspase activity can be assessed using a dye that is coupled to an activated caspase motif (e.g., INCUCYTE® Caspase 3/7 Green Apoptosis Assay Reagent), followed by analysis using a platform for live cell imaging (e.g., an INCUCYTE®
25 SX5 Live-Cell Analysis Instrument). As another example, cells expressing BCL-X_L protein (e.g., MOLT-4 cells) can be incubated with various concentrations of a compound provided herein, or a pharmaceutically acceptable salt thereof, and annexin V positivity can be assessed using phosphatidylserine dye (e.g., an INCUCYTE® Annexin V dye), followed by analysis using a platform for live cell imaging (e.g., an INCUCYTE® SX5 Live-Cell Analysis
30 Instrument).

As another example, the potency and/or efficacy of a compound provided herein, or a pharmaceutically acceptable salt thereof, can be evaluated in an animal model, for example, a cell line-derived xenograft (CDX) model (e.g., using an established cancer cell line such as

MOLT4, HEL, TF1, F36P, OCI-M1, OCI-M2, SET-2, CMK, M07E, UKE-1, or NCI-H1417), or a patient-derived xenograft (PDX) model. For example, a CDX or PDX model can be run in immunodeficient mice (e.g., athymic nude, outbred homozygous (e.g., Crl:NU(NCr)-Foxn1^{nu}) or Fox Chase SCID (CB17/Icr-Prkdc^{scid}/IcrIcoCrl), mice). The mice can be female, 6-12 weeks old at tumor implantation and have access to food and water ad libitum. Approximately 70 mg of a tumor can be implanted subcutaneously in the right flank of each mouse. Following implantation, tumors can be measured weekly and once the tumor volumes reach 150-300 mm³, the mice can be randomized into treatment and control groups. In some embodiments, one or more experimental arms can be added to evaluate pharmacokinetics and/or pharmacodynamics.

The mice can be treated with a compound provided herein, or a pharmaceutically acceptable salt thereof, (e.g., via IP or PO (oral) administration) and optionally an additional therapy or therapeutic agent (e.g., any of the additional therapies or therapeutic agents described herein). Throughout the study, health condition, body weight and tumor volumes of the mice can be recorded on a weekly basis. The mice can be sacrificed at 28 days or when the tumor reaches 1 cm³, and the tumors can be evaluated (e.g., by tumor weight, by tumor volume). At the end of each study, the Best Response can be calculated for each treatment arm. Best Response is defined as the minimum value of ΔVolume_i for $t \geq 10$ days. Best Responses between the control arm(s) and the treatment arm(s) can be compared to determine if the treatment(s) work better than the control(s). In some embodiments, tumor samples can also be collected at the end of each study and relevant proteins (e.g., BCL-X_L, BCL-2, BCL-W, MCL-1, BIM, BAX, and/or BAK) can be measured to determine if the treatment might have a better protein modulation profile compared to a control. In some embodiments, tumor samples can also be collected at the end of each study and analyzed for signaling pathway activity (e.g., via phosphoERK levels). For pharmacokinetic and pharmacodynamic studies, tumor and/or blood samples from the mice can be obtained at the same or different time points than efficacy studies. For example, for pharmacokinetic and pharmacodynamic studies, tumor and/or blood samples from the mice can be obtained at Day 5, 6 hours post dosing, and relevant proteins can be measured in the tumor samples and pharmacokinetic studies can be performed on the blood samples or a portion thereof (e.g., plasma).

In some embodiments, the PDX is a model of a myeloproliferative neoplasm (MPN) (e.g., CEL, CML, CNL, essential thrombocythemia (e.g., JAK2 mutant (e.g., JAK2 V617F mutant) essential thrombocythemia or JAK2 wild type essential thrombocythemia), polycythemia vera (e.g., JAK2 mutant (e.g., JAK2 V617F mutant) polycythemia vera or JAK2

wild type polycythemia vera), or myelofibrosis (e.g., primary myelofibrosis (e.g., JAK2 mutant (e.g., JAK2 V617F mutant) primary myelofibrosis or JAK2 wild type primary myelofibrosis), post-essential thrombocythemia myelofibrosis (e.g., JAK2 mutant (e.g., JAK2 V617F mutant) post-essential thrombocythemia myelofibrosis or JAK2 wild type post-essential thrombocythemia myelofibrosis), or post-polycythemia vera myelofibrosis (e.g., JAK2 mutant (e.g., JAK2 V617F mutant) post-polycythemia vera myelofibrosis or JAK2 wild type post-polycythemia vera myelofibrosis))))), a CRC (e.g., BRAF mutant CRC (e.g., BRAF V600E CRC) or KRAS mutant CRC (e.g., KRAS G12C mutant CRC or KRAS G12D CRC)), a SCLC (e.g., ASCL1 subtype SCLC or NEUROD1 subtype SCLC), a NSCLC (e.g., BRAF mutant NSCLC (e.g., BRAF V600E NSCLC), an EGFR mutant NSCLC (e.g., EGFR L858R NSCLC or EGFR exon 19 deletion NSCLC), MET mutant NSCLC (e.g., MET exon 14 deletion NSCLC, MET amplified NSCLC), a KRAS mutant NSCLC (e.g., KRAS G12C NSCLC)), a lung squamous cell carcinoma, a malignant pleural mesothelioma (e.g., a BAP1 mutant malignant pleural mesothelioma), a melanoma (e.g., BRAF mutant melanoma (e.g., BRAF V600E melanoma)), a breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low breast cancer), a lymphoma (e.g., a T cell lymphoma (e.g., anaplastic large T cell lymphoma, cutaneous T cell lymphoma, or peripheral T cell lymphoma), or a non-Hodgkin lymphoma (e.g., DLBCL, anaplastic large T cell lymphoma, cutaneous T cell lymphoma, or peripheral T cell lymphoma), a leukemia (e.g., T cell leukemia (e.g., a T-ALL (e.g., relapsed/refractory T-ALL)), post-MPN leukemia, M6-AML, M7-AML), a head and neck cancer, a pancreatic cancer, a bladder cancer, an ovarian cancer (e.g., BRCA1 mutant ovarian cancer or BRCA2 mutant ovarian cancer, HGSOE (e.g., BRCA1 mutant HGSOE or BRCA2 mutant HGSOE)), a cervical cancer, an intrahepatic cholangiocarcinoma, or a mesenchymal cancer (e.g., mesenchymal breast cancer or mesenchymal kidney cancer).

See, e.g., Khan, et al. *Nature Medicine* 25.12 (2019): 1938-1947, doi: 10.1038/s41591-019-0668-z; Balachander, et al. *Clinical Cancer Research* 26.24 (2020): 6535-6549, doi: 10.1158/1078-0432.CCR-20-0863.

The pharmacokinetic parameters of a compound provided herein, or a pharmaceutically acceptable salt thereof, can be evaluated in an animal model, for instance, a mouse model, a rat model, a dog model, or a nonhuman primate (e.g., cynomolgus monkey) model. An exemplary

protocol includes the following. For example, pharmacokinetics (PK) studies can be conducted on animals (e.g., male or female CD-1 mice, Sprague Dawley rats, beagle dogs, or cynomolgus monkeys) by two delivery routes: intravenous (IV) injection and oral gavage (PO). Animals in both the IV and PO groups (e.g., $n = 3$) are allowed free access to food and water, or may be fasted. A compound provided herein, or a pharmaceutically acceptable salt thereof, can be formulated in solution for the IV route and solution or suspension for the PO route. On the day of the experiment, the compound provided herein, or a pharmaceutically acceptable salt thereof, can be administered via vein injection (e.g., at 1 mg/kg) for IV route or via oral gavage (e.g., at 0.3 to 100 mg/kg) for PO route. Blood samples can be collected via serial bleeding (e.g., at 8 timepoints from 0.83 to 24 hours post dose). At each timepoint, blood can be collected (e.g., approximately 30 μ L of blood/timepoint) in a K₂EDTA tube via a vein (e.g., the saphenous vein). Blood samples can be put on wet ice and centrifuged (e.g., at 4600 RPM for 4 minutes) to obtain plasma samples. Plasma samples can be diluted 1:1 (v/v) (e.g., with an equal volume of pH 3.0 phosphate buffer) and submitted to LC-MS/MS for sample analysis. Pharmacokinetic parameters, including clearance (IV), area under the curve (AUC), maximum concentration ($C_{\max}$), the time at which maximum concentration is reached ($T_{\max}$), mean residence time (MRT) and oral bioavailability (%F) can be calculated using a non-compartmental model.

In some embodiments, the pharmacokinetic parameters of a compound provided herein, or a pharmaceutically acceptable salt thereof, can be measured in a mouse model (e.g., a CD-1 (ICR) model). An exemplary protocol follows.

Mice (e.g., male CD-1 (ICR) mice, 7-9 weeks of age) are dosed with a compound provided herein, or a pharmaceutically acceptable salt thereof, once, either orally (PO) (e.g., at 3, 10, 30, 100, or 300 mg/kg) or intravenously (IV) (e.g., at 1 mg/kg). The compound provided herein, or a pharmaceutically acceptable salt thereof, is administered to the mice in a solution formulation (e.g., 100% PEG400 for the PO groups or 5% DMSO/10% Solutol/85% water for the IV group). The mice have access to food and water ad libitum.

Blood samples (e.g., 30 μ L per sample) from the mice are taken at predetermined intervals, such as 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, and 72 hours) after the dose is administered (not every mouse will have every time point sampled, also called sparse sampling). The blood is sampled via saphenous vein puncture, then the blood samples (e.g., with K₂EDTA as anticoagulant) are temporarily put on ice and then centrifuged (e.g., at 4 °C and 4600 RPM for 5 minutes) within 30 minutes. Plasma

samples are acidified via dilution with an equal volume of pH 3.0 phosphate buffer and put on dry ice. After the completion of the last sampling, all samples are stored at -80°C or analyzed in a short time following collection. The concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, measured in an acidified plasma sample can be determined (e.g., via LC/MS/MS). For example, an acidified plasma sample is prepared for analysis using protein precipitation (e.g., by the addition of methanol), and an internal standard is spiked in at a known concentration. The spiked sample is mixed, centrifuged, and the supernatant is used in an LC/MS/MS method. The LC/MS/MS method uses a KINETEX® C18 2.6 μ m 100 Å (50 mm * 2.10 mm) column with a first mobile phase of water (0.1% formic acid) and a second mobile phase of acetonitrile (0.1% formic acid). Multiple reaction monitoring is used to measure the analyte(s) of interest. Using the concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, in the plasma sample, pharmacokinetic parameters of terminal $t_{1/2}$ (hr), t_{max} (hr), C_{max} (ng/mL), AUC_{last} (hr*ng/mL), AUC_{Inf} (hr*ng/mL), AUC_{Extr} (%), MRT_{Inf} (hr), $AUC_{Inf/D}$ (hr*kg*ng/mL/mg), and %F, are determined via noncompartmental analysis.

In some embodiments, the pharmacokinetic parameters of a compound provided herein, or a pharmaceutically acceptable salt thereof, can be measured in a rat model (e.g., a Sprague-Dawley rat model). An exemplary protocol follows.

Rats (e.g., male Sprague-Dawley rats, 7-9 weeks of age) are dosed with a compound provided herein, or a pharmaceutically acceptable salt thereof, either orally (PO) (e.g., at 10, 30, or 100 mg/kg) or intravenously (IV) (e.g., at 1 mg/kg). The compound provided herein, or a pharmaceutically acceptable salt thereof, is administered to the rats in a solution or suspension formulation (e.g., 10% 1-Methyl-2-Pyrrolidinone (NMP)/15% Solutol/75% (20% (2-Hydroxypropyl)- β -cyclodextrin (HPBCD) in water) for the PO group or 10% DMSO/10% Solutol/80% water solution for the IV group). The rats have access to food and water ad libitum.

Blood samples (e.g., 150 μ L per sample) from the rats are taken at predetermined intervals, such as 5 minutes, 15, minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, and 72 hours after the dose is administered. The blood is sampled via jugular vein puncture, then the blood samples (e.g., with K₂EDTA as anticoagulant) are temporarily put on ice and then centrifuged (e.g., at 4 °C and 6000 RPM for 5 minutes) within 30 minutes. Plasma samples are acidified via dilution with an equal volume of pH 3.0 phosphate buffer and put on dry ice. After the completion of the last sampling, all samples are stored at -80°C or analyzed in a short time following collection. The concentration of the compound provided

herein, or a pharmaceutically acceptable salt thereof, can be measured in an acidified plasma sample (e.g., diluted 1:1 v/v with pH 3 phosphate buffer) can be determined (e.g., via LC/MS/MS). For example, an acidified plasma sample is prepared for analysis using protein precipitation (e.g., by the addition of methanol, then methanol/acetonitrile 1:1, v/v containing
5 a known concentration of internal standard). The spiked sample is mixed, centrifuged, and the supernatant is used in an LC/MS/MS method. The LC/MS/MS method uses a KINETEX® C18 2.6 μm 100 Å (50 mm * 2.10 mm) column with a first mobile phase of water (0.1% formic acid (FA)) and a second mobile phase of acetonitrile (0.1% FA). Multiple reaction monitoring is used to measure the analyte(s) of interest. Using the concentration of the compound provided
10 herein, or a pharmaceutically acceptable salt thereof, in the plasma sample, pharmacokinetic parameters of terminal $t_{1/2}$ (hr), t_{max} (hr), C_{max} (ng/mL), AUC_{last} (hr*ng/mL), AUC_{Inf} (hr*ng/mL), AUC_{Extr} (%), MRT_{Inf} (hr), $\text{AUC}_{\text{Inf/D}}$ (hr*kg*ng/mL/mg), %F, AUC_{0-24} (hr*ng/mL), and AUC_{48-72} (hr*ng/mL) are determined via noncompartmental analysis.

In some embodiments, the pharmacokinetic parameters of a compound provided herein,
15 or a pharmaceutically acceptable salt thereof, can be measured in a dog model (e.g., a beagle model). An exemplary protocol follows.

Dogs (e.g., male Beagle dogs) are dosed with a compound provided herein, or a pharmaceutically acceptable salt thereof, orally (PO) (e.g., at 0.3, 1, 3 or 10 mg/kg) or intravenously (IV) (e.g., at 0.1 mg/kg). The compound provided herein, or a pharmaceutically
20 acceptable salt thereof, is administered to the dogs in a solution or suspension formulation (e.g., 10% NMP/ 15% Solutol/ 75% (20% HPBCD in water)). The dogs are in the fed state.

Blood samples (e.g., about 0.5 mL) from the dogs are taken at predetermined intervals, such as 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours, and 72 hours after the dose is administered. The blood is sampled via peripheral vein
25 puncture, then the blood samples (e.g., with K_2EDTA as anticoagulant) are temporarily put on ice and then centrifuged (e.g., at 2-8 °C and $3200 \times g$ for 10 minutes) within 30 minutes. Plasma samples are acidified via dilution with an equal volume of pH 3.0 phosphate buffer and put on dry ice. After the completion of the last sampling, all samples are stored at -60 to -80°C or analyzed in a short time following collection. The concentration of the compound provided
30 herein, or a pharmaceutically acceptable salt thereof, can be measured in an acidified plasma sample can be determined (e.g., via LC/MS/MS). For example, an acidified plasma sample is prepared for analysis using protein precipitation (e.g., by the addition of acetonitrile containing internal standard of known concentration). The spiked sample is mixed, centrifuged, and the

supernatant is used in an LC/MS/MS method. The LC/MS/MS method uses an ACQUITY UPLC HSS T3 1.8 μm 2.1 $\times$ 50 mm column (or an ACQUITY UPLC Protein BEH C4 300Å 1.7 μm 2.1 $\times$ 50 mm column) with a first mobile phase of 0.1% formic acid and 2 mM ammonium formate in water/acetonitrile (v:v, 95:5) and a second mobile phase of 0.1% formic acid and 2 mM ammonium formate in acetonitrile/water (v:v, 95:5). Multiple reaction monitoring is used to measure the analyte(s) of interest. Using the concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, in the plasma sample, pharmacokinetic parameters of terminal $t_{1/2}$ (hr), t_{max} (hr), C_{max} (ng/mL), AUC_{last} (hr*ng/mL), AUC_{Inf} (hr*ng/mL), AUC_{Ext} (%), MRT_{Inf} (hr), %F, and AUC_{0-24} (hr*ng/mL), are determined via noncompartmental analysis.

In some embodiments, the pharmacokinetic parameters of a compound provided herein, or a pharmaceutically acceptable salt thereof, can be measured in a non-human primate model (e.g., a cynomolgus monkey model). An exemplary protocol follows.

Non-human primates (e.g., male cynomolgus monkeys) are dosed with a compound provided herein, or a pharmaceutically acceptable salt thereof, orally (PO) (e.g., at 3 mg/kg) or intravenously (IV) (e.g., at 0.5 mg/kg). The compound provided herein, or a pharmaceutically acceptable salt thereof, is administered to the monkeys in a solution formulation (e.g., 10% NMP/ 15% Solutol/ 75% (20% HPBCD in water, pH 5)). The monkeys are in the fed state.

Blood samples (e.g., about 0.5 mL) from the monkeys are taken at predetermined intervals, such as 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, and 48 hours after the dose is administered. The blood is sampled via peripheral vein puncture, then the blood samples (e.g., with K₂EDTA as anticoagulant) are temporarily put on ice and then centrifuged (e.g., at 2-8 °C and 3200 $\times$ g for 10 minutes) within 30 minutes. Plasma samples are acidified via dilution with an equal volume of pH 3.0 phosphate buffer and put on dry ice. After the completion of the last sampling, all samples are stored at -60 to -80°C or analyzed in a short time following collection. The concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, can be measured in an acidified plasma sample via LC/MS/MS. For example, an acidified plasma sample is prepared for analysis using protein precipitation (e.g., by the addition of acetonitrile containing internal standard of known concentration). The spiked sample is mixed, centrifuged, and the supernatant is used in an LC/MS/MS method. The LC/MS/MS method uses an ACQUITY UPLC BEH C18 1.7 μm 2.1 $\times$ 50 mm column with a first mobile phase of 0.1% formic acid and 2 mM ammonium formate in water/acetonitrile (v:v, 95:5) and a second mobile phase of 0.1% formic acid and 2 mM

ammonium formate in acetonitrile/water (v:v, 95:5). Multiple reaction monitoring is used to measure the analyte(s) of interest. Using the concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, in the plasma sample, pharmacokinetic parameters of terminal $t_{1/2}$ (hr), t_{max} (hr), C_{max} (ng/mL), AUC_{last} (hr*ng/mL), AUC_{Inf} (hr*ng/mL), AUC_{Ext} (%), MRT_{Inf} (hr), %F, and AUC_{0-24} (hr*ng/mL), are determined via noncompartmental analysis.

In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is at least 4%. In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is at least 10%. In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is at least 20%. In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is at least 30%. In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is at least 40%. In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is about 4% to about 80% (e.g., about 4% to about 60%, about 4% to about 40%, about 4% to about 20%, about 4% to about 10%, about 20% to about 40%, or about 20% to about 30%). In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is about 4% to about 20% (e.g., about 4% to about 10%). In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is about 20% to about 40%. In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is about 40% to about 60%. In some embodiments, the %F for a compound provided herein, or a pharmaceutically acceptable salt thereof, is about 60% to about 80%.

In some embodiments, the oral clearance (CL/F) for a compound provided herein, or a pharmaceutically acceptable salt thereof, dosed PO in rats at 10 mg/kg, is less than 10 mL/min/kg (e.g., less than 5 mL/min/kg, less than 3 mL/min/kg, or less than 1 mL/min/kg). In some embodiments, clearance for a compound provided herein, or a pharmaceutically acceptable salt thereof, dosed PO in rats at 10 mg/kg, is about 0.05 mL/min/kg to about 5 mL/min/kg (e.g., about 0.05 mL/min/kg to about 3 mL/min/kg, about 0.05 mL/min/kg to about 1 mL/min/kg, or about 0.05 mL/min/kg to about 0.5 mL/min/kg).

In some embodiments, the AUC for a compound provided herein, or a pharmaceutically acceptable salt thereof, dosed PO in rats at 10 mg/kg, is about 10 $\mu\text{M}\cdot\text{h}$ to about 350 $\mu\text{M}\cdot\text{h}$ (e.g., 10 $\mu\text{M}\cdot\text{h}$ to about 150 $\mu\text{M}\cdot\text{h}$, about 50 $\mu\text{M}\cdot\text{h}$ to about 350 $\mu\text{M}\cdot\text{h}$, about 100 $\mu\text{M}\cdot\text{h}$ to

about 350 $\mu\text{M}\cdot\text{h}$, or about 150 $\mu\text{M}\cdot\text{h}$ to about 350 $\mu\text{M}\cdot\text{h}$).

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is not a substrate of a human cytochrome P450 enzyme. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is not a substrate of a human cytochrome P450 enzyme where $\geq 25\%$ of clearance is attributed to that enzyme. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is not an inhibitor and/or an inducer of one or more human cytochrome P450 enzymes. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is not an inhibitor and/or an inducer of one or more human cytochrome P450 enzymes, where the IC_{50} value and/or EC_{50} value for the one or more human cytochrome P450 enzymes, respectively, is significantly greater than the estimated free fraction concentration of a compound provided herein, or a pharmaceutically acceptable salt thereof, at a clinically relevant dose.

Exemplary human cytochrome P450 enzymes include those in the CYP1, CYP2, and CYP3 families. Of those, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2J2, CYP2S1, CYP2E1, CYP3A4, and CYP3A5 are known drug metabolizing enzymes. In some embodiments, no single cytochrome P450 enzyme is responsible for greater than or equal to 25% of the elimination of a compound provided herein, or a pharmaceutically acceptable salt thereof. Cytochrome P450 inhibition and/or inducing activity can be determined using appropriate in vitro assays, such as those described in the guidance document “In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions” provided by the U.S. F.D.A. in January 2020, and similarly in the ICH M12 guidance finalized in May 2024. For example, evaluation of cytochrome P450 inhibition can be performed in in vitro studies, in both a reversible and time-dependent manner. In an in vitro inhibition study, the ratio of intrinsic clearance values of a probe substrate for an enzymatic pathway in the absence and in the presence of a compound provided herein, or a pharmaceutically acceptable salt thereof, can be calculated based on these in vitro results; this ratio is referred to as R_1 for reversible inhibition, where $R_1 = 1 + (I_{\text{max,u}}/K_{\text{i,u}})$, and $I_{\text{max,u}}$ is the maximal unbound plasma concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, predicted in human, and $K_{\text{i,u}}$ is the unbound inhibition constant determined in vitro. Specifically, in the case of CYP3A whereas the enzyme is also expressed at significant levels in the intestine, $R_{1,\text{gut}}$ can be calculated where $R_{1,\text{gut}} = 1 + (I_{\text{gut}} + K_{\text{i,u}})$, and where I_{gut} is predicted human intestinal luminal concentration of the compound

provided herein, or a pharmaceutically acceptable salt thereof, calculated as the human oral dose/250mL. The time-dependent inhibition ratio R_2 can similarly be calculated, where $R_2 = (k_{obs} + k_{deg}) / k_{deg}$, and k_{obs} is the observed (apparent first order) inactivation rate of the affected cytochrome P450 calculated by $k_{obs} = (k_{inact} * I_{max,u}) / (K_{I,u} + I_{max,u})$, k_{deg} is the apparent first-order degradation rate constant of the affected cytochrome P450, $K_{I,u}$ is the unbound concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, causing half maximal inactivation, and k_{inact} is the maximal inactivation rate constant. Utilizing these equations for R_1 , $R_{1,gut}$, and R_2 , the compound provided herein, or a pharmaceutically acceptable salt thereof, can be evaluated for their potential to be an inhibitor of a cytochrome P450, and the drug-drug interaction (DDI) potential can be further investigated using mechanistic or physiological-based pharmacokinetic models of the liver and intestine and/or conducting a clinical DDI study with a sensitive index substrate. Additionally, a compound's propensity to activate nuclear receptors (e.g., PXR, CAR, or AhR) is evaluated through in vitro cytochrome P450 hepatocyte induction studies and the resulting data can be evaluated via the fold-change method, wherein the fold-change in cytochrome P450 enzyme mRNA levels, when incubated with the compound provided herein, or a pharmaceutically acceptable salt thereof, based on cutoff determined from known positive and negative controls to calibrate the system. For example, a compound provided herein, or a pharmaceutically acceptable salt thereof, is determined to be an inducer if: (1) it increases mRNA expression of a cytochrome P450 enzyme in a concentration-dependent manner; and (2) the fold change of cytochrome P450 mRNA expression relative to the vehicle control is ≥ 2 -fold at the expected hepatic concentrations of the drug. Additionally, evaluation of cytochrome P450 induction can be performed by a correlation method, wherein correlation methods are used to predict the magnitude of a clinical induction effect (e.g., AUC ratio of an index substrate in the presence and absence of inducers) of a compound provided herein, or a pharmaceutically acceptable salt thereof, according to a calibration curve of relative induction scores (RIS) or $I_{max,u}/EC_{50}$ for a set of known inducers of the same cytochrome P450. If the predicted magnitude is more than a predefined cut-off (e.g., AUC ratio ≤ 0.8), a compound provided herein, or a pharmaceutically acceptable salt thereof, is considered to have induction potential in vivo.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be tested for its potency in inhibiting hERG potassium channels. The cardiac potassium channel hERG is responsible for a rapid delayed rectifier current (I_{Kr}) in human ventricle, and inhibition of I_{Kr} is the most common cause of cardiac action potential

prolongation by non-cardiac drugs. Increased action potential duration causes prolongation of the QT interval that has been associated with a dangerous ventricular arrhythmia, *torsade de pointes*. There are several methods of testing hERG inhibition potency, including Fastpatch hERG and manual patch clamp experiments.

5 In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is tested for its potency in inhibiting hERG potassium channels using a manual patch clamp assay. For example, in some embodiments, solutions or suspensions of a compound provided herein, or a pharmaceutically acceptable salt thereof, at several concentrations (e.g., 0.3, 1, 3 and 10 μM) can be exposed to single cells. The effect of the
10 compound provided herein, or a pharmaceutically acceptable salt thereof, on the inhibition of hERG potassium channels can be measured in this system using an electrical pulse pattern, the data plotted, and an IC_{50} value calculated for the inhibition of hERG by the compound provided herein, or a pharmaceutically acceptable salt thereof. An exemplary protocol follows.

In this experiment, hERG potassium channels are expressed in a human embryonic
15 kidney cell line that lacks endogenous I_{Kr} (HEK-293 (ATCC 293T, CRL-3216TM)). See, e.g., Brown, Arthur M., and David Rampe. *Pharmaceutical News* 7.4 (2000): 15-20; Weirich, Jörg, and H. Antoni, *Basic Research in Cardiology* 93 (1998): s125-s132, doi: 10.1007/s003950050236; and Yap, Yee Guan, and A. J. Camm. *Clinical & Experimental Allergy* 29 (1999): 174-181, doi: 10.1046/j.1365-2222.1999.0290s3174.x.

20 All chemicals used in solution preparations are purchased from a commercial supplier (e.g., Sigma-Aldrich) and are of ACS reagent grade purity or higher. Stock solutions of the compound provided herein, or a pharmaceutically acceptable salt thereof, positive control compound(s), and reference substance(s) are prepared in dimethyl sulfoxide (DMSO) and stored frozen. Solutions of each compound provided herein, or a pharmaceutically acceptable
25 salt thereof, positive control compound, and reference substance concentrations are prepared fresh daily by diluting stock solutions into HEPES-buffered physiological saline solution (HB-PS; 137 mM NaCl, 4 mM KCl, 1.8 mM CaCl_2 , 1 mM MgCl_2 , 10 mM HEPES, and 10 mM glucose, pH 7.4). Since previous results have shown that $\leq 0.3\%$ DMSO does not affect channel current, all test and control solutions can contain 0.3% DMSO.

30 In some embodiments, a positive control compound can be included in the experiment. In some such embodiments, the positive control compound can be terfenadine (Sigma-Aldrich), for example, in a HB-PS and 0.3% DMSO solution.

In some embodiments, a reference compound can be included in the experiment. In some such embodiments, the reference compound can be E-4031 (Sigma-Aldrich), for example, in a HB-PS and 0.3% DMSO solution.

5 If necessary, solutions are sonicated to facilitate dissolution. Visible precipitate observed during preparation or exposure of formulations to the test system is noted for reference.

The effect of a compound provided herein, or a pharmaceutically acceptable salt thereof, are initially evaluated at concentration range of 1 to 10 μ M. Subsequent concentrations are evaluated based on the inhibition observed at that concentration.

10 HEK-293 cells are transfected with hERG cDNA. Stable transfectants are selected by coexpression of the G418-resistance gene incorporated into the expression plasmid. Selection pressure is maintained by including G418 in the culture medium. Cells are cultured in Dulbecco's Modified Eagle's Medium / Ham's Nutrient Mixture F-12 (DMEM/F-12) supplemented with 10% fetal bovine serum and the appropriate concentrations of penicillin G sodium, streptomycin sulfate, and G418.

15 All experiments are performed at near-physiological temperature (33 – 35 °C). Each cell acts as its own control.

The effect of a compound provided herein, or a pharmaceutically acceptable salt thereof, is evaluated at multiple (e.g., up to four) concentrations. Each concentration will be tested in at least three cells ($n \geq 3$). Additional concentration(s) may be tested due to the limits imposed by the physiochemical effects of the compound provided herein, or a pharmaceutically acceptable salt thereof (e.g., solubility or cytotoxicity).

The positive control compound is tested in at least two (2) cells ($n \geq 2$).

25 Cells are transferred to the recording chamber and superfused with vehicle control solution. Pipette (intracellular) solution for whole cell recordings is composed of 130 mM potassium aspartate, 5 mM $MgCl_2$, 5 mM EGTA, 4 mM ATP, and 10 mM HEPES, pH 7.2. Pipette solution is prepared in batches, aliquoted, stored frozen and a fresh aliquot thawed each day. The recording is performed at a temperature of 33 to 35 °C using a combination of in-line solution pre-heater, chamber heater, and feedback temperature controller. Temperature is measured using a thermistor probe in the recording chamber. Micropipettes for patch clamp recording are made from glass capillary tubing using a P-97 micropipette puller (Sutter Instruments). A commercial patch clamp amplifier (Molecular Devices) is used for whole patch clamp cell recordings. Before digitization, current records are low-pass filtered.

Cells stably expressing hERG are held at -80 mV. Onset and steady state inhibition of hERG potassium current due to the compound provided herein, or a pharmaceutically acceptable salt thereof, are measured using a pulse pattern with fixed amplitudes (conditioning prepulse of +20 mV for 1 second; repolarizing test ramp to -80 mV (at -0.5 V/second) repeated at 5 second intervals). Each recording ends with an application of a supramaximal concentration of the reference substance (e.g., E-4031 at 500 nM) to assess the contribution of endogenous currents. The remaining uninhibited current is subtracted off-line digitally from the data to determine the potency of the compound provided herein, or a pharmaceutically acceptable salt thereof, for hERG inhibition. Peak current is measured during the test ramp. A steady state is maintained for at least 20 seconds before applying the compound provided herein, or a pharmaceutically acceptable salt thereof, positive control compound, or reference substance. Peak tail currents are measured until a new steady state is achieved. If a steady state cannot be reached within 12 minutes, the response at 12 minutes is substituted for the steady state value and a notation made.

Data acquisition and analyses are performed using the commercial suite of pCLAMP programs (Molecular Devices). Steady state is defined by the limiting constant rate of change with time (linear time dependence). The steady state before and after application of each compound provided herein, or a pharmaceutically acceptable salt thereof, is used to calculate the percentage of current inhibited at each concentration.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is tested for its potency in inhibiting hERG potassium channels (e.g., encoded by the *KCNH2* gene and expressed in HEK293 cells) using a Fastpatch hERG assay. For example, in some embodiments, solutions or suspensions of a compound provided herein, or a pharmaceutically acceptable salt thereof, at several concentrations (e.g., 0.3, 1, 3 and 10 μ M) can be exposed to cells in an automatic parallel patch clamp system. The effect of the compound provided herein, or a pharmaceutically acceptable salt thereof, on the inhibition of hERG potassium channels can be measured in this system using an electrical pulse pattern, the data plotted, and an IC_{50} value calculated for the inhibition of hERG by the compound provided herein, or a pharmaceutically acceptable salt thereof. An exemplary protocol follows.

The in vitro effects of a compound provided herein, or a pharmaceutically acceptable salt thereof, are evaluated at room temperature using the QPATCH HT® (Sophion Bioscience A/S, Denmark), an automatic parallel patch clamp system. The compound provided herein, or a pharmaceutically acceptable salt thereof, is exposed to hERG at 0.3, 1, 3 and 10 μ M in at

least five cells ($n \geq 5$). The duration of exposure to each compound concentration is at least three minutes.

Solutions or suspensions of the compound(s) provided herein, or a pharmaceutically acceptable salt thereof, are prepared daily. Various concentrations are prepared by diluting stock solutions into an appropriate HEPES-buffered physiological saline solution (HB-PS).

Previous results have shown that 0.3% DMSO does not affect channel current. Therefore, all test and control solutions can contain up to 0.3% DMSO.

Each formulation of a compound provided herein, or a pharmaceutically acceptable salt thereof, can be sonicated (e.g., Model 2510/5510, Branson Ultrasonics, Danbury, CT), e.g., at room temperature, to facilitate dissolution.

In some embodiments, a positive control can be included in the experiment. In some such embodiments, the positive control compound can be cisapride (Tocris Bioscience), for example, in a 0.3% DMSO solution.

In preparation for the recording session, a glass-lined 96-well compound plate is loaded with the appropriate amounts of solutions of compound(s) provided herein, or a pharmaceutically acceptable salt thereof, and control solutions, and placed in the plate well of the QPATCH® (Sophion Bioscience A/S, Denmark).

HEK293 (ATCC 293T, CRL-3216™) cells are stably transfected with the appropriate ion channel cDNA(s). Except for cells that have been stored frozen, stable transfectants are maintained in the culture medium with the appropriate selection pressure and antibiotics.

All experiments are performed at room temperature. Each cell acts as its own control.

Vehicle is applied via the QPATCH® robot pipetting system to naive cells for a 5-10 minute exposure interval. After vehicle application, various concentrations of a compound provided herein, or a pharmaceutically acceptable salt thereof, are applied in at least three (3) minute intervals ($n \sim 3$, where n = the number of cells/concentration). Each solution exchange on the QPATCH® is performed multiple times, which results in 100% replacement of the compound in the QPlate.

Positive control(s) are applied in the same manner as the compound provided herein, or a pharmaceutically acceptable salt thereof, to verify sensitivity to ion channel blockade.

In preparation for a recording session, an intracellular solution (e.g., 137 mM NaCl, 4 mM KCl, 1.8 mM CaCl_2 , 1 mM MgCl_2 , 10 mM HEPES, and 10 mM glucose, pH 7.4) is loaded into the intracellular compartments of the QPlate and cell suspension is pipetted into the

extracellular compartments. After establishment of a whole-cell configuration, membrane currents are recorded using up to 48 parallel patch clamp amplifiers in the QPATCH® system.

Valid whole-cell recordings meet the following criteria:

1. Membrane resistance $\geq 200 \text{ M}\Omega$.

5 2. Leak current $\leq 25\%$ channel current or subtracted.

Onset and block of hERG current is measured using a stimulus voltage pattern consisting of a 500 ms prepulse to -40 mV (leakage subtraction), a 2-second activating pulse to +40 mV followed by a 2-second test pulse to -40 mV. The pulse pattern is repeated continuously at 10 s intervals from a holding potential of -80 mV. Peak tail current is measured during the -40 mV test pulse. Leakage current is calculated from the current amplitude evoked by the -40 mV prepulse and subtracted from the total membrane current record.

Data acquisition and analyses are performed using conventional software. Steady state is defined by the limiting constant rate of change with time (linear time dependence). The steady state before and after application of a compound provided herein, or a pharmaceutically acceptable salt thereof, will be used to calculate the percentage of current inhibited at each concentration. If current is blocked $\geq 50\%$, estimated IC_{50} values will be calculated using the following formula:

$$\% \text{ Inhibition} = \{1 - 1/[1 + ([\text{Test}]/\text{IC}_{50})^N]\} * 100$$

20

Where [Test] is the concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, IC_{50} is the concentration of the compound provided herein, or a pharmaceutically acceptable salt thereof, at half-maximal inhibition, N is the Hill coefficient, and % Inhibition is the percentage of current inhibited at each test article concentration. Nonlinear least squares fits are solved with the Solver add-in for Excel (Microsoft, WA). Overestimation of current inhibition, due to rundown, is avoided by a manual adjustment that uses an exponential compensation formula in the QPATCH® analysis software.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is not a hERG inhibitor. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, inhibits hERG with an IC_{50} of greater than 60 nM (e.g., greater than 100 nM, 300 nM, 500 nM, 1 μM , 3 μM , 5 μM , 10 μM , 20 μM , or 30 μM). For example, a compound provided herein, or a pharmaceutically acceptable salt thereof,

inhibits hERG with an IC₅₀ of greater than 500 nM (e.g., greater than 1 μM, 3 μM, 5 μM, 10 μM, 20 μM, or 30 μM). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, inhibits hERG with an IC₅₀ of greater than 1 μM (e.g., greater than 3 μM, 5 μM, 10 μM, 20 μM, or 30 μM). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, inhibits hERG with an IC₅₀ of greater than 10 μM (e.g., greater than 20 μM or 30 μM). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, inhibits hERG with an IC₅₀ of greater than 30 μM.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be evaluated for potential secondary pharmacology. For example, in some embodiments, solutions of a compound provided herein, or a pharmaceutically acceptable salt thereof, at a single or several concentrations can be exposed to a panel of primary cells, cell lines or isolated tissues expressing known pharmacological receptors, enzymes or transporters. The effect of the compound provided herein, or a pharmaceutically acceptable salt thereof, the secondary pharmacological target of interest can be determined, the data is initially plotted as a percent inhibition. For secondary targets exceeding an inhibition threshold (typically ≥ 50%), an IC₅₀ value is generated and calculated following an 8-point concentration curve of the compound provided herein, or a pharmaceutically acceptable salt thereof.

An exemplary list of assays is included in **Table 1** below. One or more of these assays can be used to assess the secondary pharmacological characteristics of a compound provided herein. Exemplary protocols are described in Valentin, Jean-Pierre, and Tim Hammond. *Journal of Pharmacological and Toxicological Methods* 58.2 (2008): 77-87; doi: 10.1016/j.vascn.2008.05.007; Wakefield, Ian D., et al. *Fundamental & Clinical Pharmacology* 16.3 (2002): 209-218, doi: 10.1046/j.1472-8206.2002.00099.x; Whitebread, Steven, et al. *Drug Discovery Today* 10.21 (2005): 1421-1433, doi: 10.1016/S1359-6446(05)03632-9; and Lounkine, Eugen, et al. *Nature* 486.7403 (2012): 361-367, doi: 10.1038/nature11159.

Table 1.

Protein	Organism	Assay Type	Family
Acetylcholinesterase	Human	Enzymatic	Neurotransmitter Metabolism
Angiotensin-converting peptidase	Human	Enzymatic	Protease

ATPase (Na/K)	Pig	Enzymatic	Transporter
Cathespin G chymotrypsin peptidase	Human	Enzymatic	Protease
Cyclooxygenase 1	Human	Enzymatic	Lipid Metabolism
Cyclooxygenase 2	Human	Enzymatic	Lipid Metabolism
Monoamine Oxidase A	Human	Enzymatic	Oxireductase
Monoamine Oxidase B	Human	Enzymatic	Oxireductase
Phosphodiesterase 3A	Human	Enzymatic	PDE
Phosphodiesterase 4D2	Human	Enzymatic	PDE
Insulin Receptor Kinase	Human	Enzymatic	Kinase
Irc Kinase	Human	Enzymatic	Kinase
PKC alpha Kinase	Human	Enzymatic	Kinase
Adenosine A1 Receptor	Human	Binding	GPCR
Adenosine Transporter	Human	Binding	Transporter
Alpha 1A Adrenergic Receptor	Human	Binding	GPCR
Alpha 1B Adrenergic Receptor	Human	Binding	GPCR
Alpha 1D Adrenergic Receptor	Human	Binding	GPCR
Alpha 2A Adrenergic Receptor	Human	Binding	GPCR
Alpha 2B Adrenergic Receptor	Human	Binding	GPCR
Beta 1 Adrenergic Receptor	Human	Binding	GPCR
Beta 2 Adrenergic Receptor	Human	Binding	GPCR
Androgen Receptor	Human	Binding	Nuclear Hormone Receptor
Angiotensin 1 Receptor	Human	Binding	GPCR
Bradykinin 2 Receptor	Human	Binding	GPCR

Cav1.2 (L-type Diltizem) Calcium Channel	Rat	Binding	Ion Channel
Cav1.2 (L-type Dihydropyridine) Calcium Channel	Rat	Binding	Ion Channel
Cav1.2 (L-type Verpamil) Calcium Channel	Rat	Binding	Ion Channel
Cav2.2 (N-type) Calcium Channel	Rat	Binding	Ion Channel
Cannabinoid 1	Human	Binding	GPCR
Cannabinoid 2	Human	Binding	GPCR
Chemokine Receptor 1	Human	Binding	GPCR
Cholecystokinin 1 Receptor	Human	Binding	GPCR
Cholecystokinin 2 Receptor	Human	Binding	GPCR
Dopamine 1 Receptor	Human	Binding	GPCR
Dopamine 2L Receptor	Human	Binding	GPCR
Dopamine 2L Receptor	Human	Binding	GPCR
Dopamine Transporter	Human	Binding	Transporter
Endothelial Receptor A	Human	Binding	GPCR
Estrogen Receptor Alpha	Human	Binding	Nuclear Hormone Receptor
GABA (nonselective) Transporter	Rat	Binding	Transporter
GABA A (nonselective) Flunitrazepam	Rat	Binding	Ion Channel
GABA A (nonselective) Ro-15-1788	Rat	Binding	Ion Channel
GABA A (nonselective) TBOB	Rat	Binding	Ion Channel
GABA B Receptor B1a/B2	Human	Binding	GCPR

Glucocorticoid Receptor	Human	Binding	Nuclear Hormone Receptor
Glutamate AMPA (nonselective)	Rat	Binding	Ion Channel
Glutamate Kainate (nonselective)	Rat	Binding	Ion Channel
Glutamate NMDA (nonselective) MDL 105,519	Rat	Binding	Ion Channel
Glutamate NMDA (nonselective) TCP	Rat	Binding	Ion Channel
Glutamate NMDA (nonselective) Ifenprodil	Rat	Binding	Ion Channel
Metabotropic glutamate Receptor 5	Human	Binding	GPCR
Glycine (nonselective) Strychine	Rat	Binding	Ion Channel
Histamine Receptor 1	Human	Binding	GPCR
Histamine Receptor 2	Human	Binding	GPCR
CXC Receptor 2	Human	Binding	GPCR
Cys Leukotriene Receptor 1	Human	Binding	GPCR
Melanocortin Receptor 1	Human	Binding	GPCR
Melanocortin Receptor 4	Human	Binding	GPCR
Muscarinic Receptor 1	Human	Binding	GPCR
Muscarinic Receptor 2	Human	Binding	GPCR
Muscarinic Receptor 3	Human	Binding	GPCR
Muscarinic Receptor 4	Human	Binding	GPCR
Neurokinin 1 Receptor	Human	Binding	GPCR
Neuropeptide Y Receptor	Human	Binding	GPCR
N Acetylcholine Receptor Alpha 1	Human	Binding	Ion Channel
N Acetylcholine Receptor Alpha 3/Beta4	Human	Binding	Ion Channel

Delta Opioid Receptor	Human	Binding	GPCR
Kappa Opioid Receptor	Human	Binding	GPCR
Mu-Opioid Receptor	Human	Binding	GPCR
Potassium ATP Receptor	Hamster	Binding	Ion Channel
hERG Potassium Channel Dofetilide	Human	Binding	Ion Channel
Peroxisomes proliferator Receptor (agonist)	Human	Binding	Nuclear Hormone Receptor
Serotonin 1A Receptor (Antagonist)	Human	Binding	GPCR
Serotonin 2A Receptor (Agonist)	Human	Binding	GPCR
Serotonin 2B Receptor (Antagonist)	Human	Binding	GPCR
Serotonin 2C Receptor (Antagonist)	Human	Binding	GPCR
Serotonin 3 Receptor (Antagonist)	Human	Binding	Ion Channel
Serotonin Transporter	Human	Binding	Transporter
Sodium (Nav1.5) Channel Site 2	Human	Binding	Ion Channel
Vasopressin 1A Receptor Oxytocin	Human	Binding	GPCR
Progesterone Receptor	Human	Binding	Nuclear Hormone Receptor
Platelet Activating Factor (agonist)	Human	Binding	GPCR

Heterobifunctional degraders can, in some cases, induce the degradation of off-target proteins. For heterobifunctional degraders that utilize CRBN, common off-target proteins that can be degraded include GSPT1, IKZF1, IKZF2, IKZF3, and/or CK1 α . This degradation is generally believed to be due to the E3 binding moiety of the heterobifunctional degrader facilitating ternary complex formation between the off-target protein and CRBN. GSPT1 is a translation termination factor, and CK1 α is a kinase that is involved in many key cellular

processes including cell cycle progression and chromosome segregation; these are both commonly essential genes, so undesired degradation of either or both may lead to nonspecific cytotoxicity. The IKZF proteins are zinc finger transcription factors that are involved with cell fate during hematopoiesis, and degradation of these proteins has been associated with hematotoxicity. See, e.g., Moreau, Kevin, et al. *British Journal of Pharmacology* 177.8 (2020): 1709-1718, doi: 10.1111/bph.15014.

In some embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, can exhibit potent and selective induction of degradation of a BCL-X_L protein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, can selectively target a BCL-X_L protein for degradation over an off-target protein, such as another BCL-2 family member (e.g., BCL-2 and/or MCL-1) or non-BCL-2 family member target (e.g., GSPT1, IKZF1, IKZF2, IKZF3, and/or CK1 α).

As used herein, “selective” or “selectively”, when referring to a compound provided herein, or a pharmaceutically acceptable salt thereof in a protein degradation assay, indicates at least a 5-fold (e.g., at least a 10-fold, at least a 25-fold, at least a 50-fold, or at least a 100-fold) superior performance in the protein degradation assay for a specified protein with reference to a comparator protein in the assay. In some embodiments, the specified protein is BCL-X_L protein and the comparator is BCL-2 protein. For example, if a compound provided herein, or a pharmaceutically acceptable salt thereof, “selectively” induces degradation of BCL-X_L protein over BCL-2 protein as determined by a degradation assay, then the compound has at least a 5-fold (e.g., at least a 10-fold, at least a 25-fold, at least a 50-fold, or at least a 100-fold) smaller DC₅₀ value for BCL-X_L protein than for the BCL-2 protein when measured by the degradation assay.

In some embodiments, the compounds provided herein can exhibit potency (e.g., nanomolar potency) against a BCL-X_L protein with minimal activity (e.g., micromolar potency) against BCL-2 family members (e.g., BCL-2 or MCL-1 proteins). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit potent degradation of a BCL-X_L protein and have minimal potency in degrading (e.g., as measured by Y_{min}, DC₅₀, EC₅₀, and/or D_{max} values) an off-target protein (e.g., a BCL-2 family member (e.g., BCL-2 and/or MCL-1), GSPT1, IKZF1, IKZF2, IKZF3 and/or CK1 α). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit greater induction of degradation of a BCL-X_L protein relative to induction

of degradation (e.g., as measured by $Y_{\min}$, DC_{50} , EC_{50} , and/or $D_{\max}$ values) of an off-target protein (e.g., a BCL-2 family member (e.g., BCL-2 and/or MCL-1), GSPT1, IKZF1, IKZF2, IKZF3, and/or CK1 α). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit at least 2-fold, 3-fold, 5-fold, 10-fold, 25-fold, 50-fold, or 100-fold greater induction of degradation of a BCL-X_L protein relative to induction of degradation of an off-target protein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit up to 1000-fold greater induction of degradation of a BCL-X_L protein relative to induction of degradation of an off-target protein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit from about 2-fold to about 10-fold greater induction of degradation of a BCL-X_L protein relative to induction of degradation of an off-target protein (e.g., GSPT1, IKZF1, IKZF2, and/or IKZF3 and/or CK1 α) (e.g., as measured by $Y_{\min}$, DC_{50} , EC_{50} , and/or $D_{\max}$ values). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit from about 10-fold to about 100-fold greater induction of degradation of a BCL-X_L protein relative to induction of degradation of an off-target protein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit from about 100-fold to about 1000-fold greater induction of degradation of a BCL-X_L protein relative to induction of degradation of an off-target protein. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can exhibit from about 1000-fold to about 10000-fold greater induction of degradation of a BCL-X_L protein relative to induction of degradation of an off-target protein.

Certain agents that inhibit or induce degradation of BCL-X_L have demonstrated platelet toxicity, which resulted in dose-limiting toxicity (e.g., thrombocytopenia) in the clinic. See, e.g., Adams and Cory, *Cell Death & Differentiation* 25.1 (2018): 27-36, doi: 10.1038/cdd.2017.161; Campbell and Tait. *Open Biology* 8.5 (2018): 180002, doi: 10.1098/rsob.180002; Pullarkat et al., *Cancer Discovery* (2021), doi:10.1158/2159-8290.CD-20-1465; Negi and Voisin-Chiret. *ChemBioChem* (2022), doi: 10.1002/cbic.202100689. The viability of platelets may be monitored with any appropriate assay, such as those described herein. See, for instance, **Example B4**.

In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to

administration of the compound provided herein, or a pharmaceutically acceptable salt thereof). In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in about 30% to about 100% platelet viability (e.g., about 50% to about 100% platelet viability, or about 80% to about 100% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof).

In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 50% to about 70% for a BCL-X_L protein. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of less than about 50% for a BCL-X_L protein. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 0% to about 50% for a BCL-X_L protein.

In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in between about 30% and 100% platelet viability (e.g., about 50% to about 100% platelet viability, or about 80% to about 100% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 50% to about 70% for a BCL-X_L protein.

In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in between about 30% and 100% platelet viability (e.g., about 50% to about 100% platelet viability, or about 80% to about 100% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject

prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of less than about 50% for a BCL-X_L protein. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in between about 30% and 100% platelet viability (e.g., about 50% to about 100% platelet viability, or about 80% to about 100% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 0% to about 50% for a BCL-X_L protein.

In some embodiments, therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in at least about 50% platelet viability (e.g., at least about 80% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 50% to about 70% for a BCL-X_L protein. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in at least about 50% platelet viability (e.g., at least about 80% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of less than about 50% for a BCL-X_L protein. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in at least about 50% platelet viability (e.g., at least about 80% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 0% to about 50% for a BCL-X_L protein.

In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in between about 50% and 100% platelet viability (e.g., about 80% to about 100% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 50% to about 70% for a BCL-X_L protein. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in between about 50% and 100% platelet viability (e.g., about 80% to about 100% platelet viability) when administered to a subject (e.g., compared to the platelet count of the

subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of less than about 50% for a BCL-X_L protein. In some embodiments, a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, results in between about 50% and 100% platelet viability (e.g., about 80% to about 100% platelet viability) when administered to a subject (e.g., compared to the platelet count of the subject prior to administration of the compound provided herein, or a pharmaceutically acceptable salt thereof) and has a $Y_{\min}$ value of about 0% to about 50% for a BCL-X_L protein.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μ M to about 3 μ M in the assay in **Example B4**, shows at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability). In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μ M to about 3 μ M in the assay in **Example B4**, shows about 30% to about 100% platelet viability (e.g., about 50% to about 100% platelet viability, or about 80% to about 100% platelet viability).

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μ M to about 3 μ M in the assay in **Example B4**, shows at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability) and has a $Y_{\min}$ value of about 50% to about 70% in the assay described in **Example B1**. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μ M to about 3 μ M in the assay in **Example B4**, shows at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability) and has a $Y_{\min}$ value of less than about 50% in the assay described in **Example B1**. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μ M to about 3 μ M in the assay in **Example B4**, shows at least about 30% platelet viability (e.g., at least about 50% platelet viability, or at least about 80% platelet viability) and has a $Y_{\min}$ value of about 0% to about 50% in the assay described in **Example B1**.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μ M to about 3 μ M in the assay in **Example B4**, shows between about 30% and 100% platelet viability (e.g., about 50% to about

100% platelet viability, or about 80% to about 100% platelet viability) and has a $Y_{\min}$ value of about 50% to about 70% in the assay described in **Example B1**. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to about 3 μM in the assay in **Example B4**, shows between
5 about 30% and 100% platelet viability (e.g., about 50% to about 100% platelet viability, or about 80% to about 100% platelet viability) and has a $Y_{\min}$ value of less than about 50% in the assay described in **Example B1**. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to about 3 μM in the assay in **Example B4**, shows between about 30% and 100% platelet viability
10 (e.g., about 50% to about 100% platelet viability, or about 80% to about 100% platelet viability) and has a $Y_{\min}$ value of about 0% to about 50% in the assay described in **Example B1**.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to about 3 μM in the assay in **Example B4**, shows at least about 50% platelet viability (e.g., at least about 80% platelet
15 viability) and has a $Y_{\min}$ value of about 50% to about 70% in the assay described in **Example B1**. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to about 3 μM in the assay in **Example B4**, shows at least about 50% platelet viability (e.g., at least about 80% platelet viability) and has a $Y_{\min}$ value of less than about 50% in the assay described in **Example B1**. In some
20 embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to about 3 μM in the assay in **Example B4**, shows at least about 50% platelet viability (e.g., at least about 80% platelet viability) and has a $Y_{\min}$ value of about 0% to about 50% in the assay described in **Example B1**.

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to about 3 μM in the assay in **Example B4**, shows between about 50% and 100% platelet viability (e.g., about 80% to about
25 100% platelet viability) and has a $Y_{\min}$ value of about 50% to about 70% in the assay described in **Example B1**. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to about 3 μM in the
30 assay in **Example B4**, shows between about 50% and 100% platelet viability (e.g., about 80% to about 100% platelet viability) and has a $Y_{\min}$ value of less than about 50% in the assay described in **Example B1**. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, when tested at a concentration of about 0.25 μM to

about 3 μ M in the assay in **Example B4**, shows between about 50% and 100% platelet viability (e.g., about 80% to about 100% platelet viability) and has a $Y_{\min}$ value of about 0% to about 50% in the assay described in **Example B1**.

5 Provided herein is a method of treating a cancer in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, the subject is treatment naïve with respect to the cancer. In some embodiments, the subject has received one or more lines of previous therapy for the cancer.

10 Also provided herein is a method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a monotherapy. In some embodiments, the subject is treatment naïve with respect to the cancer. In some embodiments, the subject has received one or more lines of
15 previous therapy for the cancer.

 Provided herein is a method of treating a cancer in a subject in need of such treatment, the method comprising:

- 20 (a) detecting a biomarker (e.g., a mutation, an amplification, a copy number increase, and/or expression (optionally including level of expression) of the biomarker) associated with the cancer; and
- (b) administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a monotherapy or in combination with an additional therapy or therapeutic agent.

25 Also provided herein is a method of treating a cancer in a subject, wherein the subject has been determined (e.g., prior to administration of a compound provided herein) to have a biomarker (e.g., a mutation, an amplification, a copy number increase, and/or expression (optionally including level of expression) of the biomarker) associated with the cancer, the method comprising administering to the subject a therapeutically effective amount of a
30 compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a monotherapy or in combination with an additional therapy or therapeutic agent.

 Provided herein is a method of treating a cancer in a subject in need of such treatment,

the method comprising:

- (a) detecting a biomarker (e.g., a mutation, an amplification, a copy number increase, and/or expression (optionally including level of expression) of a marker of susceptibility to particular agents (e.g., HER2 expression, ER expression, PR expression, folate receptor expression)) associated with the cancer; and
- (b) administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a monotherapy or in combination with an additional therapy or therapeutic agent.

Also provided herein is a method of treating a cancer in a subject, wherein the subject has been determined (e.g., prior to administration of a compound provided herein) to have a biomarker (e.g., a mutation, an amplification, a copy number increase, and/or expression (optionally including level of expression) of a marker of susceptibility to particular agents (e.g., HER2 expression, ER expression, PR expression, folate receptor expression)) associated with the cancer, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a monotherapy or in combination with an additional therapy or therapeutic agent.

Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the treatment of cancer, for example, any of the cancers provided herein.

Provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in the treatment of cancer, for example, any of the cancers provided herein.

Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a medicament for the treatment of cancer, for example, any of the cancers provided herein.

Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer, for example, any of the cancers provided herein.

Provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use as a medicament. Also provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a

pharmaceutical composition thereof, for use as a medicament for the treatment of cancer, for example, any of the cancers provided herein.

5 Provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in treating a cancer, for example, any of the cancers provided herein.

As used herein, “monotherapy”, when referring to a compound provided herein, or a pharmaceutically acceptable salt thereof, means that the compound provided herein, or a pharmaceutically acceptable salt thereof, is the only therapeutic agent or therapy (e.g., anticancer agent or therapy) administered to the subject during the treatment cycle (e.g., no additional targeted therapeutics, anticancer agents, chemotherapeutics, or checkpoint inhibitors are administered to the subject during the treatment cycle). As a person of ordinary skill in the art would understand, monotherapy does not exclude the co-administration of medicaments (sometimes also called supportive care measures) for the treatment of side effects or general symptoms associated with the cancer or treatment, such as pain, rash, edema, photosensitivity, pruritis, skin discoloration, hair brittleness, hair loss, brittle nails, cracked nails, discolored nails, swollen cuticles, fatigue, weight loss, general malaise, shortness of breath, infection, thrombocytopenia, neutropenia, anemia, or gastrointestinal symptoms, including nausea, diarrhea, and lack of appetite.

For example, in some embodiments, the supportive care measure can be granulocyte colony stimulating factor (G-CSF), a thrombopoietin receptor (TpoR) agonist, or a steroid.

In some embodiments, the TpoR agonist is avatrombopag (e.g., avatrombopag maleate), eltrombopag (e.g., eltrombopag olamine), lusutrombopag, megapoeitin (KRN-9000), pegacaristim, rafutrombopag (e.g., rafutrombopag olamine), recombinant human thrombopoietin, romiplostim, totrombopag (e.g., totrombopag choline), or a combination thereof.

As used herein, “the subject has previously received one or more therapeutic agents or therapies for the cancer” means that the subject has been previously administered one or more therapeutic agents or therapies (e.g., anticancer agent or therapy) for the cancer other than a compound provided herein, or a pharmaceutically acceptable salt thereof, during a prior treatment cycle. In some embodiments, the subject cannot tolerate the one or more therapeutic agents or therapies previously administered for the cancer. In some embodiments, the subject did not respond to the one or more therapeutic agents or therapies previously administered for the cancer. In some embodiments, the subject did not adequately respond to one or more

therapeutic agents or therapies previously administered for the cancer. In some embodiments, the subject has stopped responding to the one or more therapeutic agents or therapies previously administered for the cancer. In some embodiments, a lack of response, an inadequate response, or a discontinued response can be determined by objective criteria (e.g., tumor volume, or by
5 criteria such as RECIST 1.1, the Lugano 2014 criteria (Cheson, Bruce D., et al. *Journal of Clinical Oncology* 32.27 (2014): 3059-3067; doi: 10.1200/JCO.2013.54.8800) or the Global Response Criteria (Olsen, Elise A., et al. *Blood, The Journal of the American Society of Hematology* 140.5 (2022): 419-437; doi: 10.1182/blood.2021012057)). In some embodiments, a lack of response, an inadequate response, or a discontinued response can be determined by
10 the subject's physician.

As used herein, "the subject is treatment naïve with respect to the cancer" means that the subject has not been previously administered one or more therapeutic agents or therapies for the cancer.

For any of the solid tumors described herein, the solid tumor can be primary tumors or
15 metastatic (or secondary) tumors. As used herein, "primary" tumors are those located at the site where the tumor began to grow (i.e., where it originated). As used herein, "metastatic" (or "secondary") tumors are those that have spread to other parts of body from the original tumor site. In some embodiments, the metastatic or secondary tumors are the same type of cancer as the primary tumor. In some embodiments, the metastatic or secondary tumors
20 are not genetically identical to the primary tumor.

In some embodiments of any of the methods or uses described herein, the cancer is breast cancer (e.g., breast invasive carcinoma, breast invasive ductal carcinoma), central or peripheral nervous system tissue cancer (e.g., brain cancer (e.g., astrocytoma, glioblastoma, glioma, oligoastrocytoma)), endocrine or neuroendocrine cancer (e.g., adrenal cancer (e.g.,
25 adrenocortical carcinoma, neuroblastoma, pheochromocytoma, paraganglioma), multiple neuroendocrine type I and type II tumors, parathyroid cancer, pituitary tumors, thyroid cancer (e.g., papillary thyroid cancer)), eye cancer (e.g., uveal cancer (e.g., uveal melanoma)), gastrointestinal cancer (e.g., anal cancer, bile duct cancer (e.g., cholangiocarcinoma (e.g., intrahepatic cholangiocarcinoma)), colorectal cancer (e.g., colon adenocarcinoma, rectal
30 adenocarcinoma, mucinous adenocarcinoma, mucinous carcinoma), esophageal cancer (e.g., esophageal adenocarcinoma), gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), liver cancer (e.g., hepatocellular carcinoma, intrahepatic bile duct cancer), pancreatic cancer (e.g., pancreatic adenocarcinoma, pancreatic islet cell

cancer), small intestine cancer, or stomach cancer (e.g., stomach adenocarcinoma, signet ring cell carcinoma of the stomach)), genitourinary cancer (e.g., bladder cancer (e.g., bladder urothelial carcinoma), kidney cancer (e.g., renal clear cell carcinoma, renal papillary cell carcinoma, kidney chromophobe), prostate cancer (e.g., prostate adenocarcinoma), testicular cancer (e.g., testicular germ cell tumors), or ureter cancer), gynecologic cancer (e.g., cervical cancer (e.g., cervical squamous cell carcinoma, endocervical adenocarcinoma, mucinous carcinoma), ovarian cancer (e.g., serous ovarian cancer, ovarian serous cystadenocarcinoma), uterine cancer (e.g., uterine carcinosarcoma, uterine endometrioid carcinoma, uterine serous carcinoma, uterine papillary serous carcinoma, uterine corpus endometrial carcinoma), or vulvar cancer), head and neck cancer (e.g., ear cancer (e.g., middle ear cancer), head and neck squamous cell carcinoma, nasal cavity cancer, oral cancer, pharynx cancer (e.g., hypopharynx cancer, nasopharynx cancer, oropharyngeal cancer), hematological cancer (e.g., leukemia (e.g., chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), chronic neutrophilic leukemia (CNL), acute lymphocytic leukemia (ALL) (e.g., Philadelphia chromosome positive ALL or T cell ALL (T-ALL)), acute myeloid leukemia (AML) (e.g., acute promyelocytic leukemia (APL), post-MPN AML, post-myelodysplastic syndrome (post-MDS) AML, M6-AML (also known as pure erythroid leukemia (PEL)), or M7-AML (also known as acute megakaryoblastic leukemia (AKML))), chronic myeloid leukemia (CML)), lymphoma (e.g., Hodgkin lymphoma (e.g., nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)), or non-Hodgkin lymphoma (e.g., Burkitt lymphoma (BL), diffuse large B cell lymphoma (DLBCL), diffuse histiocytic lymphoma (DHL), follicular lymphoma (FL), intravascular large B cell lymphoma (IVLBCL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), a T cell lymphoma (e.g., anaplastic large T cell lymphoma, cutaneous T cell lymphoma, or peripheral T cell lymphoma))), essential thrombocythemia, polycythemia vera, myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis), a myelodysplastic syndrome (MDS) (e.g., M6 MDS or M7 MDS), or myeloma (e.g., multiple myeloma)), Li-Fraumeni tumors, mesentery cancer (e.g., omentum cancer, peritoneal cancer), pleural cancer, respiratory cancer (e.g., larynx cancer, lung cancer (e.g., lung squamous cell carcinoma, lung adenocarcinoma, malignant pleural mesothelioma, non-small cell lung cancer (NSCLC), small cell lung cancer), tracheal cancer), sarcoma (e.g., bone cancer (e.g., osteosarcoma, chondrosarcoma) or soft tissue sarcoma (Ewing sarcoma, leiomyosarcoma, myxofibrosarcoma, rhabdomyosarcoma)), skin cancer (e.g., melanoma or Merkel cell carcinoma), thymus cancer

(e.g., thymoma), or a combination thereof.

In some embodiments, the cancer is breast cancer, gastrointestinal cancer (e.g., bile duct cancer (e.g., cholangiocarcinoma (e.g., intrahepatic cholangiocarcinoma)), colorectal cancer (CRC), gastrointestinal stromal tumor, or pancreatic cancer), genitourinary cancer (e.g., bladder cancer (e.g., bladder urothelial carcinoma) or kidney cancer), gynecologic cancer (e.g., cervical cancer, ovarian cancer (e.g., high grade serous ovarian cancer (HGSOC), low grade serous ovarian cancer (LGSOC)), or uterine cancer), head and neck cancer (e.g., head and neck squamous cell carcinoma), hematological cancer (e.g., leukemia (e.g., acute lymphocytic leukemia (ALL) (e.g., T-ALL), acute myeloid leukemia (AML) (e.g., APL, post-MPN AML, post-MDS AML, M6-AML, or M7-AML), chronic lymphocytic leukemia (CLL)), lymphoma (e.g., follicular lymphoma (FL), small lymphocytic lymphoma (SLL), a T cell lymphoma (e.g., anaplastic large T cell lymphoma, cutaneous T cell lymphoma, or peripheral T cell lymphoma), or diffuse large B cell lymphoma (DLBCL)), essential thrombocythemia, polycythemia vera, myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis), or a myelodysplastic syndrome (MDS) (e.g., M6 MDS or M7 MDS)), lung cancer (e.g., non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), lung squamous cell carcinoma, or malignant pleural mesothelioma (MPM)), neuroblastoma, sarcoma (e.g., bone cancer (e.g., osteosarcoma, chondrosarcoma) or soft tissue sarcoma (Ewing sarcoma, leiomyosarcoma, myxofibrosarcoma, rhabdomyosarcoma)), or skin cancer (e.g., melanoma or Merkel cell carcinoma).

In some embodiments, the cancer is a myeloproliferative neoplasm (MPN). In some embodiments, the myeloproliferative neoplasm is CEL, CML, CNL, essential thrombocythemia, polycythemia vera, or myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis). In some embodiments, the MPN has a JAK2 mutation (e.g., a JAK2 V617F mutation). In some embodiments, the MPN does not have a JAK2 mutation. In some embodiments, the cancer is low-risk myelofibrosis. In some embodiments, the cancer is intermediate (e.g., intermediate-1 and/or intermediate-2) or high-risk myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis). In some embodiments, the cancer is intermediate or high-risk myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis) with a JAK2 mutation (e.g., a JAK2 V617F mutation). In some embodiments, the cancer is intermediate or high-risk myelofibrosis (e.g., primary myelofibrosis, post-

essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis) without a JAK2 V617F mutation. In some embodiments, the subject has a platelet count below $50 \times 10^9/L$.

5 In some embodiments, the cancer is polycythemia vera. In some embodiments, the cancer is polycythemia vera, and the subject has had an inadequate response to or is intolerant of hydroxyurea.

In some embodiments, the cancer is an MDS. In some embodiments, the cancer is M6 MDS. In some embodiments, the cancer is M7 MDS.

10 In some embodiments, the cancer is T-ALL. In some embodiments, the cancer is relapsed/refractory T-ALL.

In some embodiments, the cancer is CRC (e.g., Braf mutant CRC (e.g., Braf V600E CRC) or KRas mutant CRC (e.g., KRas G12C CRC or KRas G12D CRC)).

In some embodiments, the cancer is SCLC (e.g., ASCL1 subtype SCLC or NEUROD1 subtype SCLC).

15 In some embodiments, the cancer is NSCLC (e.g., Braf mutant NSCLC (e.g., Braf V600E NSCLC), EGFR mutant NSCLC (e.g., EGFR L858R NSCLC or EGFR exon 19 deletion NSCLC), MET mutant NSCLC (e.g., MET exon 14 deletion NSCLC, MET amplified NSCLC), KRas mutant NSCLC (e.g., KRas G12C NSCLC)).

In some embodiments, the cancer is lung squamous cell carcinoma.

20 In some embodiments, the cancer is malignant pleural mesothelioma (e.g., BAP1 mutant malignant pleural mesothelioma). In some embodiments, the cancer is malignant pleural mesothelioma, and a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered as a monotherapy.

25 In some embodiments, the cancer is melanoma (e.g., Braf mutant melanoma (e.g., Braf V600E melanoma)).

30 In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), HER2 low breast cancer, triple negative breast cancer, hormone receptor positive breast cancer (ER+ and/or PR+, with or without HER2 positivity)).

In some embodiments, the cancer is lymphoma. In some embodiments, the lymphoma is a T cell lymphoma (e.g., anaplastic large T cell lymphoma, cutaneous T cell lymphoma, or

peripheral T cell lymphoma). In some embodiments, the lymphoma is a non-Hodgkin lymphoma (e.g., DLBCL, anaplastic large T cell lymphoma, cutaneous T cell lymphoma, or peripheral T cell lymphoma). In some embodiments, the lymphoma is peripheral T cell lymphoma.

5 In some embodiments, the cancer is leukemia. In some embodiments, the leukemia is a T cell leukemia (e.g., T cell ALL). In some embodiments, the cancer is post-MPN leukemia. In some embodiments, the cancer is a T cell leukemia (e.g., T cell ALL), and a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered as a monotherapy.

10 In some embodiments, the cancer is M6-AML. In some embodiments, the M6-AML is a post-MPN AML. In some embodiments, the M6-AML is a post-myelodysplastic syndrome (MDS) AML. In some embodiments, the cancer is M6-AML, and the compound provided herein, or pharmaceutically acceptable salt thereof, is administered as a monotherapy.

15 In some embodiments, the cancer is M7-AML. In some embodiments, the M7-AML is a post-MPN AML. In some embodiments, the M7-AML is a post-MDS AML. In some embodiments, the cancer is M7-AML, and the compound provided herein, or pharmaceutically acceptable salt thereof, is administered as a monotherapy.

In some embodiments, the cancer is head and neck cancer.

In some embodiments, the cancer is essential thrombocythemia.

20 In some embodiments, the cancer is polycythemia vera.

In some embodiments, the cancer is myelofibrosis. In some embodiments, the cancer is primary myelofibrosis. In some embodiments, the cancer is post-essential thrombocythemia myelofibrosis. In some embodiments, the cancer is post-polycythemia vera myelofibrosis.

25 In some embodiments, the cancer is an MDS. In some embodiments, the MDS is M6 MDS. In some embodiments, the MDS is M7 MDS. In some embodiments, the cancer is an MDS, and a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered as a monotherapy.

In some embodiments, the cancer is pancreatic cancer.

In some embodiments, the cancer is bladder cancer (e.g., bladder urothelial carcinoma).

30 In some embodiments, the cancer is ovarian cancer (e.g., BRCA1 mutant ovarian cancer or BRCA2 mutant ovarian cancer). In some embodiments, the cancer is HGSOE (e.g., BRCA1 mutant HGSOE or BRCA2 mutant HGSOE).

In some embodiments, the cancer is cervical cancer.

In some embodiments, the cancer is colorectal cancer.

In some embodiments, the cancer is skin cancer. In some embodiments, the skin cancer is melanoma. In some embodiments, the cancer is Merkel cell carcinoma. In some embodiments, the cancer is Merkel cell carcinoma, and a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered as a monotherapy.

In some embodiments, the cancer is neuroblastoma.

In some embodiments, the cancer is intrahepatic cholangiocarcinoma.

In some embodiments, the cancer is a mesenchymal cancer. In some embodiments, the mesenchymal cancer is mesenchymal breast cancer or mesenchymal kidney cancer.

In some embodiments, a BCL-X_L copy number gain or a BCL-X_L amplification can be detected in a sample from the subject (e.g., detecting three or more copies of a *BCL2L1* gene in the sample from the subject). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having a BCL-X_L copy number gain or a BCL-X_L amplification.

In some embodiments, the cancer has a BCL-X_L copy number gain.

In some embodiments, the cancer has a BCL-X_L amplification.

Non-limiting examples of BCL-X_L involvement in cancers can be found in: Wilson, Wyndham H., et al. *The Lancet Oncology* 11.12 (2010): 1149-1159, doi: 10.1016/S1470-2045(10)70261-8; Keitel, Ulrike, et al. *Oncotarget* 5.23 (2014): 11778, doi: 10.18632/oncotarget.2634; Chonghaile, Triona Ni, et al. *Cancer Discovery* 4.9 (2014): 1074-1087, doi: 10.1158/2159-8290.CD-14-0353; Zaanani, Aziz, et al. *Journal of Biological Chemistry* 290.39 (2015): 23838-23849, doi: 10.1074/jbc.M115.657833; Zhang, Haichao, et al. *Molecular Cancer* 14.1 (2015): 1-9, doi: 10.1186/s12943-015-0397-y; Soderquist, Ryan S., et al. *Nature Communications* 9.1 (2018): 1-13, doi: 10.1038/s41467-018-05815-z; Stover, Elizabeth H., et al. *Molecular Cancer Research* 17.11 (2019): 2281-2293, doi: 10.1158/1541-7786.MCR-18-1243; Concoran, R.B., et al. *Annals of Oncology* (2019) 30 (suppl_5): v164, doi: 10.1093/annonc/mdz244.009; Lakhani, Nehal J., et al. *Journal of Clinical Oncology* (2020): 3509-3509, doi: 10.1200/JCO.2020.38; He, Yonghan, et al. *Journal of Hematology & Oncology* 13.1 (2020): 1-13, doi: 10.1186/s13045-020-00928-9; Grubb, Treg, et al. *Clinical Cancer Research* (2022), doi: 10.1158/1078-0432.CCR-22-0669; Joly, Florence, et al. *Gynecologic Oncology* 165.1 (2022): 30-39, doi: 10.1016/j.ygyno.2022.01.021; and Nanjo, Shigeki, et al. *The Journal of Clinical Investigation* (2022), doi: 10.1172/JCI145099.

In some embodiments, the subject has previously been treated with another anticancer

agent, a chemotherapeutic agent, radiation, surgery, a multi-kinase inhibitor, or a combination thereof.

5 Provided herein is a method of treating an ocular disease or condition in a subject in need of such treatment, the method comprising administering (e.g., intravitreally or topically) to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In some embodiments, the ocular disease or condition is diabetic macular edema. In some embodiments, the ocular disease or condition is age-related macular degeneration. In some embodiments, the ocular disease or condition is diabetic retinopathy. See, e.g., Crespo-Garcia, Sergio, et al. *Cell Metabolism* 33.4 (2021): 818-832, doi: 10.1016/j.cmet.2021.01.011; Hassan, Jannah Waled, and Ashay D. Bhatwadekar, *Frontiers in Pharmacology* 13 (2022): 896907, doi: 10.3389/fphar.2022.896907.

15 Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the treatment of an ocular disease or condition, for example, any of the ocular diseases or conditions provided herein.

Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a medicament for the treatment of an ocular disease or condition, for example, any of the ocular diseases or conditions provided herein.

20 Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an ocular disease or condition, for example, any of the ocular diseases or conditions provided herein.

Also provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use as a medicament for the treatment of an ocular disease or condition, for example, any of the ocular diseases or conditions provided herein.

25 Provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in treating an ocular disease or condition, for example, any of the ocular diseases or conditions provided herein.

30 Also provided herein is a method of treating a fibrotic disease or condition and/or a disease or condition associated with senescent cells in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical

composition thereof. Non-limiting examples of fibrotic diseases or conditions and/or diseases or conditions associated with senescent cells include pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis, systemic fibrosis-associated lung disease, radiation-associated pulmonary fibrosis), radiation-associated skin fibrosis, liver fibrosis, primary sclerosing cholangitis, diabetic macular edema, age-related macular degeneration, diabetic retinopathy, geographic atrophy, ischemia and reperfusion injury, heart failure, recovery from acute myocardial infarction, pulmonary hypertension, inflammatory bowel disease, colitis, Crohn's disease, diabetes, aging skin (including photoaging-related pigmentation), donor organ transplant survival and function, stem cell transplant survival and function, osteoarthritis, recovery from spinal cord injury, Alzheimer's disease, tauopathies, progressive supranuclear palsy, and age-related neurological decline (e.g., related to impaired neurovascular coupling). See, e.g., Zhu, Y. I., et al. *Aging Cell* 14.4 (2015): 644-658, doi: 10.1111/accel.12344; Zhu, Y. I., et al. *Aging Cell* 15.3 (2016): 428-435, doi: 10.1111/accel.12445; Chang, Jianhui, et al. *Nature Medicine* 22.1 (2016): 78-83, doi: 10.1038/nm.4010; Zhu, Yi, et al. *Aging (Albany NY)* 9.3 (2017): 955, doi: 10.18632/aging.101202; Lagares, David, et al. *Science Translational Medicine* 9.420 (2017): eaal3765, doi: 10.1126/scitranslmed.aal3765; Pan, Jin, et al. *International Journal of Radiation Oncology Biology Physics* 99.2 (2017): 353-361, doi: 10.1016/j.ijrobp.2017.02.216; Bussian, Tyler J., et al. *Nature* 562.7728 (2018): 578-582, doi: 10.1038/s41586-018-0543-y; Moncsek, Anja, et al. *Hepatology* 67.1 (2018): 247-259, doi: 10.1002/hep.29464; van Willigenburg, Hester, Peter LJ de Keizer, and Ron WF de Bruin. *Pharmacological Research* 130 (2018): 322-330, doi: 10.1016/j.phrs.2018.02.015; Walaszczyk, Anna, et al. *Aging Cell* 18.3 (2019): e12945, doi: 10.1111/accel.12945; Aguayo-Mazzucato, Cristina, et al. *Cell Metabolism* 30.1 (2019): 129-142, doi: 10.1016/j.cmet.2019.05.006; Sessions, Garrett A., et al. *The FASEB Journal* 33.11 (2019): 12364, doi: 10.1096/fj.201900815RR; Gerdes, Erin O. Wissler, et al. *International Review of Neurobiology* 155 (2020): 203-234, doi: 10.1016/bs.irn.2020.03.019; Sasaki, Motoko, Yasunori Sato, and Yasuni Nakanuma. *Journal of Autoimmunity* 107 (2020): 102377, doi: 10.1016/j.jaut.2019.102377; Yabluchanskiy, Andriy, et al. *Geroscience* 42 (2020): 409-428, doi: 10.1007/s11357-020-00154-8; Dookun, Emily, et al. *Aging Cell* 19.10 (2020): e13249, doi: 10.1111/accel.13249; Jia, Kangni, et al. *Journal of Cardiovascular Pharmacology* 76.4 (2020): 452-460, doi: 10.1097/FJC.0000000000000878; Sierra-Ramirez, Arantzazu, et al. *Aging (Albany NY)* 12.12 (2020): 11337, doi: 10.18632/aging.103607; Yang, Hao, et al. *Aging (Albany NY)* 12.13 (2020): 12750, doi: 10.18632/aging.103177; Lawrie, Allan, and

Sheila E. Francis. *The Journal of Clinical Investigation* 131.11 (2021): e149721, doi: 10.1172/JCI149721; Paramos-de-Carvalho, Diogo, et al. *Cell Reports* 36.1 (2021): 109334, doi: 10.1016/j.celrep.2021.109334; Tarantini, Stefano, et al. *GeroScience* 43.5 (2021): 2427-2440, doi: 10.1007/s11357-021-00440-z; Park, Ji Hee, et al. *The British Journal of Dermatology* (2022) 186(4):740-742, doi: 10.1111/bjd.20893; Fielder, Edward, et al. *ELife* 11 (2022): e75492, doi: 10.7554/eLife.75492; Suzuki, Keiji, et al. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis* 876 (2022): 503448, doi: 10.1016/j.mrgentox.2022.503448; He, An, et al. *American Journal of Transplantation* 22.11 (2022): 2529-2547, doi: 10.1111/ajt.17154; Johnson, Laura A., et al. *Inflammatory Bowel Diseases* 28.2 (2022): 161-175, doi: 10.1093/ibd/izab166; Miura, Yugo, et al. *Stem Cell Research & Therapy* 13.1 (2022): 222, doi: 10.1186/s13287-022-02901-4; Cooley, Joseph C., et al. *JCI Insight* 8.3 (2023): e163762, doi: 10.1172/jci.insight.163762; Watanabe, Yusuke, et al. *Hepatology Research* 53 (2023): 460-472, doi: 10.1111/hepr.13879; and Takaya, Kento, et al., *Rejuvenation Research* 26.1 (2023): 9-20, doi: 10.1089/rej.2022.0048.

15 Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the treatment of a fibrotic disease or condition and/or a disease or condition associated with senescent cells, for example, any of the fibrotic diseases or conditions and/or diseases or conditions associated with senescent cells provided herein.

20 Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, as a medicament for the treatment of a fibrotic disease or condition and/or a disease or condition associated with senescent cells, for example, any of the fibrotic diseases or conditions and/or diseases or conditions associated with senescent cells provided herein.

25 Provided herein is use of a compound provided herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a fibrotic disease or condition and/or a disease or condition associated with senescent cells, for example, any of the fibrotic diseases or conditions and/or diseases or conditions associated with senescent cells provided herein.

30 Also provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use as a medicament for the treatment of a fibrotic disease or condition and/or a disease or condition associated with senescent cells, for example, any of the fibrotic diseases or conditions and/or diseases or conditions associated

with senescent cells provided herein.

Provided herein is a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for use in treating a fibrotic disease or condition and/or a disease or condition associated with senescent cells, for example, any of the fibrotic diseases or conditions and/or diseases or conditions associated with senescent cells provided herein.

Also provided is a method for modulating (e.g., decreasing) BCL-X_L protein activity in a cell, comprising contacting the cell with an effective compound provided herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the contacting is in vitro. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is in vivo, wherein the method comprises administering an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, to a subject. In some embodiments, the cell is a cancer cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a mammalian cancer cell. In some embodiments, the cancer cell is any cancer as described herein.

As used herein, the term “contacting” refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, “contacting” a cell with a compound provided herein includes the administration of a compound provided herein to the cell, in vitro or in vivo, including, for example, introducing a compound provided herein into a sample containing cells (e.g., grown in culture or derived from a patient), an organoid, or an organism (e.g., an animal (e.g., an animal bearing a tumor), or a human).

Also provided is a method of modulating (e.g., decreasing) the level of BCL-X_L protein in a cell, comprising contacting the cell with a compound provided herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the level of BCL-X_L protein is decreased by at least 30% (e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or at least 99%) compared to a cell not contacted with the compound provided herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the contacting is in vitro. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is in vivo, wherein the method comprises administering an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, to a subject having a cell having a BCL-X_L protein. In some embodiments, the cell is a cancer cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a mammalian cancer cell. In some embodiments, the cancer cell is any cancer as described

herein.

Also provided is a method of inducing ubiquitination of a BCL-X_L protein in a cell, comprising contacting the cell with a compound provided herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the contacting is in vitro. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is in vivo, wherein the method comprises administering an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, to a subject having a cell having a BCL-X_L protein. In some embodiments, the cell is a cancer cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a mammalian cancer cell. In some embodiments, the cancer cell is any cancer as described herein.

Also provided is a method of forming a ternary complex comprising a BCL-X_L protein, a compound provided herein, or a pharmaceutically acceptable salt thereof, and a CRBN protein or fragment thereof in a cell, comprising contacting the cell with a compound provided herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the contacting is in vitro. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is in vivo, wherein the method comprises administering an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, to a subject having a cell having a BCL-X_L protein. In some embodiments, the cell is a cancer cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a mammalian cancer cell. In some embodiments, the cancer cell is any cancer as described herein.

Also provided herein is a method of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof as defined herein.

Further provided herein is a method of increasing cell death, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof as defined herein. Also provided herein is a method of increasing tumor cell death in a subject. The method comprises administering to the subject a compound provided herein, or a pharmaceutically acceptable salt thereof, in an amount effective to increase tumor cell death.

When employed as pharmaceuticals, the compounds provided herein, or pharmaceutically acceptable salts thereof, can be administered in the form of pharmaceutical compositions as described herein.

Also provided herein is a method for inducing degradation of a BCL-X_L protein in a mammalian cell, the method comprising contacting the mammalian cell with an effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof.

Also provided herein is a method of treating a subject having a cancer, wherein the method comprises:

administering a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, as a monotherapy or in conjunction with a first anticancer agent to the subject who has been administered one or more doses of the first anticancer agent to the subject.

Also provided herein is a method of treating a subject having a cancer, wherein the method comprises:

(a) administering one or more doses of a first anticancer agent to the subject; and

(b) after (a), administering a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, as a monotherapy or in conjunction with the first anticancer agent to the subject.

Also provided herein is a method of treating a subject having a cancer, wherein the method comprises:

(a) administering one or more doses of a first anticancer agent to the subject; and

(b) after (a), administering a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, as a monotherapy or in conjunction with a second anticancer agent to the subject.

Combinations

In any of the indications described herein, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be used as a monotherapy. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, can be used prior to administration of an additional therapeutic agent or additional therapy. For example, a subject in need thereof can be administered one or more doses of a compound provided herein, or a pharmaceutically acceptable salt thereof, for a period of time and then undergo at least partial resection of the tumor. In some embodiments, the treatment with one or more doses of a compound provided herein, or a pharmaceutically acceptable salt thereof, reduces the size of the tumor (e.g., the tumor burden) prior to the at least partial resection of the tumor.

In some embodiments, a subject in need thereof can be administered one or more doses

of a compound provided herein, or a pharmaceutically acceptable salt thereof, for a period of time and after one or more rounds of radiation therapy. In some embodiments, the treatment with one or more doses of a compound provided herein, or a pharmaceutically acceptable salt thereof, reduces the size of the tumor (e.g., the tumor burden) prior to the one or more rounds of radiation therapy.

In some embodiments of any the methods described herein, the compound provided herein, or a pharmaceutically acceptable salt thereof, is administered in combination with a therapeutically effective amount of at least one additional therapeutic agent selected from one or more additional therapies or therapeutic (e.g., chemotherapeutic) agents.

Non-limiting examples of additional therapies and therapeutic agents include: RAS pathway targeted therapeutic agents (e.g., Ras/RAF/MEK/PI3K pathway inhibitors, (e.g., Ras inhibitors (e.g., KRas inhibitors), KRas-targeted therapeutic agents, SOS1 inhibitors, SOS1/Ras protein-protein interaction inhibitors, SHP2 inhibitors, PI3K-AKT-mTOR pathway inhibitors)), kinase-targeted therapeutics (e.g., MEK inhibitors, ERK inhibitors, Raf inhibitors (e.g., BRAf inhibitors), PI3K inhibitors, Abl inhibitors (e.g., BCR-Abl inhibitors), ALK inhibitors, AKT inhibitors, AURKA inhibitors, mTOR inhibitors, CDK2 inhibitors, CDK4/5 inhibitors, CDK4/6 inhibitors, CDK7 inhibitors, CDK9 inhibitors, MET (also known as cMET) inhibitors, FAK inhibitors, FGFR1 inhibitors, FGFR2 inhibitors, FGFR3 inhibitors, FGFR4 inhibitors, ErbB family inhibitors (e.g., EGFR inhibitors, anti-EGFR antibodies or anti-EGFR antibody-drug conjugates, HER2 inhibitors, anti-HER2 antibodies or anti-HER2 antibody-utilizing biologics), JAK inhibitors (e.g., JAK inhibitors having activity against JAK1, JAK2, and/or JAK1/2), Src inhibitors, VEGFR inhibitors), LSD1 inhibitors, EZH2 inhibitors, BET inhibitors, STING agonists, telomerase inhibitors, mTORC1 inhibitors, YAP inhibitors, proteasome inhibitors, farnesyl transferase inhibitors, Hif2 α inhibitors, HSP90 inhibitors, PTEN inhibitors, PARP inhibitors, signal transduction pathway inhibitors, checkpoint inhibitors, modulators of the apoptosis pathway (e.g., BCL-2 inhibitors), chemotherapeutics, angiogenesis-targeted therapies, immune-targeted agents, including immunomodulatory imide drugs (sometimes called “IMiDs” or “CELMoDs”) and immunotherapy (e.g., anti-PD1 therapy or anti-PD-L1 therapy), and radiotherapy.

As used herein, a biosimilar antibody refers to an antibody or antigen-binding fragment that has the same primary amino acid sequence as compared to a reference antibody and optionally, may have detectable differences in post-translation modifications (e.g., glycosylation and/or phosphorylation) as compared to the reference antibody (e.g., a different

glycoform).

In some embodiments, the additional therapy or therapeutic agent is an Abl inhibitor (e.g., a BCR-Abl inhibitor), an ALK inhibitor, an AURKA inhibitor, a BCL-2 inhibitor, a Braf inhibitor, a CDK2 inhibitor, a CDK4/6 inhibitor, a CDK7 inhibitor, a CDK9 inhibitor, an EGFR inhibitor, an anti-EGFR antibody or anti-EGFR antibody-drug conjugate, an ERK inhibitor, an EZH2 inhibitor, a FGFR1 inhibitor, a FGFR2 inhibitor, a FGFR3 inhibitor, a FGFR4 inhibitor, a HER2 inhibitor, an anti-HER2 antibody or anti-HER2 antibody-drug conjugate, a JAK inhibitor, a KRas inhibitor, a MEK inhibitor, a MET inhibitor, a Hif2 α inhibitor, a PARP inhibitor, a VEGFR inhibitor, an LSD1 inhibitor, a BET inhibitor, a STING agonist, a telomerase inhibitor, a TORC1/2 inhibitor, an immunomodulatory imide drug, immunotherapy (e.g., a PD-1 inhibitor (e.g., anti-PD1 therapy), a PD-L1 inhibitor (e.g., anti-PD-L1 therapy)), L-asparaginase, chemotherapy, radiotherapy, or a combination thereof.

In some embodiments, the additional therapy or therapeutic agent is an Abl degrader (e.g., a BCR-Abl degrader), an ALK degrader, an AURKA degrader, a BCL-2 degrader, a BRAF degrader, a CDK2 degrader, a CDK4/6 degrader, a CDK7 degrader, a CDK9 degrader, an EGFR degrader, an ERK degrader, an EZH2 degrader, a FGFR1 degrader, a FGFR2 degrader, a FGFR3 degrader, a FGFR4 degrader, a HER2 degrader, a JAK2 degrader, a KRas degrader, a MEK degrader, a MET degrader, a Hif2 α degrader, a PARP degrader, a VEGFR degrader, an LSD1 degrader, a BET degrader, a telomerase degrader, a TORC1/2 degrader, an immunomodulatory imide drug, immunotherapy (e.g., anti-PD1 therapy or anti-PD-L1 therapy), chemotherapy, radiotherapy, or a combination thereof.

In some embodiments, the Abl inhibitor (e.g., BCR-Abl inhibitor) is asciminib (e.g., asciminib hydrochloride), bafetinib, bosutinib (e.g., bosutinib monohydrate), danusertib, dasatinib (e.g., dasatinib monohydrate), flumatinib (e.g., flumatinib mesylate), imatinib (e.g., imatinib mesylate), nilotinib (e.g., nilotinib monochloride monohydrate), olverembatinib (e.g., olverembatinib mesylate), ponatinib (e.g., ponatinib hydrochloride), radotinib (e.g., radotinib dihydrochloride), ruserontinib, vandetanib, AN-019, AT-9283, IKT-148009, NPB-001-056, or a combination thereof.

In some embodiments, the ALK inhibitor is alectinib (e.g., alectinib hydrochloride), brigatinib, ceritinib, crizotinib, ensartinib (e.g., ensartinib hydrochloride), entrectinib, fidrisertib, lorlatinib, TQ-B-3101, TQ-B-3139, or a combination thereof. In some embodiments, the ALK inhibitor is alectinib (e.g., alectinib hydrochloride), brigatinib, ceritinib, crizotinib, ensartinib (e.g., ensartinib hydrochloride), fidrisertib, lorlatinib, TQ-B-

3101, TQ-B-3139, or a combination thereof.

In some embodiments, the AURKA inhibitor is alisertib, danusertib, ilorasertib, tinengotinib, AT-9283, BI-811283, ENMD-2076, or a combination thereof.

In some embodiments, the BCL-2 inhibitor is lisaftoclax, navitoclax, obatoclax, 5 venetoclax, oblimersen (e.g., oblimersen sodium), beclanorsen, AZD-0466, BGB-11417, UBX-1325 (or a phosphate prodrug thereof), UBX-1967 (or a phosphate prodrug thereof), ZN-d5, or a combination thereof.

In some embodiments, the cancer is a lung cancer (e.g., SCLC), and the additional therapy or therapeutic agent is a BCL-2 inhibitor (e.g., lisaftoclax, navitoclax, obatoclax, 10 venetoclax, oblimersen (e.g., oblimersen sodium), beclanorsen, AZD-0466, BGB-11417, UBX-1325 (or a phosphate prodrug thereof), UBX-1967 (or a phosphate prodrug thereof), or ZN-d5). In some embodiments, the cancer is a lung cancer (e.g., SCLC), and the additional therapy or therapeutic agent is venetoclax.

In some embodiments, the cancer is a non-Hodgkin lymphoma, and the additional therapy or therapeutic agent is a BCL-2 inhibitor (e.g., lisaftoclax, navitoclax, obatoclax, 15 venetoclax, oblimersen (e.g., oblimersen sodium), beclanorsen, AZD-0466, BGB-11417, UBX-1325 (or a phosphate prodrug thereof), UBX-1967 (or a phosphate prodrug thereof), or ZN-d5). In some embodiments, the cancer is a non-Hodgkin lymphoma, and the additional therapy or therapeutic agent is venetoclax.

In some embodiments, the BRAf inhibitor is avutometinib (RO5126766), dabrafenib 20 (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), naporafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-25 3603, PLX-4720, or a combination thereof.

In some embodiments, a BRAf V600E mutation can be detected in a sample from the subject (e.g., detecting a *BRAF* gene having a mutation corresponding to a V600E mutation in BRAf protein and/or detecting a BRAf protein having a V600E mutation). In some 30 embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having a BRAf V600E mutation

In some embodiments, the cancer is a BRAf mutant CRC (e.g., BRAf V600E mutant CRC), and the additional therapy or therapeutic agent is a BRAf inhibitor (e.g., avutometinib (RO5126766), dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g.,

BRAFTOVI™, LGX818), naporafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-3603, or PLX-4720). In some embodiments, the cancer is a Braf mutant CRC (e.g., Braf V600E mutant CRC), and the additional therapy or therapeutic agent is a Braf inhibitor (e.g., avutometinib (RO5126766), dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), naporafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-3603, or PLX-4720) and an anti-EGFR antibody or anti-EGFR antibody-drug conjugate (e.g., amivantamab (e.g., amivantamab-vmjw, or a biosimilar thereof), cetuximab (e.g., ERBITUX® (cetuximab), or a biosimilar thereof (e.g., CMAB-009, CPGJ-602, or KL-140)), cetuximab sarotalocan (AKALUX® (cetuximab sarotalocan), or a biosimilar thereof), depatuxizumab, duligotuzumab, futuximab, imgatuzumab, modotuximab, necitumumab (e.g., PORTRAZZA® (necitumumab), or a biosimilar thereof), nimotuzumab (e.g., BIOMAb EGFR® (nimotuzumab), or a biosimilar thereof), panitumumab (e.g., VECTIBIX® (panitumumab), or a biosimilar thereof), tomuzotuximab, zalutumumab, EMD-55900, EMD-82633, GC-1118, HLX-07, ICR-62, SCT-200, SI-B-001, TAS-0313, or biosimilars thereof). In some embodiments, the cancer is a Braf mutant CRC (e.g., Braf V600E mutant CRC), and the additional therapy or therapeutic agent is a Braf inhibitor (e.g., avutometinib (RO5126766), dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), naporafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-3603, or PLX-4720) and cetuximab (e.g., ERBITUX® (cetuximab), or a biosimilar thereof (e.g., CMAB-009, CPGJ-602, or KL-140)). In some embodiments, the cancer is a Braf mutant CRC (e.g., Braf V600E mutant CRC), and the additional therapy or therapeutic agent is a Braf inhibitor (e.g., avutometinib (RO5126766), dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), naporafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-3603, or PLX-4720) and panitumumab (e.g., VECTIBIX®

(panitumumab), or a biosimilar thereof). In some embodiments, the cancer is a BRAf mutant CRC (e.g., BRAf V600E mutant CRC), and the additional therapy or therapeutic agent is a dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), or vemurafenib (e.g., ZELBORAF®, RO5185426) and cetuximab (e.g., ERBITUX® (cetuximab), or a biosimilar thereof (e.g., CMAB-009, CPGJ-602, or KL-140)).

In some embodiments, the cancer is a BRAf mutant CRC (e.g., BRAf V600E mutant CRC), and the additional therapy or therapeutic agent is dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), or vemurafenib (e.g., ZELBORAF®, RO5185426) and panitumumab (e.g., VECTIBIX® (panitumumab), or a biosimilar thereof). In some embodiments, the cancer is a BRAf mutant CRC (e.g., BRAf V600E mutant CRC), and the additional therapy or therapeutic agent is a dabrafenib (e.g., dabrafenib mesylate, GSK2118436) and cetuximab (e.g., ERBITUX® (cetuximab), or a biosimilar thereof (e.g., CMAB-009, CPGJ-602, or KL-140)). In some embodiments, the cancer is a BRAf mutant CRC (e.g., BRAf V600E mutant CRC), and the additional therapy or therapeutic agent is dabrafenib (e.g., dabrafenib mesylate, GSK2118436) and panitumumab (e.g., VECTIBIX® (panitumumab), or a biosimilar thereof).

In some embodiments, the cancer is a BRAf mutant NSCLC (e.g., BRAf V600E mutant NSCLC), and the additional therapy or therapeutic agent is a BRAf inhibitor (e.g., avutemetinib (RO5126766), dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), naprafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-3603, or PLX-4720) and a MEK inhibitor (e.g., avutemetinib, binimetinib, cobimetinib (e.g., cobimetinib fumarate), mirdametinib, pimasertib, refametinib, selumetinib (e.g., selumetinib sulfate), trametinib (e.g., trametinib dimethyl sulfoxide), zapnometinib, FCN-159, GSK-1120212, NFX-179, or TAK-733). In some embodiments, the cancer is a BRAf mutant NSCLC (e.g., BRAf V600E mutant NSCLC), and the additional therapy or therapeutic agent is dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), or vemurafenib (e.g., ZELBORAF®, RO5185426), and binimetinib, cobimetinib (e.g., cobimetinib fumarate), selumetinib (e.g., selumetinib sulfate), or trametinib (e.g., trametinib dimethyl sulfoxide). In some embodiments, the cancer is a BRAf mutant NSCLC (e.g., BRAf V600E mutant NSCLC), and the additional therapy or therapeutic agent is dabrafenib (e.g., dabrafenib mesylate, GSK2118436) and

trametinib (e.g., trametinib dimethyl sulfoxide). In some embodiments, the cancer is a BRAf mutant NSCLC (e.g., BRAf V600E mutant NSCLC), and the additional therapy or therapeutic agent is vemurafenib (e.g., ZELBORAF®, RO5185426), and cobimetinib (e.g., cobimetinib fumarate). In some embodiments, the cancer is a BRAf mutant NSCLC (e.g., BRAf V600E mutant NSCLC), and the additional therapy or therapeutic agent is encorafenib (e.g., BRAFTOVI™, LGX818) and binimetinib.

In some embodiments, the cancer is a BRAf mutant melanoma (e.g., BRAf V600E mutant melanoma), and the additional therapy or therapeutic agent is a BRAf inhibitor (e.g., avutometinib (RO5126766), dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), naporafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-3603, or PLX-4720). In some embodiments, the cancer is a BRAf mutant melanoma (e.g., BRAf V600E mutant melanoma), and the additional therapy or therapeutic agent is a BRAf inhibitor (e.g., avutometinib (RO5126766), dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), naporafenib (LXH254), sorafenib (e.g., sorafenib tosylate), vemurafenib (e.g., ZELBORAF®, RO5185426), ARQ-736, AZ304, BMS-908662 (XL281), C17071479-F, CHIR-265 (RAF265), FORE-8394 (PLX-8394), GDC-0879, GDC-5573 (HM95573), HLX-208, PLX-3603, or PLX-4720) and a MEK inhibitor (e.g., avutometinib, binimetinib, cobimetinib (e.g., cobimetinib fumarate), mirdametinib, pimasertib, refametinib, selumetinib (e.g., selumetinib sulfate), trametinib (e.g., trametinib dimethyl sulfoxide), zapnometinib, FCN-159, GSK-1120212, NFX-179, or TAK-733). In some embodiments, the cancer is a BRAf mutant melanoma (e.g., BRAf V600E mutant melanoma), and the additional therapy or therapeutic agent is dabrafenib (e.g., dabrafenib mesylate, GSK2118436), encorafenib (e.g., BRAFTOVI™, LGX818), or vemurafenib (e.g., ZELBORAF®, RO5185426), and binimetinib, cobimetinib (e.g., cobimetinib fumarate), selumetinib (e.g., selumetinib sulfate), or trametinib (e.g., trametinib dimethyl sulfoxide). In some embodiments, the cancer is a BRAf mutant melanoma (e.g., BRAf V600E mutant melanoma), and the additional therapy or therapeutic agent is dabrafenib (e.g., dabrafenib mesylate, GSK2118436) and trametinib (e.g., trametinib dimethyl sulfoxide). In some embodiments, the cancer is a BRAf mutant melanoma (e.g., BRAf V600E mutant melanoma), and the additional therapy or therapeutic agent is vemurafenib (e.g., ZELBORAF®, RO5185426), and cobimetinib (e.g., cobimetinib fumarate).

In some embodiments, the cancer is a BRAf mutant melanoma (e.g., BRAf V600E mutant melanoma), and the additional therapy or therapeutic agent is encorafenib (e.g., BRAFTOVI™, LGX818) and binimetinib. In some such embodiments, the subject has previously been treated with an immunotherapy.

5 In some embodiments, the CDK2 inhibitor is ebvaciclib, fadraciclib, milciclib, pacritinib (e.g., pacritinib citrate), roniciclib, roscovitine, BLU-222, NUV-422, PF-07104091, TQB-3616, or a combination thereof.

 In some embodiments, the CDK4/6 inhibitor is abemaciclib, birociclib, dalpiciclib, lerociclib, milciclib, palbociclib, ribociclib (e.g., ribociclib succinate), riviciclib, roniciclib, 10 trilaciclib (e.g., trilaciclib dihydrochloride), FCN-437, TQB-3616, or a combination thereof.

 In some embodiments, the CDK7 inhibitor is milciclib, roscovitine, samuraciclib, or a combination thereof.

 In some embodiments, the CDK9 inhibitor is fadraciclib, riviciclib, roniciclib, roscovitine, zotiraciclib, AZD-4573, KB-0742, or a combination thereof.

15 In some embodiments, the EGFR inhibitor is abivertinib, afatinib (e.g., afatinib dimaleate), alflutinib (e.g., alflutinib mesylate), almonertinib (e.g., almonertinib mesylate), befotertinib, brigatinib, canertinib, dacomitinib (e.g., dacomitinib monohydrate), dovitinib, erlotinib (e.g., erlotinib hydrochloride), gefitinib, icotinib, lapatinib (e.g., lapatinib ditosylate monohydrate), larotinib, lazertinib, limertinib, mobocertinib (e.g., mobocertinib succinate), 20 nazartinib, neratinib (e.g., neratinib maleate), olmutinib, osimertinib (e.g., osimertinib mesylate), pelitinib, poziotinib, pyrotinib (e.g., pyrotinib maleate), ruserontinib (SKLB-1028), sapitinib, sunvozertinib, tesevatinib, vandetanib, varlitinib, zorifertinib, BIBW-2948, BPI-7711, HA-121-28, SH-1028, an anti-EGFR antibody or anti-EGFR antibody-drug conjugate, or a combination thereof.

25 In some embodiments, the anti-EGFR antibody or anti-EGFR antibody-drug conjugate is amivantamab (e.g., amivantamab-vmjw, or a biosimilar thereof), cetuximab (e.g., ERBITUX® (cetuximab), or a biosimilar thereof (e.g., CMAB-009, CPGJ-602, or KL-140)), cetuximab sarotalocan (AKALUX® (cetuximab sarotalocan), or a biosimilar thereof), depatuxizumab, duligotuzumab, futuximab, imgatuzumab, modotuximab, necitumumab (e.g., 30 PORTRAZZA® (necitumumab), or a biosimilar thereof), nimotuzumab (e.g., BIOMAb EGFR® (nimotuzumab), or a biosimilar thereof), panitumumab (e.g., VECTIBIX® (panitumumab), or a biosimilar thereof), tomuzotuximab, zalutumumab, EMD-55900, EMD-82633, GC-1118, HLX-07, ICR-62, SCT-200, SI-B-001, TAS-0313, biosimilars thereof, or a

combination thereof. In some embodiments, the anti-EGFR antibody or anti-EGFR antibody-drug conjugates is amivantamab (e.g., amivantamab-vmjw, or a biosimilar thereof), cetuximab (e.g., ERBITUX® (cetuximab), or a biosimilar thereof (e.g., CMAB-009, CPGJ-602, or KL-140)), cetuximab sarotalocan (AKALUX® (cetuximab sarotalocan), or a biosimilar thereof),
5 depatuxizumab, duligotuzumab, futuximab, imgatuzumab, modotuximab, necitumumab (e.g., PORTRAZZA® (necitumumab), or a biosimilar thereof), nimotuzumab (e.g., BIOMAB EGFR® (nimotuzumab), or a biosimilar thereof), panitumumab (e.g., VECTIBIX® (panitumumab), or a biosimilar thereof), tomuzotuximab, zalutumumab, EMD-55900, EMD-82633, GC-1118, HLX-07, ICR-62, SCT-200, SI-B-001, biosimilars thereof, or a combination
10 thereof.

In some embodiments, an EGFR mutation (e.g., an EGFR exon 19 deletion or an EGFR L858R mutation (with or without an EGFR T790M mutation)) can be detected in a sample from the subject (e.g., detecting an *EGFR* gene having a mutation (e.g., a mutation corresponding to an EGFR exon 19 deletion or an EGFR L858R mutation (with or without an
15 EGFR T790M mutation) in an EGFR protein) and/or detecting an EGFR protein having a mutation (e.g., an EGFR exon 19 deletion or an EGFR L858R mutation (with or without an EGFR T790M mutation))). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having an EGFR mutation (e.g., an EGFR exon 19 deletion or an EGFR L858R mutation (with or without an EGFR
20 T790M mutation)).

In some embodiments, the cancer is an EGFR mutant NSCLC (e.g., EGFR exon 19 deletion NSCLC or EGFR L858R (with or without T790M) mutant NCLC), and the additional therapy or therapeutic agent is an EGFR inhibitor (e.g., abivertinib, afatinib (e.g., afatinib dimaleate), alflutinib (e.g., alflutinib mesylate), almonertinib (e.g., almonertinib mesylate),
25 befortertinib, brigatinib, canertinib, dacomitinib (e.g., dacomitinib monohydrate), dovitinib, erlotinib (e.g., erlotinib hydrochloride), gefitinib, icotinib, lapatinib (e.g., lapatinib ditosylate monohydrate), larotinib, lazertinib, limertinib, mobocertinib (e.g., mobocertinib succinate), nazartinib, neratinib (e.g., neratinib maleate), olmutinib, osimertinib (e.g., osimertinib mesylate), pelitinib, poziotinib, pyrotinib (e.g., pyrotinib maleate), ruserontinib (SKLB-1028),
30 sapitinib, sunvozertinib, tesevatinib, vandetanib, varlitinib, zorifertinib, BIBW-2948, BPI-7711, HA-121-28, SH-1028, or an anti-EGFR antibody or anti-EGFR antibody-drug conjugate). In some embodiments, the cancer is an EGFR mutant NSCLC (e.g., EGFR exon 19 deletion NSCLC or EGFR L858R (with or without T790M) mutant NCLC), and the

additional therapy or therapeutic agent is osimertinib (e.g., osimertinib mesylate).

In some embodiments, the ERK inhibitor is rineterkib, temuterkib, ulixertinib, ASN-0007, ASTX-029, ATG-017, BPI-27336, HH-2710, JSI-1187, MK-8353, or a combination thereof.

5 In some embodiments, the EZH2 inhibitor is lirametostat, tazemetostat (e.g., tazemetostat hydrobromide), valemetostat (e.g., valemetostat tosylate), tulmimetostat (CPI-0209), EBI-2511, HH-2853, HM-97662, PF-6821497, SHR-2554, XNW-5004, or a combination thereof. In some embodiments, the EZH2 inhibitor also inhibits EZH1 (also referred to as an EZH1/2 inhibitor).

10 In some embodiments, the cancer is peripheral T cell lymphoma, and the additional therapy or therapeutic agent is an EZH2 inhibitor (e.g., lirametostat, tazemetostat (e.g., tazemetostat hydrobromide), valemetostat (e.g., valemetostat tosylate), tulmimetostat (CPI-0209), EBI-2511, HH-2853, HM-97662, PF-6821497, SHR-2554, or XNW-5004).

15 In some embodiments, the FGFR1 inhibitor is danusertib, dovitinib, erdafitinib, futibatinib, infigratinib (e.g., infigratinib phosphate), lenvatinib (e.g., lenvatinib mesylate), lucitanib, nintedanib (e.g., nintedanib esylate), pemigatinib, surufatinib, tasurgratinib, tinengotinib, zoligratinib, FH-2001, HMPL-453, LY-2874455, or a combination thereof.

20 In some embodiments, the FGFR2 inhibitor is erdafitinib, futibatinib, infigratinib (e.g., infigratinib phosphate), lucitanib, pemigatinib, tasurgratinib, zoligratinib, bemarituzumab (or biosimilars thereof), FH-2001, HMPL-453, LY-2874455, or a combination thereof.

In some embodiments, the FGFR3 inhibitor is dovitinib, erdafitinib, futibatinib, infigratinib (e.g., infigratinib phosphate), lucitanib, masitinib, nintedanib, pemigatinib, tasurgratinib, zoligratinib, vofatamab (or biosimilars thereof), EXEL-0999, FH-2001, HMPL-453, LY-2874455, or a combination thereof.

25 In some embodiments, the FGFR4 inhibitor is axitinib, erdafitinib, futibatinib, infigratinib (e.g., infigratinib phosphate), irpagratinib, nintedanib, pemigatinib, FH-2001, H3B-6527, LY-2874455, or a combination thereof.

30 In some embodiments, the HER2 inhibitor is afatinib (e.g., afatinib dimaleate), dacomitinib (e.g., dacomitinib monohydrate), lapatinib (e.g., lapatinib ditosylate monohydrate), mobocertinib (e.g., mobocertinib succinate), neratinib (e.g., neratinib maleate), poziotinib, pyrotinib (e.g., pyrotinib maleate), sunvozertinib, tesevatinib, tucatinib, varlitinib, an anti-HER2 antibody or anti-HER2 antibody-drug conjugate, or a combination thereof.

In some embodiments, the anti-HER2 antibody or anti-HER2 antibody-drug conjugate is anbenitamab, cinrebafusp alfa, coprelotamab, disitamab vedotin, ertumaxomab, gancotamab, inetetamab, margetuximab (e.g., margetuximab-cmkb, or a biosimilar thereof), pertuzumab (e.g., PERJETA® (pertuzumab), or a biosimilar thereof (e.g., HLX-11)), trastuzumab (e.g., HERCEPTIN® (trastuzumab), or a biosimilar thereof (e.g., FACEPTOR® (trastuzumab), HERTICAD® (trastuzumab), TUZNUE® (trastuzumab), ZERCEPAC® (trastuzumab), trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, EG-12014, or TX-05)), trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof), trastuzumab duocarmazine, trastuzumab emtansine (e.g., KADCYLA® (trastuzumab emtansine), or a biosimilar thereof (e.g., UJVIRA® (trastuzumab emtansine))), trastuzumab hyaluronidase (e.g., trastuzumab hyaluronidase-oysk, or a biosimilar thereof), zanidatamab, zenocutuzumab, AVX-901, IDM-1, TPIV-100, TAA-013, SHR-A1811, BAT-8001, MDX-210, Alpha-Her2-pAF1-AS-269, MRG-002, DF-1001, AC-101, MM-111, biosimilars thereof, or a combination thereof. In some embodiments, the anti-HER2 antibody or anti-HER2 antibody-drug conjugate is anbenitamab, cinrebafusp alfa, coprelotamab, disitamab vedotin, ertumaxomab, gancotamab, inetetamab, margetuximab (e.g., margetuximab-cmkb, or a biosimilar thereof), pertuzumab (e.g., PERJETA® (pertuzumab), or a biosimilar thereof (e.g., HLX-11)), trastuzumab (e.g., HERCEPTIN® (trastuzumab), or a biosimilar thereof (e.g., FACEPTOR® (trastuzumab), HERTICAD® (trastuzumab), TUZNUE® (trastuzumab), ZERCEPAC® (trastuzumab), trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, EG-12014, or TX-05)), trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof), trastuzumab duocarmazine, trastuzumab emtansine (e.g., KADCYLA® (trastuzumab emtansine), or a biosimilar thereof (e.g., UJVIRA® (trastuzumab emtansine))), trastuzumab hyaluronidase (e.g., trastuzumab hyaluronidase-oysk, or a biosimilar thereof), zanidatamab, zenocutuzumab, TAA-013, SHR-A1811, BAT-8001, MDX-210, Alpha-Her2-pAF1-AS-269, MRG-002, DF-1001, AC-101, MM-111, biosimilars thereof, or a combination thereof.

In some embodiments, HER2⁺ status can be detected in a sample from the subject (e.g., via immunohistochemistry (IHC) and/or fluorescent *in situ* hybridization (FISH)). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer with HER2⁺ status.

In some embodiments, HER2 low status can be detected in a sample from the subject (e.g., via IHC and/or FISH). In some embodiments, the subject was determined (e.g., prior to

administration of a compound provided herein) to have a cancer with HER2 low status.

In some embodiments, HER2- status can be detected in a sample from the subject (e.g., via IHC and/or FISH). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer with HER2- status.

5 In some embodiments, ER expression status can be detected in a sample from the subject (e.g., via IHC and/or FISH). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer with ER expression. In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer without ER expression.

10 In some embodiments, PR expression status can be detected in a sample from the subject (e.g., via IHC, and/or FISH). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer with PR expression. In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer without PR expression.

15 In some embodiments, the cancer is a HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), and the additional therapy is a HER2 inhibitor (e.g., afatinib (e.g., afatinib dimaleate), dacomitinib (e.g., dacomitinib monohydrate), lapatinib (e.g., lapatinib ditosylate monohydrate), mobocertinib (e.g., mobocertinib succinate), neratinib (e.g., neratinib maleate), poziotinib, pyrotinib (e.g.,
20 pyrotinib maleate), sunvozertinib, tesevatnib, tucatinib, varlitinib, or an anti-HER2 antibody or anti-HER2 antibody-drug conjugate). In some embodiments, the cancer is a HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), and the additional therapy is tucatinib. In some embodiments, the cancer is a HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer
25 without ER expression), and the additional therapy is an anti-HER2 antibody or anti-HER2 antibody-drug conjugate (e.g., anbenitamab, cinrebafusp alfa, coprelotamab, disitamab vedotin, ertumaxomab, gancotamab, inetetamab, margetuximab (e.g., margetuximab-cmkb, or a biosimilar thereof), pertuzumab (e.g., PERJETA® (pertuzumab), or a biosimilar thereof (e.g., HLX-11)), trastuzumab (e.g., HERCEPTIN® (trastuzumab), or a biosimilar thereof (e.g.,
30 FACEPTOR® (trastuzumab), HERTICAD® (trastuzumab), TUZNUE® (trastuzumab), ZERCEPAC® (trastuzumab), trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, EG-12014, or TX-05)), trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof), trastuzumab duocarmazine,

trastuzumab emtansine (e.g., KADCYLA® (trastuzumab emtansine), or a biosimilar thereof (e.g., UJVIRA® (trastuzumab emtansine))), trastuzumab hyaluronidase (e.g., trastuzumab hyaluronidase-oysk, or a biosimilar thereof), zanidatamab, zenocutuzumab, AVX-901, IDM-1, TPIV-100, TAA-013, SHR-A1811, BAT-8001, MDX-210, Alpha-Her2-pAF1-AS-269, 5 MRG-002, DF-1001, AC-101, MM-111, or biosimilars thereof). In some embodiments, the cancer is a HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), and the additional therapy is trastuzumab (e.g., HERCEPTIN® (trastuzumab), or a biosimilar thereof (e.g., FACEPTOR® (trastuzumab), HERTICAD® (trastuzumab), TUZNUE® (trastuzumab), ZERCEPAC® (trastuzumab), trastuzumab-anns, 10 trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, EG-12014, or TX-05)). In some embodiments, the cancer is a HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), and the additional therapy is trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof). In some embodiments, the cancer is a HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), and the additional therapy is 15 trastuzumab emtansine, or a biosimilar thereof. In some embodiments, the cancer is a HER2 low breast cancer, and the additional therapy is an anti-HER2 antibody or anti-HER2 antibody-drug conjugate. In some embodiments, the cancer is a HER2 low breast cancer, and the additional therapy is trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a 20 biosimilar thereof).

In some embodiments, the JAK inhibitor is adelatinib, baricitinib, brepocitinib, deuruxolitinib, fedratinib (e.g., fedratinib dihydrochloride monohydrate), filgotinib (e.g., filgotinib maleate), gandotinib, gusacitinib, ilginatinib, izencitinib, jaktinib, momelotinib (e.g., momelotinib dihydrochloride), nezulcitinib, pacritinib (e.g., pacritinib citrate), peficitinib (e.g., 25 peficitinib hydrobromide), ropsacitinib, ruxolitinib (e.g., ruxolitinib phosphate), tasocitinib (e.g., tofacitinib citrate), AT-9283, TQ-05105, or a combination thereof. In some embodiments, the JAK inhibitor is fedratinib (e.g., fedratinib dihydrochloride monohydrate), momelotinib (e.g., momelotinib dihydrochloride), pacritinib (e.g., pacritinib citrate), ruxolitinib (e.g., ruxolitinib phosphate), or a combination thereof. In some embodiments, the JAK inhibitor is 30 fedratinib (e.g., fedratinib dihydrochloride monohydrate). In some embodiments, the JAK inhibitor is momelotinib (e.g., momelotinib dihydrochloride). In some embodiments, the JAK inhibitor is pacritinib (e.g., pacritinib citrate). In some embodiments, the JAK inhibitor is ruxolitinib (e.g., ruxolitinib phosphate).

In some embodiments, a JAK V617F mutation can be detected in a sample from the subject (e.g., detecting a *JAK2* gene having a mutation corresponding to a V617F mutation in JAK2 protein and/or detecting a JAK2 protein having a V617F mutation). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided
5 herein) to have a cancer having a JAK2 V617F mutation. In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer lacking a JAK2 V617F mutation.

In some embodiments, the cancer is post-MPN AML, M6-AML, or M7-AML, and the additional therapy or therapeutic agent is a JAK inhibitor (e.g., ruxolitinib (e.g., ruxolitinib
10 phosphate), fedratinib (e.g., fedratinib dihydrochloride monohydrate), momelotinib (e.g., momelotinib dihydrochloride), or pacritinib (e.g., pacritinib citrate)). In some embodiments, the patient has received a previous line of therapy including a JAK inhibitor. In some embodiments, the patient has not received a previous line of therapy including a JAK inhibitor.

In some embodiments, the cancer is intermediate (e.g., intermediate-1 and/or
15 intermediate-2) or high-risk myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis), and the additional therapy or therapeutic agent is a JAK inhibitor (e.g., ruxolitinib (e.g., ruxolitinib phosphate), fedratinib (e.g., fedratinib dihydrochloride monohydrate), momelotinib (e.g., momelotinib dihydrochloride), or pacritinib (e.g., pacritinib citrate)). In some embodiments, the cancer is
20 intermediate (e.g., intermediate-1 and/or intermediate-2) or high-risk myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis), and the additional therapy or therapeutic agent is a JAK inhibitor (e.g., ruxolitinib (e.g., ruxolitinib phosphate), fedratinib (e.g., fedratinib dihydrochloride monohydrate), momelotinib (e.g., momelotinib dihydrochloride), or pacritinib (e.g., pacritinib
25 citrate)) and a BET inhibitor (e.g., alobresib, apabetalone, mivebresib, pelabresib, trotabresib, ABBV-744, BI-2536, BMS-986158, INCB-057643, JAB-8263, ODM-207, PLX-2853, or ZEN-003694). In some embodiments, the cancer is intermediate (e.g., intermediate-1 and/or intermediate-2) or high-risk myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis) with a JAK2
30 mutation (e.g., a JAK2 V617F mutation), and the additional therapy or therapeutic agent is a JAK inhibitor (e.g., ruxolitinib (e.g., ruxolitinib phosphate), fedratinib (e.g., fedratinib dihydrochloride monohydrate), momelotinib (e.g., momelotinib dihydrochloride), or pacritinib (e.g., pacritinib citrate)). In some embodiments, the cancer is intermediate (e.g., intermediate-

1 and/or intermediate-2) or high-risk myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis) with a JAK2 mutation (e.g., a JAK2 V617F mutation), and the additional therapy or therapeutic agent is a JAK inhibitor (e.g., ruxolitinib (e.g., ruxolitinib phosphate), fedratinib (e.g., fedratinib dihydrochloride monohydrate), momelotinib (e.g., momelotinib dihydrochloride), or pacritinib (e.g., pacritinib citrate)) and a BET inhibitor (e.g., alobresib, apabetalone, mivebresib, pelabresib, trotabresib, ABBV-744, BI-2536, BMS-986158, INCB-057643, JAB-8263, ODM-207, PLX-2853, or ZEN-003694). In some embodiments, the JAK inhibitor is fedratinib (e.g., fedratinib dihydrochloride monohydrate). In some embodiments, the JAK inhibitor is momelotinib (e.g., momelotinib dihydrochloride). In some embodiments, the JAK inhibitor is pacritinib (e.g., pacritinib citrate). In some embodiments, the JAK inhibitor is ruxolitinib (e.g., ruxolitinib phosphate). In some embodiments, the patient has received a previous line of therapy including a JAK inhibitor. In some embodiments, the patient has not received a previous line of therapy including a JAK inhibitor. In some embodiments, treatment effect can be measured by Spleen Volume Reduction (e.g., Spleen Volume Reduction of greater than or equal to 35% (SVR₃₅), for example, measured by MRI or CT), Total Symptom Score (e.g., Total Symptom Score reduction of greater than or equal to 50% (TSS₅₀), for example, measured by the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0), or both, such as at 24 weeks after beginning of treatment; see, e.g., Harrison, Claire, et al., *New England Journal of Medicine* 366.9 (2012): 787-798, doi: 10.1056/NEJMoa1110556; and Verstovsek, Srdan, et al. *New England Journal of Medicine* 366.9 (2012): 799-807, doi: 10.1056/NEJMoa1110557. In some embodiments, treatment effect can be measured (e.g., in addition to or instead of SVR₃₅ and/or TSS₅₀) by anemia response (e.g., measured by current International Working Group-Myeloproliferative Neoplasms Research and European LeukemiaNet (IWG-MRT/ELN) criteria), bone marrow fibrosis (e.g., according to the European Consensus Grading System through bone marrow biopsy, such as at 24 or 96 weeks after beginning of treatment), variant allele fraction (e.g., JAK2 V617F variant allele fraction), transfusion independence, overall survival, leukemia-free survival, change in physical functioning (e.g., measured by the physical functioning domain of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 or death), change in fatigue (e.g., assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue SF 7a), or a combination thereof.

In some embodiments, the KRas inhibitor is adagrasib, divarasib (GDC-6036),

sotorasib, ARS-1620, ARS-3248, ARS-853, ASP-3082, ATG-012, BI-1701963, BI-1823911, BPI-421286, D-1553, ERAS-3490, GFH-925, JAB-21822, JDQ-443, LY-3537982, MRTX-1133, MRTX-1257, RMC-6236, RMC-6291, RSC-1255, or a combination thereof. Additional KRas inhibitors are disclosed in, for example, International Publication Nos. WO 2024/040131 and WO 2024/112654.

In some embodiments, a KRas mutation (e.g., a KRas G12C mutation or a KRas G12D mutation) can be detected in a sample from the subject (e.g., detecting a *KRAS* gene having a mutation corresponding to a G12C mutation or a G12D mutation in KRas protein and/or detecting a KRas protein having a G12C mutation or a G12D mutation). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having a KRas G12C mutation. In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having a KRas G12D mutation.

In some embodiments, the cancer is a KRas mutant lung cancer (e.g., a KRas mutant NSCLC), a KRas mutant CRC, or a KRas mutant pancreatic cancer, and the additional therapy or therapeutic agent is a KRas inhibitor (e.g., adagrasib, divarasil (GDC-6036), sotorasib, ARS-1620, ARS-3248, ARS-853, ASP-3082, ATG-012, BI-1701963, BI-1823911, BPI-421286, D-1553, ERAS-3490, GFH-925, JAB-21822, JDQ-443, LY-3537982, MRTX-1133, MRTX-1257, RMC-6236, RMC-6291, or RSC-1255). In some embodiments, the cancer is a KRas mutant lung cancer (e.g., a KRas mutant NSCLC (e.g., a KRas G12C mutant NSCLC)), a KRas mutant CRC (e.g., a KRas G12C mutant CRC), or a KRas mutant pancreatic cancer (e.g., a KRas G12C mutant pancreatic cancer), and the additional therapy or therapeutic agent is adagrasib. In some embodiments, the cancer is a KRas mutant lung cancer (e.g., a KRas mutant NSCLC (e.g., a KRas G12C mutant NSCLC)), a KRas mutant CRC (e.g., a KRas G12C mutant CRC), or a KRas mutant pancreatic cancer (e.g., a KRas G12C mutant pancreatic cancer), and the additional therapy or therapeutic agent is divarasil. In some embodiments, the cancer is a KRas mutant lung cancer (e.g., a KRas mutant NSCLC (e.g., a KRas G12C mutant NSCLC)), a KRas mutant CRC (e.g., a KRas G12C mutant CRC), or a KRas mutant pancreatic cancer (e.g., a KRas G12C mutant pancreatic cancer), and the additional therapy or therapeutic agent is sotorasib. In some embodiments, the cancer is a KRas mutant lung cancer (e.g., a KRas mutant NSCLC (e.g., a KRas G12D mutant NSCLC)), a KRas mutant CRC (e.g., a KRas G12D mutant CRC), or a KRas mutant pancreatic cancer (e.g., a KRas G12D mutant pancreatic cancer), and the additional therapy or therapeutic agent is MRTX1133.

In some embodiments, the MEK inhibitor is avutometinib, binimetinib, cobimetinib (e.g., cobimetinib fumarate), mirdametinib, pimasertib, refametinib, selumetinib (e.g., selumetinib sulfate), trametinib (e.g., trametinib dimethyl sulfoxide), zapnometinib, FCN-159, GSK-1120212, NFX-179, TAK-733, or a combination thereof.

5 In some embodiments, a BRCA1 mutation can be detected in a sample from the subject (e.g., detecting a *BRCA1* gene having a mutation and/or detecting a BRCA1 protein having a mutation). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having a BRCA1 mutation.

10 In some embodiments, a BRCA2 mutation can be detected in a sample from the subject (e.g., detecting a *BRCA2* gene having a mutation and/or detecting a BRCA2 protein having a mutation). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having a BRCA2 mutation.

In some embodiments, the cancer is ovarian cancer (e.g., BRCA1 mutant ovarian cancer or BRCA2 mutant ovarian cancer, HGSOC (e.g., BRCA1 mutant HGSOC or BRCA2 mutant HGSOC), or LGSOC), and the additional therapy or therapeutic agent is a MEK inhibitor (e.g., binimetinib, cobimetinib, selumetinib, or trametinib). In some embodiments, the cancer is BRCA1 mutant ovarian cancer, and the additional therapy or therapeutic agent is a MEK inhibitor (e.g., binimetinib, cobimetinib, selumetinib, or trametinib). In some embodiments, the cancer is BRCA2 mutant ovarian cancer, and the additional therapy or therapeutic agent is a MEK inhibitor (e.g., binimetinib, cobimetinib, selumetinib, or trametinib). In some embodiments, the cancer is HGSOC (e.g., BRCA1 mutant HGSOC or BRCA2 mutant HGSOC), and the additional therapy or therapeutic agent is a MEK inhibitor (e.g., binimetinib, cobimetinib, selumetinib, or trametinib). In some embodiments, the cancer is LGSOC (e.g., BRCA1 mutant HGSOC or BRCA2 mutant HGSOC), and the additional therapy or therapeutic agent is a MEK inhibitor (e.g., binimetinib, cobimetinib, selumetinib, or trametinib).

25 In some embodiments, the cancer is a KRas mutant CRC (e.g., a KRas G12C mutant NSCLC), and the additional therapy or therapeutic agent is a MEK inhibitor (e.g., binimetinib, cobimetinib, selumetinib, or trametinib).

30 In some embodiments, the MET inhibitor is cabozantinib (e.g., cabozantinib *S*-malate), capmatinib (e.g., capmatinib hydrochloride), crizotinib, foritinib, glesatinib, gumarontinib, merestinib, pamufetinib, savolitinib, sitravatinib, tepotinib (e.g., tepotinib hydrochloride hydrate), vebreltinib, zanzalintinib (XL-092), amivantamab (e.g., amivantamab-vmjw, or a biosimilar thereof), emibetuzumab (or biosimilars thereof), RC-108, telisotuzumab vedotin (or

biosimilars thereof), ABBV-400, ABN-401, AL-2846, AMG-337, SAR-125844, TQ-B-3139, or a combination thereof.

5 In some embodiments, a MET alteration can be detected in a sample from the subject (e.g., detecting a *MET* gene having an alteration (e.g., gene amplification or exon14 skipping) and/or detecting a MET protein having a mutation (e.g., exon14 skipping)). In some
embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer having a MET alteration.

10 In some embodiments, the cancer is a MET-altered NCLC (e.g., MET amplified NSCLC or MET exon14 skipping NSCLC), and the additional therapy or therapeutic agent is a MET inhibitor (e.g., cabozantinib (e.g., cabozantinib *S*-malate), capmatinib (e.g., capmatinib hydrochloride), crizotinib, foritinib, glesatinib, gumarontinib, merestinib, pamufetinib, savolitinib, sitravatinib, tepotinib (e.g., tepotinib hydrochloride hydrate), vebreltinib, zanzalintinib (XL-092), amivantamab (e.g., amivantamab-vmjw, or a biosimilar thereof), emibetuzumab (or biosimilars thereof), RC-108, telisotuzumab vedotin (or biosimilars
15 thereof), ABBV-400, ABN-401, AL-2846, AMG-337, SAR-125844, or TQ-B-3139). In some embodiments, the cancer is a MET-altered NCLC (e.g., MET amplified NSCLC or MET exon14 skipping NSCLC), and the additional therapy or therapeutic agent is capmatinib (e.g., capmatinib hydrochloride) or tepotinib (e.g., tepotinib hydrochloride hydrate). In some
embodiments, the cancer is a MET-altered NCLC (e.g., MET amplified NSCLC or MET
20 exon14 skipping NSCLC), and the additional therapy or therapeutic agent is telisotuzumab vedotin (or biosimilars thereof).

In some embodiments, the Hif2 α inhibitor is belzutifan, AB-521, DFF-332, NKT-2152, PT-2399, or a combination thereof.

25 In some embodiments, the PARP inhibitor is fuzuloparib (fluzoparib), niraparib (e.g., niraparib tosylate monohydrate), olaparib, pamiparib, rucaparib (e.g., rucaparib camsylate), saruparib (AZD5305), senaparib, stenoparib, talazoparib (e.g., talazoparib tosylate), veliparib, CEP-9722, JPI-289, NMS-03305293, or a combination thereof. In some embodiments, the PARP inhibitor is a PARP1 inhibitor. In some embodiments, the PARP1 inhibitor is saruparib (AZD5305), NMS-03305293, or a combination thereof.

30 In some embodiments, the cancer is BRCA1 mutant breast cancer or BRCA2 mutant breast cancer, and the additional therapy or therapeutic agent is a PARP inhibitor (e.g., fuzuloparib (fluzoparib), niraparib (e.g., niraparib tosylate monohydrate), olaparib, pamiparib, rucaparib (e.g., rucaparib camsylate), saruparib (AZD5305), senaparib, stenoparib, talazoparib

(e.g., talazoparib tosylate), veliparib, CEP-9722, JPI-289, or NMS-03305293). In some embodiments, the cancer is BRCA1 mutant breast cancer or BRCA2 mutant breast cancer, and the additional therapy or therapeutic agent is saruparib.

5 In some embodiments, the cancer is triple negative breast cancer, and the additional therapy or therapeutic agent is a PARP inhibitor (e.g., fuzuloparib (fluzoparib), niraparib (e.g., niraparib tosylate monohydrate), olaparib, pamiparib, rucaparib (e.g., rucaparib camsylate), saruparib (AZD5305), senaparib, stenoparib, talazoparib (e.g., talazoparib tosylate), veliparib, CEP-9722, JPI-289, or NMS-03305293). In some embodiments, the cancer is triple negative breast cancer, and the additional therapy or therapeutic agent is saruparib.

10 In some embodiments, the cancer is HGSOE (e.g., BRCA1 mutant HGSOE or BRCA2 mutant HGSOE), and the additional therapy or therapeutic agent is a PARP inhibitor (e.g., fuzuloparib (fluzoparib), niraparib (e.g., niraparib tosylate monohydrate), olaparib, pamiparib, rucaparib (e.g., rucaparib camsylate), saruparib (AZD5305), senaparib, stenoparib, talazoparib (e.g., talazoparib tosylate), veliparib, CEP-9722, JPI-289, or NMS-03305293). In some
15 embodiments, the cancer is HGSOE (e.g., BRCA1 mutant HGSOE or BRCA2 mutant HGSOE), and the additional therapy or therapeutic agent is saruparib.

In some embodiments, the LSD1 inhibitor is bomedemstat, iadademstat, pulrodemstat, seclidemstat (HCI-2577), vafidemstat, GSK-2879552, INCB-059872, JBI-802, or a combination thereof.

20 In some embodiments, the BET inhibitor is alobresib, apabetalone, mivebresib, pelabresib, trotabresib, ABBV-744, BI-2536, BMS-986158, INCB-057643, JAB-8263, ODM-207, PLX-2853, ZEN-003694, or a combination thereof.

In some embodiments, the cancer is myelofibrosis (e.g., primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis), and the
25 additional therapy or therapeutic agent is a BET inhibitor (e.g., alobresib, apabetalone, mivebresib, pelabresib, trotabresib, ABBV-744, BI-2536, BMS-986158, INCB-057643, JAB-8263, ODM-207, PLX-2853, or ZEN-003694).

In some embodiments, the STING agonist is ulevostinag, ADU-S100, or a combination thereof.

30 In some embodiments, the telomerase inhibitor is imetelstat (e.g., imetelstat sodium).

In some embodiments, the TORC1/2 inhibitor is apitolisib, bimiralisib, dactolisib, deforolimus, everolimus, fosciclopirox (e.g., fosciclopirox sodium), gedatolisib, onatasertib, paxalisib, sapanisertib, sirolimus, sodium 2-hydroxylinoleate, temsirolimus, umirolimus,

vistusertib, zandelisib, zotarolimus, BI-860585, CC-115, CLL-442, PF-04691502, or a combination thereof.

In some embodiments, the VEGFR inhibitor is apatinib, axitinib, cabozantinib (e.g., cabozantinib *S*-malate), catequentinib (alontinib), cediranib, dovitinib, famitinib, fruquintinib, glesatinib, ibcasertib, ilorasertib, lenvatinib (e.g., lenvatinib mesylate), lucitanib, nintedanib (e.g., nintedanib esylate), pamufetinib, pazopanib (e.g., pazopanib hydrochloride), regorafenib (e.g., regorafenib monohydrate), sitravatinib, sorafenib (e.g., sorafenib tosylate), sunitinib (e.g., sunitinib malate), surufatinib (sulfatinib), telatinib, tinengotinib, tivozanib (e.g., tivozanib hydrochloride monohydrate), vandetanib, vorolanib, zanzalintinib, olinvacimab (or biosimilars thereof), ramucirumab (or biosimilars thereof), CEP-11981, ENMD-2076, ODM-203, or a combination thereof.

In some embodiments, the chemotherapy is a platinum complex, a microtubule inhibitor (e.g., a microtubule destabilizer or a microtubule stabilizer), a topoisomerase inhibitor, a hypomethylating agent, or an antibody-drug conjugate including any thereof. In some embodiments, the platinum complex is carboplatin, cisplatin, lobaplatin, miriplatin, oxaliplatin, or a combination thereof. In some embodiments, the microtubule inhibitor is cabazitaxel, colchicine, desoxyepothilone B, docetaxel, eribulin, ixabepilone, nab-paclitaxel, paclitaxel, plinabulin, sabizabulin, tirbanibulin, vinblastine, vinflunine, vinorelbine, or a combination thereof. In some embodiments, the microtubule inhibitor is cabazitaxel, docetaxel, nab-paclitaxel, paclitaxel, or a combination thereof. In some embodiments, the topoisomerase inhibitor is aclarubicin, amsacrine, belotecan, camptothecin, daunorubicin, dexrazoxane, elliptinium, epirubicin, etoposide, gepotidacin, idarubicin, mitoxantrone, nemonoxacin, pirarubicin, pixantrone, razoxane, rubitecan, sobuzoxane, temozolomide, teniposide, topotecan, SN-38, or a combination thereof. In some embodiments, the hypomethylating agent is azacitidine, decitabine, or a combination thereof. In some embodiments, the chemotherapy is a platinum complex and a topoisomerase inhibitor (e.g., cisplatin and etoposide). In some embodiments, the antibody-drug conjugate including the microtubule inhibitor is belantamab mafodotin, brentuximab vedotin, cofetuzumab pelidotin, disitamab vedotin, enfortumab vedotin (e.g., enfortumab vedotin-ejfv, or a biosimilar thereof), mirvetuximab soravtansine (e.g., mirvetuximab soravtansine-gynx, or a biosimilar thereof), polatuzumab vedotin, telisotuzumab vedotin, tisotumab vedotin, trastuzumab emtansine (e.g., ado-trastuzumab emtansine, or a biosimilar thereof), tusamitamab ravtansine, upifitamab rilsodotin, zilovetamab vedotin, Alpha-Her2-pAF1-AS-269, BAT-8001, TAA-013, biosimilars thereof,

or a combination thereof. In some embodiments, the antibody-drug conjugate including the microtubule inhibitor is enfortumab vedotin (e.g., enfortumab vedotin-ejfv, or a biosimilar thereof). In some embodiments, the antibody-drug conjugate including the microtubule inhibitor is mirvetuximab soravtansine (e.g., mirvetuximab soravtansine-gynx, or a biosimilar thereof). In some embodiments, the antibody-drug conjugate including the microtubule inhibitor is trastuzumab emtansine (e.g., ado-trastuzumab emtansine, or a biosimilar thereof). In some embodiments, the antibody-drug conjugate including the topoisomerase inhibitor is datopotamab deruxtecan, patritumab deruxtecan, sacituzumab govitecan (e.g., sacituzumab govitecan-hziy, or a biosimilar thereof), trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof), or a combination thereof. In some embodiments, the antibody-drug conjugate including the topoisomerase inhibitor is sacituzumab govitecan (e.g., sacituzumab govitecan-hziy, or a biosimilar thereof). In some embodiments, the antibody-drug conjugate including the topoisomerase inhibitor is trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof).

In some embodiments, the cancer is a lung cancer (e.g., NSCLC (e.g., squamous cell carcinoma)), and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel). In some embodiments, the cancer is a lung cancer (e.g., NSCLC (e.g., squamous cell carcinoma)), and the additional therapy or therapeutic agent is docetaxel.

In some embodiments, the cancer is NSCLC (e.g., NSCLC with a MET amplification), and the additional therapy or therapeutic agent is telisotuzumab vedotin.

In some embodiments, the cancer is a lung cancer (e.g., NSCLC), and the additional therapy or therapeutic agent is a platinum complex (e.g., carboplatin, cisplatin, lobaplatin, miriplatin, or oxaliplatin) and anti-PD1 therapy.

In some embodiments, the cancer is a lung cancer (e.g., NSCLC), and the additional therapy or therapeutic agent is a platinum complex (e.g., carboplatin, cisplatin, lobaplatin, miriplatin, or oxaliplatin) and anti-PD-L1 therapy.

In some embodiments, the cancer is a lung cancer (e.g., NSCLC), and the additional therapy or therapeutic agent is a pemetrexed and anti-PD1 therapy.

In some embodiments, the cancer is a lung cancer (e.g., NSCLC), and the additional therapy or therapeutic agent is a pemetrexed and anti-PD-L1 therapy.

In some embodiments, the cancer is a lung cancer (e.g., SCLC), and the additional therapy or therapeutic agent is a platinum complex (e.g., carboplatin, cisplatin, lobaplatin,

miriplatin, or oxaliplatin) and a topoisomerase inhibitor (e.g., aclarubicin, amsacrine, belotecan, camptothecin, daunorubicin, dexrazoxane, elliptinium, epirubicin, etoposide, gepotidacin, idarubicin, mitoxantrone, nemonoxacin, pirarubicin, pixantrone, razoxane, rubitecan, sobuzoxane, temozolomide, teniposide, topotecan, or SN-38). In some
5 embodiments, the cancer is a lung cancer (e.g., SCLC), and the additional therapy or therapeutic agent is carboplatin and etoposide. In some embodiments, the cancer is a lung cancer (e.g., SCLC), and the additional therapy or therapeutic agent is cisplatin and etoposide.

In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression),
10 HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low breast cancer), and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel). In some embodiments, the cancer is triple negative breast cancer, and the additional therapy or therapeutic agent is a microtubule inhibitor
15 (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel). In some embodiments, the cancer is triple negative breast cancer, and the additional therapy or therapeutic agent is nab-paclitaxel or paclitaxel.

In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression),
20 HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low breast cancer), and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel) and anti-PD1 therapy.

In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression),
25 HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low breast cancer), and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel) and anti-PD-L1 therapy.

30 In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low

breast cancer), and the additional therapy or therapeutic agent is capecitabine.

In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low breast cancer), and the additional therapy or therapeutic agent is sacituzumab govitecan (e.g., sacituzumab govitecan-hziy, or a biosimilar thereof).

In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low breast cancer), and the additional therapy or therapeutic agent is trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof).

In some embodiments, the cancer is breast cancer (e.g., HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), HER2 negative breast cancer (e.g., HER2 negative breast cancer with ER expression, HER2 negative breast cancer without ER expression), triple negative breast cancer, or HER2 low breast cancer), and the additional therapy or therapeutic agent is trastuzumab (e.g., HERCEPTIN® (trastuzumab), or a biosimilar thereof (e.g., FACEPTOR® (trastuzumab), HERTICAD® (trastuzumab), TUZNUE® (trastuzumab), ZERCEPAC® (trastuzumab), trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, EG-12014, or TX-05)).

In some embodiments, the cancer is hormone receptor positive breast cancer, and the additional therapy or therapeutic agent is hormone therapy (e.g., tamoxifen, toremifene, or a combination thereof).

In some embodiments, the cancer is hormone receptor positive breast cancer, and the additional therapy or therapeutic agent is a selective estrogen receptor degrader (SERD) (e.g., fulvestrant, elacestrant, or a combination thereof).

In some embodiments, the cancer is a HER2+ breast cancer (e.g., HER2+ breast cancer with ER expression, HER2+ breast cancer without ER expression), and the additional therapy or therapeutic agent is trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof) or trastuzumab emtansine (e.g., KADCYLA® (trastuzumab emtansine), or a biosimilar thereof (e.g., UJVIRA® (trastuzumab emtansine))).

In some embodiments, the cancer is a HER2 low breast cancer, and the additional therapy or therapeutic agent is trastuzumab deruxtecan (e.g., fam-trastuzumab deruxtecan-nxki, or a biosimilar thereof).

5 In some embodiments, the cancer is a head and neck cancer, and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel). In some embodiments, the cancer is a head and neck cancer, and the additional therapy or therapeutic agent is docetaxel.

10 In some embodiments, the cancer is a cervical cancer, and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel).

In some embodiments, the cancer is an endometrial cancer, and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel).

15 In some embodiments, the cancer is a prostate cancer, and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel).

20 In some embodiments, the cancer is an ovarian cancer (e.g., HGSOC) and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel). In some embodiments, the cancer is an ovarian cancer (e.g., HGSOC) and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel) and a platinum complex (e.g., carboplatin, cisplatin, lobaplatin, miriplatin, or oxaliplatin). In some embodiments, the cancer is an ovarian cancer (e.g., HGSOC) and the additional therapy or therapeutic agent is nab-paclitaxel or paclitaxel and carboplatin.

25 In some embodiments, the cancer is a pancreatic cancer, and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel). In some embodiments, the cancer is a pancreatic cancer, and the additional therapy or therapeutic agent is a microtubule inhibitor (e.g., cabazitaxel, docetaxel, nab-paclitaxel, or paclitaxel) and gemcitabine.

30 In some embodiments, the cancer is a bladder cancer (e.g., bladder urothelial carcinoma), and the additional therapy or therapeutic agent is enfortumab vedotin (e.g., enfortumab vedotin-ejfv, or a biosimilar thereof).

In some embodiments, the cancer is a bladder cancer (e.g., bladder urothelial

carcinoma), and the additional therapy or therapeutic agent is sacituzumab govitecan (e.g., sacituzumab govitecan-hziy, or a biosimilar thereof).

5 In some embodiments, the cancer is triple negative breast cancer, and the additional therapy or therapeutic agent is sacituzumab govitecan (e.g., sacituzumab govitecan-hziy, or a biosimilar thereof).

In some embodiments, folate receptor positivity status can be detected in a sample from the subject (e.g., via immunohistochemistry (IHC) and/or fluorescent *in situ* hybridization (FISH)). In some embodiments, the subject was determined (e.g., prior to administration of a compound provided herein) to have a cancer that is folate receptor positive.

10 In some embodiments, the cancer is folate receptor positive ovarian cancer (e.g., folate receptor positive HGSO), and the additional therapy or therapeutic agent is mirvetuximab soravtansine (e.g., mirvetuximab soravtansine-gynx, or a biosimilar thereof).

In some embodiments the immunomodulatory imide drug is thalidomide, lenalidomide, pomalidomide, iberdomide, avadomide, CC-99282, or a combination thereof.

15 In some embodiments, the anti-PD1 therapy is balstilimab, budigalimab, cadonilimab, camrelizumab, cemiplimab (e.g., cemiplimab-rwlc, or a biosimilar thereof), cetrelimab, dostarlimab (e.g., dostarlimab-gxly, or a biosimilar thereof), ezabenlimab, geptanolimab, ivonescimab, nivolumab (e.g., OPDIVO® (nivolumab), or a biosimilar thereof), nofazinlimab, pembrolizumab (e.g., KEYTRUDA® (pembrolizumab), or a biosimilar thereof), penpulimab, pidilizumab, pimivalimab, prolgolimab, pucotenlimab, retifanlimab (e.g., retifanlimab-dlwr, or a biosimilar thereof), rilvegostomig, rosnilimab, rulonilimab, sasanlimab, serplulimab, sintilimab (e.g., TYVYT® (sintilimab), or a biosimilar thereof), spartalizumab, tebotelimab, tislelizumab, toripalimab, volrustomig, vudalimab, zimberelimab, QL-1604, HX-009, INCB-086550, RG-6139, BAT-1306, SG-001, biosimilars thereof, or a combination thereof.

25 In some embodiments, the PD-L1 inhibitor is INCB-086550.

In some embodiments, the anti-PD-L1 therapy is adebrelimab, atezolizumab (e.g., TECENTRIQ® (atezolizumab), or a biosimilar thereof), avelumab (e.g., BAVENCIO® (avelumab), or a biosimilar thereof), bintrafusp alfa, cosibelimab, danburstotug, durvalumab (e.g., IMFINZI® (durvalumab), or a biosimilar thereof), envafolimab (e.g., ENWEIDA® (envafolimab), or a biosimilar thereof), erfonrilimab, pacmilimab, socazolimab, sugemalimab (e.g., CEJEMLY® (sugemalimab), or a biosimilar thereof), A-167, APL-502, AUPM-170, BNT-311, SHR-1701, biosimilars thereof, or a combination thereof.

In some embodiments, the additional therapy is radiotherapy.

In some embodiments, the cancer is head and neck cancer (e.g., head and neck squamous cell carcinoma), and the additional therapy is radiotherapy.

In some embodiments, the additional therapy includes a BRAf inhibitor and a MEK inhibitor. For example, the additional therapy can include dabrafenib and trametinib,
5 vemurafenib and cobimetinib, or encorafenib and binimetinib.

Exemplary descriptions of agents in combination with BCL-2 family inhibitors can be found in: Hikita, Hayato, et al. *Hepatology* 52.4 (2010): 1310-1321, doi: 10.1002/hep.23836; Chen, Jun, et al. *Molecular Cancer Therapeutics* 10.12 (2011): 2340-2349, doi: 10.1158/1535-7163.MCT-11-0415; Inuzuka, Hiroyuki, et al. *Nature* 471.7336 (2011): 104-109, doi: 10.1038/nature09732; Wertz, Ingrid E., et al. *Nature* 471.7336 (2011): 110-114, doi: 10.1038/nature09779; Tan, Nguyen, et al. *Clinical Cancer Research* 17.6 (2011): 1394-1404, doi: 10.1158/1078-0432.CCR-10-2353; Wong, Maureen, et al. *Molecular Cancer Therapeutics* 11.4 (2012): 1026-1035, doi: 10.1158/1535-7163.MCT-11-0693; Corcoran, Ryan B., et al. *Cancer Cell* 23.1 (2013): 121-128, doi: 10.1016/j.ccr.2012.11.007; Waibel, Michaela, et al. *Cell Reports* 5.4 (2013): 1047-1059, doi: 10.1016/j.celrep.2013.10.038; Frederick, Dennie T., et al. *PloS One* 9.7 (2014): e101286, doi: 10.1371/journal.pone.0101286; Vlahovic, Gordana, et al. *Investigational New Drugs* 32.5 (2014): 976-984, doi: 10.1007/s10637-014-0116-3; Faber, Anthony C., et al. *Cancer Discovery* 4.1 (2014): 42-52, doi: 10.1158/2159-8290.CD-13-0315; Levenson, Joel D., et al. *Science Translational Medicine* 7.279 (2015): 279ra40-279ra40, doi: 10.1126/scitranslmed.aaa4642; Guo, Jun, et al. *PLoS One* 10.3 (2015): e0114363, doi: 10.1371/journal.pone.0114363; Lheureux, Stéphanie, et al. *International Journal of Cancer* 136.5 (2015): E340-E350, doi: 10.1002/ijc.29104; Zoeller, Jason J., et al. *Cancer Research* 76.14_Supplement (2016): 4358-4358, doi: 10.1158/1538-7445.AM2016-4358; Weeden, Clare E., et al. *Oncogene* 37.32 (2018): 4475-4488, doi: 10.1038/s41388-018-0268-2; Lucantoni, Federico, et al. *Cell Death & Disease* 9.2 (2018): 1-13, doi: 10.1038/s41419-017-0039-y; Iavarone, Claudia, et al. *Molecular Cancer Therapeutics* 18.3 (2019): 642-655, doi: 10.1158/1535-7163.MCT-18-0413; Fleury, Hubert, et al. *Nature Communications* 10.1 (2019): 2556, doi: 10.1038/s41467-019-10460-1; Lohard, Steven, et al. *Nature Communications* 11.1 (2020): 259, doi: 10.1038/s41467-019-13689-y; Bertino, Erin M., et al. *Clinical Cancer Research* 27.6 (2021): 1604-1611, doi: 10.1158/1078-0432.CCR-20-4084; Guo, Ting, et al. *Aging* 13.15 (2021): 19750, doi: 10.18632/aging.203386; Puglisi, Martina, et al. *Future Oncology* 17.21 (2021): 2747-2758, doi: 10.2217/fon-2021-0140; Harrison, Claire N., et al. *Journal of Clinical Oncology* 40.15 (2022): 1671, doi:

10.1200/JCO.21.02188; Köhler, Jens, et al. *Molecular Cancer Therapeutics* 20.4 (2021): 641-654, doi: 10.1158/1535-7163.MCT-20-0531; Jaaks, Patricia, et al. *Nature* 603.7899 (2022): 166-173, doi: 10.1038/s41586-022-04437-2; Sobol, Benjamin, et al. *International Journal of Molecular Sciences* 23.14 (2022): 7850, doi: 10.3390/ijms23147850; Passamonti, *J Clin Oncol* 40, (2022) (suppl 16; abstr 7015), doi: 10.1200/JCO.2022.40.16_suppl.7015; Qin, *J Clin Oncol* 40, (2022) (suppl 16; abstr e20612), doi: 10.1200/JCO.2022.40.16_suppl.e20612; Potter, Danielle S., et al. *Cancer Research* 82.12_Supplement (2022): 3691-3691, doi: 10.1158/1538-7445.AM2022-3691; and Shebl, Bassem, et al. *Cancer Research* 82.12_Supplement (2022): 3888-3888, doi: 10.1158/1538-7445.AM2022-3888.

Also provided herein is a method of treating cancer, comprising administering to a subject in need thereof (a) a compound provided herein, or a pharmaceutically acceptable salt thereof, and (b) an additional therapeutic agent, for simultaneous, separate or sequential use for the treatment of cancer, wherein the amounts of the compound provided herein, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are together effective in treating the cancer. In some embodiments, the method comprises administering (c) at least one pharmaceutically acceptable carrier.

These additional therapeutic agents may be administered with one or more doses of the compound provided herein, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof, as part of the same or separate dosage forms, via the same or different routes of administration, and/or on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art. In some embodiments, the compound provided herein, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are administered simultaneously as separate dosages. In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are administered as separate dosages sequentially in any order, in jointly therapeutically effective amounts, e.g., in daily or intermittently dosages. In some embodiments, the compound provided herein, or a pharmaceutically acceptable salt thereof, and the additional therapeutic agent are administered simultaneously as a combined dosage.

Also provided herein is (i) a pharmaceutical combination for treating a cancer in a subject in need thereof, which comprises (a) a compound provided herein, or a pharmaceutically acceptable salt thereof, and (b) at least one additional therapeutic agent (e.g., any of the exemplary additional therapeutic agents described herein or known in the art), for simultaneous, separate or sequential use for the treatment of cancer, wherein the amounts of

the compound provided herein, or a pharmaceutically acceptable salt thereof, and of the additional therapeutic agent are together effective in treating the cancer; (ii) a pharmaceutical composition comprising such a combination; (iii) the use of such a combination for the preparation of a medicament for the treatment of cancer; and (iv) a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of cancer in a subject in need thereof. In some embodiments, the pharmaceutical combination comprises (c) at least one pharmaceutically acceptable carrier.

As used herein, terms “treat” or “treatment” refer to therapeutic or palliative measures. Beneficial or desired clinical results include, but are not limited to, alleviation, in whole or in part, of symptoms associated with a disease or disorder or condition, diminishment of the extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state (e.g., one or more symptoms of the disease), and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.

As used herein, the terms “subject,” “individual,” or “patient,” are used interchangeably, refers to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans. In some embodiments, the subject is a human. In some embodiments, the subject has experienced and/or exhibited at least one symptom of the disease, disorder, or condition to be treated and/or prevented.

In some embodiments, the subject is a pediatric subject.

The term “pediatric subject” as used herein refers to a subject under the age of 21 years at the time of diagnosis or treatment. The term “pediatric” can be further be divided into various subpopulations including: neonates (from birth through the first month of life); infants (1 month up to two years of age); children (two years of age up to 12 years of age); and adolescents (12 years of age through 21 years of age (up to, but not including, the twenty-second birthday)). Berhman RE, Kliegman R, Arvin AM, Nelson WE. Nelson *Textbook of Pediatrics*, 15th Ed. Philadelphia: W.B. Saunders Company, 1996; Rudolph AM, et al. *Rudolph’s Pediatrics*, 21st Ed. New York: McGraw-Hill, 2002; and Avery MD, First LR. *Pediatric Medicine*, 2nd Ed. Baltimore: Williams & Wilkins; 1994. In some embodiments, a pediatric subject is from birth through the first 28 days of life, from 29 days of age to less than two years of age, from two years of age to less than 12 years of age, or 12 years of age through 21 years of age (up to, but

not including, the twenty-second birthday). In some embodiments, a pediatric subject is from birth through the first 28 days of life, from 29 days of age to less than 1 year of age, from one month of age to less than four months of age, from three months of age to less than seven months of age, from six months of age to less than 1 year of age, from 1 year of age to less than 2 years of age, from 2 years of age to less than 3 years of age, from 2 years of age to less than seven years of age, from 3 years of age to less than 5 years of age, from 5 years of age to less than 10 years of age, from 6 years of age to less than 13 years of age, from 10 years of age to less than 15 years of age, or from 15 years of age to less than 22 years of age.

The term “preventing” as used herein means to delay the onset, recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.

The term “regulatory agency” refers to a country's agency for the approval of the medical use of pharmaceutical agents with the country. For example, a non-limiting example of a regulatory agency is the U.S. Food and Drug Administration (FDA).

The phrase “therapeutically effective amount” means an amount of compound that, when administered to a subject in need thereof, is sufficient to (i) treat a disease, disorder, or condition, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, disorder, or condition, or (iii) delay the onset of one or more symptoms of the particular disease, disorder, or condition described herein. The amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the subject in need of treatment, but can nevertheless be routinely determined by one skilled in the art.

The phrase “effective amount” of a compound provided herein, as used herein, means an amount of the compound that, when administered to a cell, in vitro or in vivo, is sufficient to reduce proliferation of the cell or to kill the cell. The amount of a compound provided herein, or a pharmaceutically acceptable salt thereof, that will correspond to such an amount will vary depending upon factors such as the particular compound and genetics of the cell to be treated, but can nevertheless be routinely determined by one skilled in the art.

Pharmaceutical Compositions and Administration

General

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition that includes the compound, or a

pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, and optionally one or more additional therapeutic agents as described herein.

In some embodiments, the compounds can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- α -tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α -, β -, and γ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- β -cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic excipient may be prepared. The contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington: The Science and Practice of Pharmacy*, 22nd Edition (Pharmaceutical Press, London, UK. 2012).

Routes of Administration and Composition Components

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition thereof, can be administered to a subject in need thereof by any accepted route of administration. Acceptable routes of administration include, but are not limited to, buccal, cutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal,

intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, intravitreal, nasal, nasogastric, oral, parenteral, percutaneous, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral and vaginal. In certain embodiments, a preferred route of administration is parenteral (e.g., intratumoral).

In some embodiments, a compound provided herein, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition thereof, can be administered orally to a subject in need thereof. Without being bound by any particular theory, it is believed that oral dosing (e.g., versus IV dosing) can be preferred by patients for convenience, perception of efficacy, and/or past experience.

Compositions can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified. The preparation of such formulations will be known to those of skill in the art in light of the present disclosure.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

The carrier also can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

5 Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques, which yield a powder
10 of the active ingredient, plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Intratumoral injections are discussed, e.g., in Lammers, et al., "Effect of Intratumoral Injection on the Biodistribution and the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems" *Neoplasia*. **2006**, *10*, 788–795, doi: 10.1593/neo.06436.

15 Pharmacologically acceptable excipients usable in the rectal composition as a gel, cream, enema, or rectal suppository, include, without limitation, any one or more of cocoa butter glycerides, synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), glycerine, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol
20 Vaseline, anhydrous lanolin, shark liver oil, sodium saccharinate, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid SBN, vanilla essential oil, aerosol, parabens in phenoxyethanol, sodium methyl p-oxybenzoate, sodium propyl p-oxybenzoate, diethylamine, carbomers, carbopol, methyloxybenzoate, macrogol cetostearyl ether, cocoyl caprylocaprates, isopropyl alcohol, propylene glycol, liquid paraffin, xanthan gum, carboxy-metabisulfite,
25 sodium edetate, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methyl sulfonyl methane (MSM), lactic acid, glycine, vitamins, such as vitamin A and E and potassium acetate.

In certain embodiments, suppositories can be prepared by mixing the compound described herein with suitable non-irritating excipients or carriers such as cocoa butter,
30 polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound. In other embodiments, compositions for rectal administration are in the form of an enema.

In other embodiments, the compounds described herein, or a pharmaceutical

composition thereof, are suitable for local delivery to the digestive or GI tract by way of oral administration (e.g., solid or liquid dosage forms.).

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compound is mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or dicalcium phosphate and/or:
5 a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain
10 silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage
15 form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound, or
20 pharmaceutically acceptable salt thereof, as provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives, or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEGs, poloxamer 124 or triglycerides) is
25 encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.

30 Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives that are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid.

In certain embodiments the excipients are sterile and generally free of undesirable matter. These compositions can be sterilized by conventional, well-known sterilization techniques. For various oral dosage form excipients such as tablets and capsules sterility is not required. The USP/NF standard is usually sufficient.

5 In certain embodiments, solid oral dosage forms can further include one or more components that chemically and/or structurally predispose the composition for delivery of the compounds to the stomach or the lower GI; e.g., the ascending colon and/or transverse colon and/or distal colon and/or small bowel. Exemplary formulation techniques are described in, e.g., Filipski, K.J., et al., *Current Topics in Medicinal Chemistry*, **2013**, *13*, 776-802, doi:
10 10.2174/1568026611313070002.

Examples include upper-GI targeting techniques, e.g., Accordion Pill (Intec Pharma), floating capsules, and materials capable of adhering to mucosal walls.

Other examples include lower-GI targeting techniques. For targeting various regions in the intestinal tract, several enteric/pH-responsive coatings and excipients are available. These
15 materials are typically polymers that are designed to dissolve or erode at specific pH ranges, selected based upon the GI region of desired drug release. These materials also function to protect acid labile drugs from gastric fluid or limit exposure in cases where the active ingredient may be irritating to the upper GI (e.g., hydroxypropyl methylcellulose phthalate series, Coateric (polyvinyl acetate phthalate), cellulose acetate phthalate, hydroxypropyl
20 methylcellulose acetate succinate, Eudragit series (methacrylic acid–methyl methacrylate copolymers), and Marcoat). Other techniques include dosage forms that respond to local flora in the GI tract, Pressure-controlled colon delivery capsule, and Pulsincap.

Ocular compositions can include, without limitation, one or more of any of the following: viscosogens (e.g., Carboxymethylcellulose, Glycerin, Polyvinylpyrrolidone,
25 Polyethylene glycol); Stabilizers (e.g., Pluronic (triblock copolymers), Cyclodextrins); Preservatives (e.g., Benzalkonium chloride, ETDA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (stabilized oxychloro complex; Allergan, Inc.)).

Topical compositions can include ointments and creams. Ointments are semisolid
30 preparations that are typically based on petrolatum or other petroleum derivatives. Creams containing the selected active agent are typically viscous liquid or semisolid emulsions, often either oil-in-water or water-in-oil. Cream bases are typically water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, also sometimes called the

“internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation is generally a nonionic, anionic, cationic, or amphoteric surfactant. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating, and non-sensitizing.

In any of the foregoing embodiments, pharmaceutical compositions described herein can include one or more one or more of the following: lipids, interbilayer crosslinked multilamellar vesicles, biodegradable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.

Dosages

The dosages may be varied depending on the requirement of the patient, the severity of the condition being treated, and the particular compound being employed. Determination of the proper dosage for a particular situation can be determined by one skilled in the medical arts. The total daily dosage may be divided and administered in portions throughout the day or by means providing continuous delivery.

In some embodiments, the compounds described herein are administered at a dosage of from about 0.001 mg/kg to about 500 mg/kg (e.g., from about 0.001 mg/kg to about 200 mg/kg; from about 0.01 mg/kg to about 200 mg/kg; from about 0.01 mg/kg to about 150 mg/kg; from about 0.01 mg/kg to about 100 mg/kg; from about 0.01 mg/kg to about 50 mg/kg; from about 0.01 mg/kg to about 10 mg/kg; from about 0.01 mg/kg to about 5 mg/kg; from about 0.01 mg/kg to about 1 mg/kg; from about 0.01 mg/kg to about 0.5 mg/kg; from about 0.01 mg/kg to about 0.1 mg/kg; from about 0.1 mg/kg to about 200 mg/kg; from about 0.1 mg/kg to about 150 mg/kg; from about 0.1 mg/kg to about 100 mg/kg; from about 0.1 mg/kg to about 50 mg/kg; from about 0.1 mg/kg to about 10 mg/kg; from about 0.1 mg/kg to about 5 mg/kg; from about 0.1 mg/kg to about 1 mg/kg; from about 0.1 mg/kg to about 0.5 mg/kg).

Regimens

The foregoing dosages can be administered on a daily basis (e.g., as a single dose or as two or more divided doses) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weeks, once every two weeks, once a month).

In some embodiments, the period of administration of a compound described herein is

for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In a further embodiment, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In an embodiment, a compound provided herein is administered to an individual for a period of time followed by a separate period of time (e.g., a dosing holiday). In another embodiment, a compound provided herein is administered for a first period and a second period following the first period, with administration stopped during the second period (e.g., a dosing holiday), followed by a third period where administration of the compound provided herein is started and then a fourth period following the third period where administration is stopped (e.g., a dosing holiday). In an aspect of this embodiment, the period of administration of a compound provided herein followed by a period where administration is stopped (e.g., a dosing holiday) is repeated for a determined or undetermined period of time. In a further embodiment, a period of administration is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In a further embodiment, a period of during which administration is stopped (e.g., a dosing holiday) is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.

The term “acceptable” with respect to a formulation, composition, or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.

“API” refers to an active pharmaceutical ingredient.

The term “excipient” or “pharmaceutically acceptable excipient” means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In one embodiment, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a

pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio. *See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.*; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; *Handbook of Pharmaceutical Excipients, 6th ed.*; Rowe *et al.*, Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; *Handbook of Pharmaceutical Additives, 3rd ed.*; Ash and Ash Eds.; Gower Publishing Company: 2007; *Pharmaceutical Preformulation and Formulation, 2nd ed.*; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009.

The term “pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In certain instances, pharmaceutically acceptable salts are obtained by reacting a compound described herein, with acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. In some instances, pharmaceutically acceptable salts are obtained by reacting a compound having acidic group described herein with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, *N*-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like, or by other methods previously determined. The term “pharmacologically acceptable salts” is not specifically limited as far as it can be used in medicaments. Examples of a salt that the compounds described herein form with a base include the following: salts thereof with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; salts thereof with organic bases such as methylamine, ethylamine, and ethanolamine; salts thereof with basic amino acids such as lysine and ornithine; and ammonium salt. The salts can be acid addition salts, which are specifically exemplified by acid addition salts with the following: mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; acidic amino acids such as aspartic acid and glutamic acid.

In some embodiments, a pharmaceutically acceptable salt is an anion salt selected from the group consisting of: a mesylate salt, a besylate salt, an acetate salt, a benzenesulfonate salt, a benzoate salt, a bicarbonate salt, a bitartrate salt, a bromide salt, a calcium edetate salt, a camsylate salt, a carbonate salt, a chloride salt, a citrate salt, a dihydrochloride salt, an edetate salt, an edisylate salt, an estolate salt, an esylate salt, a fumarate salt, a gluceptate salt, a gluconate salt, a glucuronate salt, a glutamate salt, a glycolylarsanilate salt, a hexylresorcinol salt, a hydramine salt, a hydrobromide salt, a hydrochloride salt, a hydroxynaphthoate salt, an iodide salt, an isethionate salt, a lactate salt, a lactobionate salt, a malate salt, a maleate salt, a mandelate salt, a mesylate salt, a methylbromide salt, a methylnitrate salt, a methylsulfate salt, a mucate salt, a napsylate salt, a nitrate salt, a pamoate (embonate) salt, a pantothenate salt, a phosphate/diphosphate salt, a polygalacturonate salt, a salicylate salt, a stearate salt, a subacetate salt, a succinate salt, a sulfate salt, an oleate salt, a tannate salt, a tartrate salt, a teoclate salt, and a triethiodide salt.

In some embodiments, a pharmaceutically acceptable salt is a cation salt selected from the group consisting of: a benzathine salt, a chloroprocaine salt, a choline salt, a tromethamine salt, a diethanolamine salt, an ethylenediamine salt, a meglumine salt, a procaine salt, an aluminum salt, a calcium salt, a lithium salt, a magnesium salt, a potassium salt, a sodium salt, and a zinc salt.

Examples of pharmaceutically acceptable salts also include those disclosed in e.g., Berge, Stephen M., Lyle D. Bighley, and Donald C. Monkhouse. "Pharmaceutical salts." *Journal of pharmaceutical sciences* 66.1 (1977): 1-19 doi: 10.1002/jps.2600660104, Bharate, Sonali S. "Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019." *Drug Discovery Today* 26.2 (2021): 384-398 doi: 10.1016/j.drudis.2020.11.016, and Bharate, Sonali S. "Modulation of biopharmaceutical properties of drugs using sulfonate counterions: A critical analysis of FDA-approved pharmaceutical salts." *Journal of Drug Delivery Science and Technology* 66 (2021): 102913 doi: 10.1016/j.jddst.2021.102913.

The term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components (referred to collectively herein as "excipients"), such as carriers, stabilizers, diluents, dispersing agents, suspending agents, and/or thickening agents. The pharmaceutical composition facilitates administration of the compound to a subject. Multiple techniques of administering a compound exist in the art including, but not limited to: rectal, oral, intravenous, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

Compound Preparation

The compounds disclosed herein can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or in light of the teachings herein.


Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as R. Larock, *Comprehensive Organic Transformations*, VCH Publishers (1989); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); Smith, M. B., March, J., *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, 5th edition, John Wiley & Sons: New York, 2001 ; and Greene, T.W., Wuts, P.G. M., *Protective Groups in Organic Synthesis*, 3rd edition, John Wiley & Sons: New York, 1999, are useful and recognized reference textbooks of organic synthesis known to those in the art. The following descriptions of synthetic methods are designed to illustrate, but not to limit, general procedures for the preparation of compounds of the present disclosure.

The synthetic processes disclosed herein can tolerate a wide variety of functional groups; therefore, various substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt thereof.

EXAMPLES

Example 1. Preparation of

6-[8-(1,3-Benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-7-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylic acid (Compound 109)



A. (*E*)-*tert*-Butyl 4-(4-((3-bromoallyl)oxy)benzyl)piperidine-1-carboxylate

To a solution of *tert*-butyl 4-(4-hydroxybenzyl)piperidine-1-carboxylate (300 mg, 1.03 mmol, 1.0 equiv.) in MeCN (2 mL) was added K₂CO₃ (426.88 mg, 3.09 mmol, 3.0 *eq.*), KI (170.91 mg, 1.03 mmol, 1.0 *eq.*) and (*E*)-1,3-dibromoprop-1-ene (205.78 mg, 1.03 mmol, 1.0 *eq.*). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=50/1 to 20/1) to give (*E*)-*tert*-butyl 4-(4-((3-bromoallyl)oxy)benzyl)piperidine-1-carboxylate (400 mg, 974.79 umol, 94 % yield) as yellow oil. MS (ESI) *m/z*: 355.8 [M + H]⁺; ¹H NMR (400 MHz, CDCl₃) δ = 7.06 (d, *J* = 6.8 Hz, 2H), 6.85 - 6.81 (m, 2H), 6.48 - 6.38 (m, 2H), 4.70 (d, *J* = 5.2 Hz, 1H), 4.47 (d, *J* = 5.2 Hz, 1H), 4.11 - 4.06 (m, 2H), 2.64 (t, *J* = 11.6 Hz, 2H), 2.48 (d, *J* = 6.8 Hz, 2H), 1.62-1.58 (m, 4H), 1.46 (s, 9H), 1.18 - 1.11 (m, 1H).

B. 4-[[4-[(*E*)-3-Bromoallyloxy]phenyl]methyl]piperidine

To a solution of *tert*-butyl 4-[[4-[(*E*)-3-bromoallyloxy]phenyl]methyl]piperidine-1-carboxylate (400 mg, 974.79 umol, 1.0 *eq.*) in DCM (2 mL) was added HCl/dioxane (4 M, 1 mL, 4.1 *eq.*). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove solvent to give compound 4-[[4-[(*E*)-3-bromoallyloxy]phenyl]methyl]piperidine (300 mg, 967.03 umol, 99 % yield) as a yellow solid. MS (ESI) *m/z*: 311.8 [M + H]⁺.

C. Ethyl 2-[4-[[4-[(*E*)-3-bromoallyloxy]phenyl]methyl]-1-piperidyl]acetate

To a solution of 4-[[4-[(*E*)-3-bromoallyloxy]phenyl]methyl]piperidine (300 mg, 967.03 umol, 1.0 *eq.*) in ACN (3 mL) was added K₂CO₃ (400.95 mg, 2.90 mmol, 3.0 *eq.*), KI (16.05 mg, 96.70 umol, 0.1 *eq.*) and ethyl 2-bromoacetate (161.49 mg, 967.03 umol, 106.95 uL, 1.0 *eq.*). The mixture was stirred at 25 °C for 20 min. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate = 20/1 to 2/1) to give ethyl 2-[4-[[4-[(*E*)-3-bromoallyloxy]phenyl]methyl]-1-piperidyl]acetate (80 mg, 201.86 umol, 21% yield) as yellow oil. MS (ESI) *m/z*: 397.8 [M + H]⁺; ¹H NMR (400 MHz, CDCl₃) δ = 6.98 (dd, *J* = 2.0, 8.8 Hz,

2H), 6.76 - 6.72 (m, 2H), 6.40 - 6.29 (m, 2H), 4.62 (dd, $J = 1.6, 4.8$ Hz, 1H), 4.39 (d, $J = 4.8$ Hz, 1H), 4.10 (q, $J = 7.2$ Hz, 2H), 3.11 (s, 2H), 2.84 (d, $J = 11.2$ Hz, 2H), 2.41 (d, $J = 6.8$ Hz, 2H), 2.04 (t, $J = 11.2$ Hz, 2H), 1.55 (d, $J = 10.4$ Hz, 4H), 1.43 - 1.37 (m, 1H), 1.19 (t, $J = 7.2$ Hz, 3H).

5 **D. *tert*-Butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[(*E*)-3-[4-[[1-(2-ethoxy-2-oxoethyl)-4-piperidyl]methyl]phenoxy]prop-1-enyl]pyridine-2-carboxylate**

To a solution of ethyl 2-[4-[[4-[(*E*)-3-bromoallyloxy]phenyl]methyl]-1-piperidyl]acetate (70 mg, 176.63 μ mol, 1.0 *eq.*) in dioxane (2 mL) and H₂O (0.5 mL) was added
10 [2-(2-aminophenyl)phenyl]palladium(1+); bis(1-adamantyl)-butylphosphane; methanesulfonate (12.86 mg, 17.66 μ mol, 0.1 *eq.*), *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxylate (108.19 mg, 176.63 μ mol, 1.0 *eq.*) and KF (30.78 mg, 529.88 μ mol, 12.41 μ L, 3.0 *eq.*). The mixture was stirred at 100 °C for 1 hour. The reaction mixture was
15 concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate = 20/1 to 1/1) to give *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[(*E*)-3-[4-[[1-(2-ethoxy-2-oxoethyl)-4-piperidyl]methyl]phenoxy]prop-1-enyl]pyridine-2-carboxylate (120 mg, 149.63 μ mol, 85 % yield) as a yellow solid. MS (ESI) m/z : 802.6 [M + H]⁺.

20 **E. *tert*-Butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-(2-ethoxy-2-oxoethyl)-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate**

To a solution of *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[(*E*)-3-[4-[[1-(2-ethoxy-2-oxoethyl)-4-piperidyl]methyl]phenoxy]prop-1-enyl]pyridine-2-carboxylate (120 mg, 149.63 μ mol, 1.0 *eq.*) in THF (2 mL) was added Pd/C
25 (50 mg, 149.63 μ mol, 10% purity, 1.0 *eq.*) under N₂ atmosphere. The suspension was degassed and purged with H₂ 3 times. The mixture was stirred under H₂ (15 Psi.) at 40 °C for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to give *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-(2-ethoxy-2-oxoethyl)-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate (110 mg,
30 136.8 μ mol, 91.4% yield) as yellow oil. MS (ESI) m/z : 804.4 [M + H]⁺.

F. 2-[4-[[4-[3-[6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-2-*tert*-butoxycarbonyl-3-pyridyl]propoxy]phenyl]methyl]-1-piperidyl]acetic acid

To a solution of *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-(2-ethoxy-2-oxoethyl)-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate (110 mg, 136.81 μmol , 1.0 *eq.*) in THF (2 mL) and H₂O (0.5 mL) was added LiOH•H₂O (17.22 mg, 410.44 μmol , 3.0 *eq.*). The mixture was stirred at 40 °C for 1 hour. The reaction mixture was acidified to pH = 5 with 1M HCl and extracted with EA 30 mL (30 mL $\times$ 3). The combined organic layers were washed with brine 30 mL, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 2-[4-[[4-[3-[6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-2-*tert*-butoxycarbonyl-3-pyridyl]propoxy]phenyl]methyl]-1-piperidyl]acetic acid (100 mg, 128.87 μmol , 94.20% yield) as a yellow solid. MS (ESI) *m/z*: 776.3 [M + H]⁺.

G. *tert*-Butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-7-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate

To a solution of 2-[4-[[4-[3-[6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-2-*tert*-butoxycarbonyl-3-pyridyl]propoxy]phenyl]methyl]-1-piperidyl]acetic acid (120 mg, 154.65 μmol , 1.0 *eq.*) in pyridine (1 mL) was added EDCI (38.54 mg, 201.04 μmol , 1.3 *eq.*) and 3-(7-amino-1-methyl-indazol-3-yl)piperidine-2,6-dione (43.94 mg, 170.11 μmol , 1.1 *eq.*). The mixture was stirred at 40 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate = 4/1 to 0/1) to give *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-7-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate (100 mg, 98.40 μmol , 63.63% yield) as a yellow solid. MS (ESI) *m/z*: 509.3 [M + H]⁺.


H. 6-[8-(1,3-Benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-7-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylic acid

To a solution of *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-7-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate (100 mg, 98.40 μmol , 1.0 *eq.*) in DCM (1 mL) was added trifluoroacetic acid (1 mL). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-HPLC (column: Phenomenex luna C¹⁸ 150 $\times$ 25 mm

× 10 μm; mobile phase: [water (1% formic acid)-MeCN]; B %: 28 %-58 %, 10 min) to give 6-[8-(1,3-benzothiazol-2-ylcarbonyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-7-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylic acid (20.62 mg, 20.76 μmol, 21.09% yield, 96.65% purity) as a yellow solid. MS (ESI) *m/z*: 960.8 [M + H]⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ = 12.84 (s, 1H), 10.91 (s, 1H), 10.59 - 10.48 (m, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.66 (d, *J* = 8.4 Hz, 1H), 7.60 (d, *J* = 7.6 Hz, 1H), 7.56 (d, *J* = 8.4 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 1H), 7.43 - 7.39 (m, 1H), 7.38 - 7.32 (m, 2H), 7.20 (s, 1H), 7.12 (t, *J* = 7.6 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 2H), 6.96 (d, *J* = 8.8 Hz, 1H), 6.83 (d, *J* = 8.4 Hz, 2H), 4.92 (s, 2H), 4.43 - 4.35 (m, 1H), 4.23 (s, 1H), 4.06 (s, 3H), 3.91 - 3.84 (m, 4H), 3.68 - 3.48 (m, 4H), 3.13 - 3.03 (m, 1H), 2.98 (t, *J* = 5.6 Hz, 2H), 2.80 (t, *J* = 7.2 Hz, 2H), 2.74 - 2.56 (m, 4H), 2.39 - 2.31 (m, 1H), 2.22 - 2.11 (m, 1H), 1.97 - 1.88 (m, 2H), 1.71 (s, 3H), 1.49 (s, 2H).

Example 3. Preparation of

6-[8-(1,3-benzothiazol-2-ylcarbonyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-6-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylic acid (Compound 115)



A. *tert*-Butyl 6-[8-(1,3-benzothiazol-2-ylcarbonyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-6-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate

To a solution of 2-[4-[[4-[3-[6-[8-(1,3-benzothiazol-2-ylcarbonyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-2-*tert*-butoxycarbonyl-3-pyridyl]propoxy]phenyl]methyl]-1-piperidyl]acetic acid (100 mg, 128.87 μmol, 1.00 *equiv.*) in pyridine (1 mL) was added EDCI (32.12 mg, 167.54 μmol, 1.30 *equiv.*) and 3-(6-amino-1-methyl-indazol-3-yl)piperidine-2,6-dione (39.94 mg, 154.65 μmol, 1.20 *equiv.*). The mixture was stirred at 40 °C for 1 hour. The reaction was diluted with water (20 mL) and extracted with DCM 20 mL (20 mL × 2). The combined organic layers were washed with brine 30 mL, dried over Na₂SO₄, filtered and concentrated under reduced


pressure to give as a residue. The residue was purified by column chromatography (SiO₂, dichloromethane/methanol=50/1 to 20/1) to give *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-6-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate (100 mg, 98.4 umol, 76.4% yield) as a white solid. MS (ESI) *m/z*: 1016.4 [M + H]⁺.

B. 6-[8-(1,3-Benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-6-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylic acid

To a solution of *tert*-butyl 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-6-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylate (100 mg, 98.40 umol, 1 equiv.) in DCM (1 mL) was added trifluoroacetic acid (1.54 g, 13.51 mmol, 1 mL, 137.25 equiv.). The mixture was stirred at 40 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150 × 25 mm × 10 um; mobile phase: [water (formic acid)-MeCN]; B%: 25%-55%, 10 min) to give 6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1*H*-isoquinolin-2-yl]-3-[3-[4-[[1-[2-[[3-(2,6-dioxo-3-piperidyl)-1-methyl-indazol-6-yl]amino]-2-oxo-ethyl]-4-piperidyl]methyl]phenoxy]propyl]pyridine-2-carboxylic acid (34.37 mg, 35.70 umol, 36.28% yield, 99.72% purity) as a white solid. MS (ESI) *m/z*: 960.3 [M + H]⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ = 13.02 - 12.48 (m, 1H), 10.88 (s, 1H), 9.86 (s, 1H), 8.14 (s, 1H), 8.09 - 8.01 (m, 2H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.66 - 7.58 (m, 2H), 7.55 (d, *J* = 8.8 Hz, 1H), 7.48 (t, *J* = 7.6 Hz, 1H), 7.43 - 7.39 (m, 1H), 7.39 - 7.33 (m, 2H), 7.21 (d, *J* = 8.8 Hz, 1H), 7.05 (d, *J* = 8.4 Hz, 2H), 6.95 (d, *J* = 8.8 Hz, 1H), 6.81 (d, *J* = 8.4 Hz, 2H), 4.93 (s, 2H), 4.36 - 4.30 (m, 1H), 3.92 (s, 3H), 3.91 - 3.85 (m, 4H), 3.16 (s, 2H), 2.98 (t, *J* = 4.8 Hz, 2H), 2.89 (d, *J* = 10.4 Hz, 2H), 2.80 (t, *J* = 7.6 Hz, 2H), 2.66 - 2.54 (m, 4H), 2.44 (d, *J* = 6.4 Hz, 2H), 2.19 - 2.11 (m, 2H), 1.97 - 1.87 (m, 2H), 1.60 - 1.51 (m, 2H), 1.50 - 1.40 (m, 1H), 1.37 - 1.25 (m, 2H).

Example 4. Preparation of

6-(8-(Benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinic acid (Compound 116)



A. *tert*-Butyl 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinate

5 To a solution of 2-(4-(4-(3-(6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-2-(*tert*-butoxycarbonyl)pyridin-3-yl)propoxy)benzyl)piperidin-1-yl)acetic acid (140 mg, 180.42 μ mol, 1.0 equiv.) in pyridine (1 mL) was added EDCI (44.96 mg, 234.55 μ mol, 1.3 equiv.) and 3-(1-methyl-6-(piperazin-1-yl)-1*H*-indazol-3-yl)piperidine-2,6-dione (64.97 mg, 198.47 μ mol, 1.1 equiv.). The mixture was stirred at 40 °C for 1 hour.

10 The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-TLC (SiO₂, DCM : MeOH = 10 : 1) to give *tert*-butyl 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinate (60 mg, 55.28 μ mol, 30.6% yield) as a white solid. MS

15 (ESI) *m/z*: 1085.4 [M+H]⁺.

B. 6-(8-(Benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinic acid


20 To a solution of *tert*-butyl 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinate (60 mg, 55.28 μ mol, 1.0 equiv.) in DCM (1 mL) was added TFA (6.30 mg, 55.28 μ mol, 4.09 μ L, 1.0 equiv.). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-HPLC (column: Phenomenex luna C 18 150 $\times$ 25 mm $\times$ 10 μ m; mobile phase: [water (1% formic acid)-MeCN];

25 B %: 30 % - 50 %, 58 min) to give 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-

dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-6-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinic acid (13.91 mg, 12.8 umol, 23.1% yield, 99.1% purity) as a yellow solid. MS (ESI) *m/z*: 1029.4 [M+H]⁺; ¹H NMR (400 MHz, DMSO-*d*₆) δ = 10.85 (s, 1H), 8.17 (s, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.82 - 7.77 (m, 1H), 7.60 (d, *J* = 7.2 Hz, 1H), 7.53 (d, *J* = 8.8 Hz, 2H), 7.48 (t, *J* = 7.2 Hz, 1H), 7.44 - 7.39 (m, 1H), 7.38 - 7.31 (m, 2H), 7.02 (d, *J* = 8.4 Hz, 2H), 6.98 - 6.88 (m, 3H), 6.79 (d, *J* = 8.4 Hz, 2H), 4.92 (s, 2H), 4.27 (dd, *J* = 5.2, 9.2 Hz, 1H), 3.91 (s, 3H), 3.88 - 3.84 (m, 4H), 3.73 (s, 2H), 3.61 (d, *J* = 1.2 Hz, 2H), 3.17 (s, 4H), 2.99 (d, *J* = 6.0 Hz, 2H), 2.82 - 2.77 (m, 4H), 2.69 - 2.60 (m, 4H), 2.40 (d, *J* = 7.2 Hz, 2H), 2.20 - 2.14 (m, 1H), 1.97 - 1.88 (m, 4H), 1.57 - 1.49 (m, 2H), 1.48 - 1.33 (m, 2H), 1.21 - 1.10 (m, 2H).

Example 5. Preparation of

6-(8-(Benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinic acid (Compound 117)



A. *tert*-Butyl 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinate

To a solution of 2-(4-(4-(3-(6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-2-(*tert*-butoxycarbonyl)pyridin-3-yl)propoxy)benzyl)piperidin-1-yl)acetic acid (140 mg, 180.42 umol, 1.0 equiv.) in pyridine (1 mL) was added EDCI (44.96 mg, 234.55 umol, 1.3 equiv.) and 3-(1-methyl-7-(piperazin-1-yl)-1*H*-indazol-3-yl)piperidine-2,6-dione (64.97 mg, 198.47 umol, 1.1 equiv.). The mixture was stirred at 40 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-TLC (SiO₂, DCM : MeOH = 10 : 1) to give *tert*-butyl 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-

yl)methyl)phenoxy)propyl)picolinate (80 mg, 73.7 umol, 40.9 % yield) as a white solid. MS (ESI) m/z : 1085.4 $[M+H]^+$.

B. 6-(8-(Benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinic acid

To a solution of *tert*-butyl 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinate (80 mg, 73.71 umol, 1.0 equiv.) in DCM (1 mL) was added TFA (8.40 mg, 73.71 umol, 5.46 uL, 1.0 equiv.). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-HPLC (column: Phenomenex luna C 18 150 × 25 mm × 10 um; mobile phase: [water (1% formic acid)-MeCN]; B % : 30 % - 50 %, 58 min) to give 6-(8-(benzo[*d*]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1*H*)-yl)-3-(3-(4-((1-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-1-methyl-1*H*-indazol-7-yl)piperazin-1-yl)-2-oxoethyl)piperidin-4-yl)methyl)phenoxy)propyl)picolinic acid (35.18 mg, 31.63 umol, 42.91 % yield, 96.67% purity) as a yellow solid. MS (ESI) m/z : 1029.4 $[M+H]^+$; 1H NMR (400 MHz, DMSO-*d*₆) δ = 10.89 (s, 1H), 8.14 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.62 - 7.54 (m, 2H), 7.51 - 7.41 (m, 3H), 7.37 - 7.35 (m, 2H), 7.08 - 7.02 (m, 4H), 6.96 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 8.4 Hz, 2H), 4.93 (s, 2H), 4.49 - 4.40 (m, 1H), 4.35 (dd, J = 5.2, 9.6 Hz, 1H), 4.28 (s, 3H), 3.94 - 3.82 (m, 6H), 2.99 (t, J = 5.6 Hz, 2H), 2.85 - 2.75 (m, 4H), 2.71 - 2.61 (m, 4H), 2.59 - 2.54 (m, 2H), 2.46 (s, 6H), 2.37 - 2.30 (m, 2H), 2.24 - 2.11 (m, 2H), 1.96 - 1.89 (m, 2H), 1.67 - 1.60 (m, 2H), 1.47 - 1.33 (m, 2H).

The following examples were synthesized using methods similar to those described in the examples above:

Example No.	Compound No.	LC-MS (ESI)	1H NMR
6	101	m/z = 918.6 $[M+H]^+$	1H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.02 - 12.60 (m, 1H), 10.89 (s, 1H), 10.17 - 9.83 (m, 1H), 8.10 - 8.01 (m, 2H), 7.78 (t, J = 9.2 Hz, 2H), 7.68 - 7.57 (m, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.45 - 7.41 (m, 1H), 7.39 - 7.33 (m, 2H), 7.23 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 8.8 Hz, 2H), 7.02 (d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.4 Hz, 2H), 5.19 (s, 2H), 4.98 (s, 2H), 4.38 - 4.30 (m, 1H), 3.94 (s, 3H), 3.93 - 3.88 (m, 2H), 3.12 - 3.04 (m, 2H), 3.00 (t, J = 5.6 Hz, 2H), 2.67 - 2.61 (m, 2H), 2.55 (s, 4H), 2.40 - 2.32 (m, 2H), 2.24 - 2.14 (m, 1H), 1.77 (s, 4H)
7	102	m/z = 918.7 $[M+H]^+$	1H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 9.96 (s, 1H), 8.12 - 8.00 (m, 1H), 7.85 (dd, J = 2.4, 6.0 Hz, 1H), 7.66 (s, 1H), 7.63 - 7.52 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 10.0

			Hz, 1H), 7.24 - 7.15 (m, 4H), 7.06 - 6.99 (m, 1H), 6.89 (s, 1H), 6.80 (s, 2H), 6.74 (d, J = 8.8 Hz, 1H), 5.20 (s, 2H), 5.14 (s, 2H), 4.38 - 4.22 (m, 1H), 3.93 - 3.90 (m, 2H), 3.79 (t, J = 5.6 Hz, 2H), 3.19 (s, 2H), 3.00 - 2.93 (m, 4H), 2.67 (d, J = 2.0 Hz, 2H), 2.27 (d, J = 5.2 Hz, 2H), 2.17 (s, 1H), 1.84 - 1.69 (m, 4H), 1.24 (s, 3H)
8	143	m/z = 972.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.86 - 10.82 (m, 1H), 8.22 - 8.18 (m, 1H), 8.03 - 7.99 (m, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.62 - 7.57 (m, 1H), 7.48 - 7.43 (m, 2H), 7.40 - 7.31 (m, 3H), 7.13 (t, J = 7.6 Hz, 1H), 6.92 - 6.85 (m, 2H), 6.80 (s, 2H), 6.75 (t, J = 6.4 Hz, 2H), 5.13 (s, 2H), 4.95 (s, 2H), 4.24 (dd, J = 9.2, 5.2 Hz, 1H), 3.87 (s, 5H), 3.74 (d, J = 10.8 Hz, 2H), 3.07 (d, J = 9.2 Hz, 2H), 2.96 (s, 2H), 2.71 - 2.65 (m, 2H), 2.60 (t, J = 5.2 Hz, 2H), 2.54 (s, 2H), 2.34 - 2.11 (m, 5H), 1.78 - 1.66 (m, 6H), 1.47 (d, J = 0.8 Hz, 3H), 1.32 - 1.23 (m, 2H)
9	147	m/z = 973.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.17 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.54 - 7.43 (m, 2H), 7.43 - 7.38 (m, 1H), 7.38 - 7.28 (m, 2H), 7.15 (t, J = 8.0 Hz, 1H), 6.99 - 6.87 (m, 2H), 6.86 - 6.71 (m, 4H), 5.15 (s, 2H), 4.96 (s, 2H), 4.25 (dd, J = 5.2, 9.2 Hz, 1H), 3.88 (s, 5H), 3.21 (s, 4H), 3.08 (d, J = 10.0 Hz, 2H), 2.98 (t, J = 5.6 Hz, 2H), 2.60 (s, 10H), 2.36 - 2.26 (m, 2H), 2.25 - 2.09 (m, 3H), 1.76 - 1.60 (m, 4H).
10	144	m/z = 1018.6 [M+32+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.19 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.64 - 7.58 (m, 1H), 7.46 (t, J = 6.8 Hz, 2H), 7.42 - 7.29 (m, 3H), 7.13 (t, J = 7.8 Hz, 1H), 6.92 - 6.83 (m, 2H), 6.82 - 6.68 (m, 4H), 5.13 (s, 2H), 4.95 (s, 2H), 4.24 (dd, J = 5.2, 9.2 Hz, 1H), 3.90 - 3.85 (m, 5H), 3.75 - 3.73 (m, 3H), 3.58 - 3.55 (m, 2H), 3.06 (d, J = 10.4 Hz, 2H), 2.97 (t, J = 5.2 Hz, 2H), 2.70 - 2.58 (m, 3H), 2.46 (s, 2H), 2.22 - 2.11 (m, 3H), 1.80 - 1.63 (m, 6H), 1.54 (s, 2H), 1.38 (d, J = 5.0 Hz, 1H), 1.24 - 1.23 (m, 4H).
11	152	m/z = 987.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.18 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 9.2 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.52 - 7.43 (m, 2H), 7.43 - 7.38 (m, 1H), 7.37 - 7.31 (m, 2H), 7.15 (t, J = 7.8 Hz, 1H), 6.90 (dd, J = 8.8, 3.2 Hz, 2H), 6.84 - 6.73 (m, 4H), 5.14 (s, 2H), 4.96 (s, 2H), 4.25 (dd, J = 9.2, 5.2 Hz, 1H), 3.92 - 3.83 (m, 7H), 3.21 (s, 4H), 3.03 (d, J = 10.8 Hz, 2H), 2.98 (t, J = 5.4 Hz, 2H), 2.67 - 2.59 (m, 2H), 2.54 (s, 2H), 2.45 (s, 2H), 2.38 - 2.27 (m, 4H), 2.14 (dd, J = 11.6, 7.6 Hz, 3H), 1.72 - 1.63 (m, 6H).
12	153	m/z = 973.7 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.16 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.51 - 7.44 (m, 2H), 7.42 - 7.38 (m, 1H), 7.38 - 7.31 (m, 2H), 7.10 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 7.0 Hz, 2H), 6.84 (d, J = 7.6 Hz, 3H), 5.13 (s, 2H), 4.96 (s, 2H), 4.25 (d, J = 9.2, 4.8 Hz, 1H), 3.91 - 3.87 (m, 5H), 3.21 (d, J = 4.0 Hz, 4H), 3.07 (d, J = 2.4 Hz, 2H), 2.98 (t, J = 5.6 Hz, 2H), 2.61 - 2.57 (m, 8H), 2.39 (s, 2H), 2.20 - 2.11 (m, 4H), 1.74 - 1.56 (m, 5H).
13	145	m/z = 986.7 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.17 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.50 - 7.42 (m, 2H), 7.40 - 7.31 (m, 3H), 7.03 (d, J = 8.4 Hz, 2H), 6.87 (t, J = 8.4 Hz, 2H), 6.82 - 6.76 (m, 3H), 5.10 (s, 2H), 4.94 (s, 2H), 4.24 (d, J = 9.2, 5.2 Hz, 1H), 3.92 - 3.84 (m, 5H), 3.75 (d, J = 12.4 Hz, 2H), 3.19 - 3.12 (m, 2H), 2.97 (t, J = 4.8 Hz, 2H), 2.67 (s, 4H), 2.61 - 2.58 (m, 2H), 2.33 (d, J = 3.6, 1.6 Hz, 4H), 2.16 (s, 1H), 1.73 (d, J =

			19.2, 10.8 Hz, 6H), 1.59 (s, 2H), 1.45 - 1.32 (m, 1H), 1.24 (d, J = 8.4 Hz, 4H).
14	154	m/z = 987.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.17 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.59 (d, J = 7.2 Hz, 1H), 7.52 - 7.42 (m, 2H), 7.41 - 7.27 (m, 3H), 7.02 (d, J = 8.0 Hz, 2H), 6.96 - 6.63 (m, 5H), 5.09 (s, 2H), 4.94 (s, 2H), 4.25 (dd, J = 5.2, 8.8 Hz, 1H), 3.87 (s, 5H), 3.20 (s, 4H), 2.96 (s, 2H), 2.71 - 2.53 (m, 10H), 2.45 - 2.24 (m, 6H), 2.21 - 2.09 (m, 1H), 1.94 - 1.52 (m, 6H)
15	146	m/z = 986.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.14 (s, 1H), 8.05 - 8.00 (m, 1H), 7.80 (s, 1H), 7.75 (s, 1H), 7.58 (s, 1H), 7.50 - 7.43 (m, 2H), 7.41 - 7.32 (m, 3H), 7.10 (d, J = 2.0 Hz, 1H), 6.96 - 6.91 (m, 1H), 6.88 (d, J = 9.2 Hz, 1H), 6.81 - 6.77 (m, 1H), 6.76 - 6.66 (m, 3H), 5.20 - 5.13 (m, 2H), 5.00 - 4.93 (m, 2H), 4.24 (dd, J = 4.8, 9.2 Hz, 1H), 3.91 - 3.86 (m, 5H), 3.78 - 3.72 (m, 2H), 3.02 - 2.95 (m, 4H), 2.68 - 2.57 (m, 6H), 2.42 (s, 2H), 2.34 - 2.27 (m, 2H), 2.19 - 2.12 (m, 2H), 1.75 - 1.69 (m, 2H), 1.56 - 1.52 (m, 2H), 1.51 - 1.38 (m, 4H), 1.28 - 1.18 (m, 4H).
16	155	m/z = 987.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.89 - 10.80 (m, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.41 - 7.32 (m, 3H), 7.17 - 7.10 (m, 1H), 6.89 (d, J = 8.6 Hz, 2H), 6.81 (s, 1H), 6.75 - 6.67 (m, 3H), 5.15 (s, 2H), 4.96 (s, 2H), 4.25 (dd, J = 5.2, 8.8 Hz, 1H), 3.91 - 3.86 (m, 5H), 3.20 - 3.15 (m, 4H), 3.00 - 2.91 (m, 4H), 2.69 - 2.58 (m, 4H), 2.47 - 2.38 (m, 7H), 2.35 - 2.26 (m, 2H), 2.20 - 1.99 (m, 4H), 1.52 - 1.47 (m, 2H), 1.24 - 1.15 (m, 2H)
17	160	m/z = 501.1 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.87 - 10.81 (m, 1H), 8.05 - 7.98 (m, 1H), 7.81 - 7.68 (m, 2H), 7.64 - 7.57 (m, 1H), 7.49 - 7.30 (m, 5H), 7.26 - 7.09 (m, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.77 - 6.83 (m, 1H), 6.77 - 6.68 (m, 3H), 5.21 - 5.08 (m, 2H), 4.96 (s, 2H), 4.26 - 4.20 (m, 1H), 3.90 - 3.87 (m, 3H), 3.77 - 3.72 (m, 2H), 3.12 - 3.06 (m, 3H), 2.98 (s, 3H), 2.68 - 2.59 (m, 4H), 2.34 - 2.12 (m, 6H), 1.76 - 1.69 (m, 2H), 1.59 - 1.51 (m, 4H), 1.38 - 1.13 (m, 8H)
18	161	m/z = 1001.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.19 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.50 - 7.43 (m, 2H), 7.41 - 7.29 (m, 3H), 7.13 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 8.4 Hz, 2H), 6.80 (s, 1H), 6.77 - 6.69 (m, 2H), 6.66 (d, J = 7.2 Hz, 1H), 5.15 - 5.10 (m, 2H), 4.97 - 4.93 (m, 2H), 4.27 - 4.23 (m, 1H), 3.90 - 3.86 (m, 5H), 3.25 - 3.2 (m, 6H), 3.07 - 3.05 (m, 2H), 2.98 - 2.95 (m, 2H), 2.64 - 2.59 (m, 5H), 2.40 - 2.38 (m, 2H), 2.32 - 2.28 (m, 5H), 2.17 - 2.13 (m, 2H), 1.73 - 1.68 (m, 2H), 1.54 - 1.51 (m, 3H), 1.30 - 1.22 (m, 2H).
19	156	m/z = 987.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.20 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.63 - 7.58 (m, 1H), 7.50 - 7.43 (m, 2H), 7.41 - 7.30 (m, 3H), 7.01 (d, J = 8.4 Hz, 2H), 6.90 - 6.83 (m, 4H), 6.80 (s, 1H), 5.11 (s, 2H), 4.95 (s, 2H), 4.25 (dd, J = 5.6, 8.8 Hz, 1H), 3.88 (s, 5H), 3.74 (d, J = 11.6 Hz, 2H), 2.96 (d, J = 5.2 Hz, 4H), 2.69 - 2.60 (m, 4H), 2.40 - 2.32 (m, 4H), 2.19 - 2.06 (m, 3H), 1.77 - 1.70 (m, 2H), 1.57 - 1.38 (m, 7H), 1.29 - 1.18 (m, 4H).
20	162	m/z = 1001.4 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.95 - 11.63 (m, 1H), 10.85 (s, 1H), 8.14 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 7.2 Hz, 1H), 7.52 - 7.44 (m, 2H), 7.44 - 7.40 (m, 1H), 7.38 - 7.32 (m, 2H), 7.05 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 9.2 Hz, 1H), 6.88 - 6.82 (m,

			3H), 5.16 - 5.14 (m, 2H), 4.98 - 4.96 (m, 2H), 4.27 - 4.23 (m, 1H), 3.93 - 3.87 (m, 5H), 3.23 - 3.21 (m, 4H), 3.00 - 2.97 (m, 2H), 2.84 - 2.82 (m, 2H), 2.64 - 2.59 (m, 4H), 2.57 - 2.53 (m, 6H), 2.46 - 2.37 (m, 4H), 2.31 - 2.24 (m, 1H), 2.20 - 2.11 (m, 1H), 1.81 - 1.73 (m, 2H), 1.68 - 1.62 (m, 3H), 1.39 - 1.23 (m, 2H).
21	148	m/z = 494.1 [2M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.17 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.72 (m, 1H), 7.61 (m, 1H), 7.50 - 7.44 (m, 2H), 7.42 - 7.38 (m, 1H), 7.37 - 7.31 (m, 2H), 7.17 - 7.11 (m, 1H), 6.94 (m, 1H), 6.88 (m, 1H), 6.80 (s, 1H), 6.78 - 6.71 (m, 3H), 5.16 (s, 2H), 4.96 (s, 2H), 4.24 (m, 1H), 3.93 - 3.88 (m, 2H), 3.87 (s, 3H), 3.75 (m, 2H), 2.98 (m, 2H), 2.86 (m, 2H), 2.68 (m, 2H), 2.64 - 2.58 (m, 2H), 2.33 - 2.26 (m, 1H), 2.23 - 2.12 (m, 3H), 1.90 (m, 2H), 1.82 - 1.58 (m, 6H), 1.46 (m, 2H), 1.29 - 1.11 (m, 6H).
22	149		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.18 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.66 (m, 1H), 7.60 (m, 1H), 7.45 (m, 2H), 7.38 - 7.31 (m, 3H), 7.13 (m, 1H), 6.86 (m, 2H), 6.78 (m, 2H), 6.72 (m, 2H), 5.13 (s, 2H), 5.00 - 4.88 (m, 2H), 4.24 (m, 1H), 3.87 (s, 6H), 3.73 (m, 3H), 3.02 (m, 2H), 2.95 (m, 2H), 2.70 - 2.65 (m, 3H), 2.34 - 2.30 (m, 2H), 2.20 - 2.11 (m, 3H), 1.72 (m, 2H), 1.62 (m, 2H), 1.54 - 1.38 (m, 6H), 1.32 - 1.18 (m, 6H).
23	158	m/z = 1001.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.21 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.69 - 7.57 (m, 2H), 7.50 - 7.43 (m, 2H), 7.41 - 7.31 (m, 3H), 7.13 (t, J = 7.6 Hz, 1H), 6.92 - 6.81 (m, 3H), 6.78 - 6.70 (m, 3H), 5.13 (s, 2H), 4.95 (s, 2H), 4.25 (dd, J = 5.2, 8.8 Hz, 1H), 3.88 (s, 5H), 3.18 (s, 6H), 3.01 - 2.89 (m, 5H), 2.63 - 2.54 (m, 7H), 2.29 (dd, J = 4.8, 8.8 Hz, 1H), 2.21 - 2.10 (m, 2H), 2.01 (t, J = 9.6 Hz, 2H), 1.64 - 1.57 (m, 2H), 1.49 - 1.42 (m, 2H), 1.26 - 1.12 (m, 4H).
24	163		¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.19 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.80 - 7.75 (m, 1H), 7.65 (m, 1H), 7.60 (m, 1H), 7.45 (m, 2H), 7.35 (m, 3H), 7.12 (m, 1H), 6.88 - 6.81 (m, 2H), 6.80 - 6.67 (m, 4H), 5.12 (s, 2H), 4.94 (m, 2H), 4.24 (m, 1H), 3.87 (s, 5H), 3.72 (m, 2H), 3.04 (m, 2H), 2.96 (m, 2H), 2.68 - 2.56 (m, 6H), 2.45 - 2.43 (m, 1H), 2.36 - 2.11 (m, 5H), 1.71 (m, 2H), 1.66 - 1.51 (m, 4H), 1.42 (m, 2H), 1.37 - 1.31 (m, 1H), 1.28 - 1.13 (m, 7H).
25	159	m/z = 1015.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.87 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.51 - 7.43 (m, 2H), 7.40 - 7.31 (m, 3H), 7.12 (t, J = 7.6 Hz, 1H), 6.90 - 6.79 (m, 3H), 6.77 - 6.68 (m, 3H), 5.11 (s, 2H), 4.94 (s, 2H), 4.25 (dd, J = 5.2, 9.2 Hz, 1H), 3.87 (s, 5H), 3.18 (s, 4H), 3.07 (d, J = 10.8 Hz, 2H), 2.96 (s, 2H), 2.67 - 2.58 (m, 6H), 2.34 - 2.12 (m, 11H), 1.76 - 1.59 (m, 4H), 1.42 (s, 2H), 1.25 (s, 2H).
26	150	m/z = 986.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.15 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.76 - 7.72 (m, 1H), 7.60 (bd, J = 7.2 Hz, 1H), 7.46 (d, J = 6.2 Hz, 2H), 7.43 - 7.40 (m, 1H), 7.37 - 7.33 (m, 2H), 7.07 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 9.6 Hz, 1H), 6.85 - 6.80 (m, 3H), 5.15 (s, 2H), 4.96 (s, 2H), 4.24 (dd, J = 5.6, 9.2 Hz, 1H), 3.93 - 3.89 (m, 2H), 3.88 (s, 3H), 3.77 (d, J = 12.0 Hz, 2H), 2.99 (t, J = 4.8 Hz, 2H), 2.94 (d, J = 8.0 Hz, 2H), 2.76 - 2.65 (m, 4H), 2.33 (s, 2H), 2.21 - 2.10 (m, 2H), 2.07 - 1.98 (m, 2H), 1.83 - 1.71 (m, 4H), 1.70 (s, 2H), 1.48 - 1.41 (m, 2H), 1.29 - 1.17 (m, 6H).

27	151	m/z = 1000.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.18 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 6.8 Hz, 1H), 7.49 - 7.42 (m, 2H), 7.39 - 7.29 (m, 3H), 6.99 (d, J = 8.4 Hz, 2H), 6.91 - 6.77 (m, 5H), 5.09 (s, 2H), 4.93 (s, 2H), 4.24 (dd, J = 5.2, 9.1 Hz, 1H), 3.87 (s, 3H), 3.73 (d, J = 11.2 Hz, 2H), 3.07 (d, J = 9.6 Hz, 2H), 2.95 (d, J = 4.0 Hz, 2H), 2.73 - 2.63 (m, 4H), 2.63 - 2.57 (m, 4H), 2.43 (s, 2H), 2.31 - 2.11 (m, 4H), 1.74 (d, J = 11.2 Hz, 2H), 1.66 (d, J = 4.8 Hz, 1H), 1.53 - 1.40 (m, 3H), 1.34 (d, J = 6.8 Hz, 2H), 1.25 (s, 5H)
28	164	m/z = 501.4 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.89 - 10.81 (m, 1H), 8.15 (s, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.83 - 7.72 (m, 2H), 7.61 (d, J = 6.8 Hz, 1H), 7.52 - 7.46 (m, 2H), 7.44 - 7.41 (m, 1H), 7.39 - 7.34 (m, 2H), 7.12 - 7.05 (m, 2H), 7.02 - 6.97 (m, 1H), 6.93 (d, J = 9.6 Hz, 1H), 6.88 - 6.81 (m, 3H), 5.16 (s, 2H), 4.97 (s, 2H), 4.26 (dd, J = 9.2, 5.2 Hz, 1H), 3.89 (s, 5H), 3.24 (s, 6H), 3.00 (t, J = 6.0 Hz, 2H), 2.61 (s, 10H), 2.55 (s, 2H), 2.21 - 2.11 (m, 2H), 1.82 - 1.73 (m, 2H), 1.51 - 1.44 (m, 2H), 1.37 - 1.23 (m, 4H), 1.19 - 1.14 (m, 1H)
29	165	m/z = 1014.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.17 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.67 (dd, J = 2.0, 9.2 Hz, 1H), 7.63 - 7.57 (m, 1H), 7.50 - 7.43 (m, 2H), 7.42 - 7.31 (m, 3H), 7.01 (dd, J = 2.4, 4.8 Hz, 2H), 6.93 - 6.85 (m, 2H), 6.82 (d, J = 11.6 Hz, 3H), 5.10 (s, 2H), 4.95 (s, 2H), 4.24 (dd, J = 5.2, 8.4 Hz, 1H), 3.87 (s, 5H), 3.78 - 3.72 (m, 2H), 3.11 - 2.94 (m, 6H), 2.64 - 2.58 (m, 4H), 2.21 - 2.10 (m, 3H), 1.78 - 1.71 (m, 2H), 1.67 (dd, J = 2.4, 6.0 Hz, 2H), 1.62 - 1.45 (m, 3H), 1.44 - 1.31 (m, 4H), 1.29 - 1.15 (m, 8H)
30	157	m/z = 1015.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.86 (s, 1H), 8.24 (s, 2H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.66 - 7.58 (m, 2H), 7.51 - 7.44 (m, 2H), 7.41 - 7.31 (m, 3H), 7.04 - 6.97 (m, 2H), 6.90 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 7.6 Hz, 4H), 5.08 (s, 2H), 4.94 (s, 2H), 4.28 - 4.23 (m, 1H), 3.88 (s, 5H), 3.19 (s, 4H), 2.97 (s, 4H), 2.62 - 2.55 (m, 4H), 2.47 - 2.41 (m, 4H), 2.33 (s, 4H), 2.16 - 2.04 (m, 3H), 1.67 (d, J = 1.6 Hz, 4H), 1.44 - 1.34 (m, 2H), 1.26 - 1.09 (m, 4H)
31	177b	m/z = 1000.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.21 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.63 - 7.57 (m, 2H), 7.50 - 7.43 (m, 3H), 7.40 - 7.31 (m, 3H), 7.07 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 6.85 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.90 (s, 2H), 4.32 (dd, J = 4.8, 9.6 Hz, 1H), 3.95 (s, 3H), 3.86 (td, J = 12.4, 6.0 Hz, 5H), 3.03 - 2.88 (m, 7H), 2.74 (t, J = 6.4 Hz, 3H), 2.69 - 2.58 (m, 5H), 2.39 (d, J = 6.4 Hz, 3H), 2.33 (s, 1H), 2.29 - 2.25 (m, 1H), 2.16 (dd, J = 5.6, 13.2 Hz, 1H), 1.97 - 1.89 (m, 4H), 1.82 (dd, J = 8.0, 13.2 Hz, 1H), 1.50 (d, J = 12.4 Hz, 2H), 1.44 - 1.38 (m, 1H), 1.21 - 1.13 (m, 2H)
32	177a	m/z = 1000.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.18 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.63 - 7.57 (m, 2H), 7.52 - 7.43 (m, 3H), 7.41 - 7.37 (m, 1H), 7.36 - 7.30 (m, 2H), 7.07 (d, J = 8.4 Hz, 1H), 7.00 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.90 (s, 2H), 4.32 (dd, J = 5.2, 9.6 Hz, 1H), 3.95 (s, 3H), 3.90 - 3.80 (m, 5H), 3.46 - 3.40 (m, 3H), 3.03 (t, J = 9.2 Hz, 1H), 2.97 - 2.91 (m, 4H), 2.80 - 2.72 (m, 4H), 2.69 - 2.59 (m, 5H), 2.39 (d, J = 6.4 Hz, 2H), 2.34 - 2.32 (m, 1H), 2.20 - 2.13 (m, 1H), 2.02 - 1.96 (m, 2H), 1.94 - 1.89 (m, 2H), 1.86 - 1.80 (m, 1H), 1.51 (d, J = 11.6 Hz, 2H), 1.46 - 1.40 (m, 1H), 1.23 - 1.13 (m, 2H)

33	166	m/z = 1000.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 7.2 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.42 - 7.38 (m, 1H), 7.37 - 7.32 (m, 2H), 7.02 (d, J = 8.0 Hz, 2H), 6.94 - 6.83 (m, 4H), 6.80 (s, 1H), 5.12 (s, 2H), 4.96 (s, 2H), 4.24 (dd, J = 5.2, 9.2 Hz, 1H), 3.92 - 3.85 (m, 5H), 3.75 (d, J = 11.6 Hz, 2H), 3.10 - 3.04 (m, 2H), 2.98 (t, J = 5.6 Hz, 2H), 2.67 (d, J = 2.0 Hz, 2H), 2.65 - 2.56 (m, 4H), 2.39 (d, J = 5.2 Hz, 2H), 2.34 - 2.26 (m, 3H), 2.18 - 2.13 (m, 1H), 1.77 - 1.70 (m, 2H), 1.59 - 1.52 (m, 4H), 1.40 - 1.34 (m, 1H), 1.30 - 1.14 (m, 7H)
34	167	m/z = 987.7 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 9.6 Hz, 1H), 7.60 (d, J = 6.8 Hz, 1H), 7.51 - 7.44 (m, 2H), 7.42 - 7.38 (m, 1H), 7.38 - 7.32 (m, 2H), 7.01 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 8.0 Hz, 2H), 6.87 - 6.79 (m, 3H), 5.12 (s, 2H), 4.96 (s, 2H), 4.25 (dd, J = 5.2, 9.2 Hz, 1H), 3.92 - 3.86 (m, 5H), 3.19 (s, 4H), 3.00 - 2.94 (m, 4H), 2.64 - 2.59 (m, 2H), 2.56 (s, 6H), 2.38 (d, J = 4.0 Hz, 2H), 2.31 - 2.23 (m, 2H), 2.18 - 2.12 (m, 1H), 2.09 - 1.98 (m, 2H), 1.57 - 1.32 (m, 4H), 1.24 - 1.13 (m, 2H)
35	170a	m/z = 972.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.83 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.70 - 7.64 (m, 1H), 7.61 (d, J = 7.2 Hz, 1H), 7.49 - 7.32 (m, 5H), 7.10 - 7.00 (m, 2H), 6.92 - 6.80 (m, 3H), 6.54 (d, J = 8.4 Hz, 1H), 6.33 (s, 1H), 5.12 (s, 2H), 4.96 (s, 2H), 4.22 (dd, J = 5.2, 8.8 Hz, 1H), 3.88 (d, J = 4.8 Hz, 2H), 3.84 (s, 3H), 3.06 - 2.94 (m, 4H), 2.87 (s, 1H), 2.68 - 2.58 (m, 4H), 2.39 - 2.24 (m, 4H), 2.20 - 2.06 (m, 2H), 1.91 (s, 3H), 1.81 - 1.57 (m, 4H), 1.45 (s, 2H), 1.27 - 1.12 (m, 4H)
36	170b	m/z = 972.8 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.95 - 12.32 (m, 1H), 10.83 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.76 - 7.72 (m, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.41 (d, J = 8.4 Hz, 1H), 7.37 - 7.33 (m, 2H), 7.07 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 8.4 Hz, 2H), 6.55 - 6.51 (m, 1H), 6.32 (s, 1H), 5.15 (s, 2H), 4.96 (s, 2H), 4.22 (dd, J = 5.2, 8.8 Hz, 1H), 3.90 (t, J = 5.6 Hz, 2H), 3.83 (s, 3H), 3.46 - 3.41 (m, 2H), 3.03 - 2.96 (m, 4H), 2.91 - 2.86 (m, 1H), 2.64 - 2.56 (m, 4H), 2.40 - 2.35 (m, 2H), 2.29 - 2.23 (m, 1H), 2.18 - 2.07 (m, 2H), 2.00 - 1.88 (m, 2H), 1.82 - 1.61 (m, 4H), 1.50 - 1.40 (m, 2H), 1.25 - 1.12 (m, 4H)
37	171a	m/z = 972.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.81 - 7.73 (m, 2H), 7.61 (d, J = 7.2 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.44 - 7.40 (m, 1H), 7.36 (t, J = 7.6 Hz, 3H), 7.09 - 7.03 (m, 2H), 7.03 - 6.97 (m, 3H), 6.86 - 6.81 (m, 2H), 5.15 (s, 2H), 4.97 (s, 2H), 4.36 - 4.30 (m, 1H), 4.19 - 4.15 (m, 3H), 3.90 (t, J = 6.0 Hz, 2H), 3.15 - 3.10 (m, 2H), 3.08 - 3.03 (m, 2H), 3.00 (t, J = 5.6 Hz, 3H), 2.95 - 2.88 (m, 2H), 2.65 - 2.55 (m, 5H), 2.35 - 2.30 (m, 1H), 2.20 - 2.05 (m, 4H), 1.74 - 1.64 (m, 2H), 1.63 - 1.57 (m, 1H), 1.49 - 1.41 (m, 2H), 1.27 - 1.13 (m, 4H)
38	171b	m/z = 972.8 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.91 - 10.85 (m, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.73 - 7.69 (m, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.49 - 7.44 (m, 1H), 7.43 - 7.39 (m, 1H), 7.35 (t, J = 7.6 Hz, 3H), 7.05 (d, J = 8.4 Hz, 2H), 7.02 - 6.97 (m, 2H), 6.94 (d, J = 9.2 Hz, 1H), 6.83 (d, J = 8.4 Hz, 2H), 5.15 - 5.11 (m, 2H), 4.96 (s, 2H), 4.33 (dd, J = 4.8, 9.6 Hz, 1H), 4.18 - 4.14 (m, 3H), 3.90 - 3.88 (m, 2H), 3.10 - 3.08 (m, 2H), 3.04 - 3.01 (m, 1H), 2.99 - 2.97 (m, 3H), 2.94 - 2.91 (m, 1H), 2.88 - 2.83 (m, 1H), 2.71 - 2.60 (m, 3H), 2.41 - 2.39 (m, 1H), 2.38 - 2.26 (m, 3H), 2.20 - 2.06 (m, 2H), 1.98 - 1.83 (m, 2H), 1.70 - 1.54 (m, 3H), 1.47 - 1.38 (m, 2H), 1.24 - 1.11 (m, 4H)

39	175a	m/z = 986.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.83 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.49 - 7.43 (m, 2H), 7.42 - 7.38 (m, 1H), 7.37 - 7.32 (m, 2H), 7.02 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 6.56 - 6.50 (m, 1H), 6.32 (s, 1H), 4.91 (s, 2H), 4.24 - 4.19 (m, 1H), 3.91 - 3.84 (m, 4H), 3.83 (s, 3H), 3.04 - 2.91 (m, 5H), 2.89 - 2.72 (m, 4H), 2.64 - 2.53 (m, 4H), 2.42 (d, J = 6.4 Hz, 2H), 2.37 - 2.31 (m, 2H), 2.31 - 2.21 (m, 2H), 2.18 - 2.06 (m, 2H), 1.94 - 1.81 (m, 4H), 1.69 (t, J = 4.8, 8.0 Hz, 1H), 1.52 (d, J = 12.0 Hz, 2H), 1.20 (s, 2H)
40	175b	m/z = 986.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.83 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.49 - 7.43 (m, 2H), 7.42 - 7.39 (m, 1H), 7.35 (m, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 8.4 Hz, 2H), 6.55 - 6.50 (m, 1H), 6.32 (s, 1H), 4.91 (s, 2H), 4.22 (dd, J = 5.2, 8.8 Hz, 1H), 3.92 - 3.84 (m, 4H), 3.83 (s, 3H), 3.05 - 2.89 (m, 5H), 2.81 - 2.76 (m, 2H), 2.59 (m, 4H), 2.42 (d, J = 6.8 Hz, 4H), 2.32 (m, 2H), 2.29 - 2.22 (m, 2H), 2.18 - 2.09 (m, 2H), 1.96 - 1.83 (m, 4H), 1.73 - 1.65 (m, 1H), 1.56 - 1.49 (m, 2H), 1.24 - 1.20 (m, 2H)
41	176a	m/z = 986.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.49 - 7.44 (m, 1H), 7.42 - 7.38 (m, 1H), 7.37 - 7.31 (m, 3H), 7.04 - 6.96 (m, 4H), 6.92 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.91 (s, 2H), 4.33 (dd, J = 4.4, 9.2 Hz, 1H), 4.16 (s, 3H), 3.90 - 3.83 (m, 4H), 3.12 - 3.01 (m, 4H), 2.97 (t, J = 6.0 Hz, 3H), 2.93 - 2.88 (m, 2H), 2.80 - 2.76 (m, 2H), 2.68 - 2.61 (m, 2H), 2.43 - 2.35 (m, 4H), 2.34 - 2.28 (m, 2H), 2.19 - 2.05 (m, 2H), 1.95 - 1.80 (m, 4H), 1.61 - 1.55 (m, 1H), 1.54 - 1.48 (m, 2H), 1.23 - 1.12 (m, 2H)
42	176b	m/z = 494.0 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.81 - 7.76 (m, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 9.2 Hz, 1H), 7.47 (s, 1H), 7.43 - 7.38 (m, 1H), 7.37 - 7.32 (m, 3H), 7.04 - 6.98 (m, 4H), 6.94 - 6.90 (m, 1H), 6.79 (d, J = 8.0 Hz, 2H), 4.91 (s, 2H), 4.37 - 4.28 (m, 1H), 4.16 (s, 3H), 3.91 - 3.82 (m, 4H), 3.13 - 3.04 (m, 4H), 2.98 (d, J = 4.8 Hz, 2H), 2.94 - 2.89 (m, 2H), 2.81 - 2.76 (m, 2H), 2.67 (s, 2H), 2.41 - 2.39 (m, 4H), 2.19 - 2.14 (m, 1H), 2.10 - 2.04 (m, 1H), 1.94 - 1.87 (m, 3H), 1.84 - 1.77 (m, 1H), 1.62 - 1.46 (m, 4H), 1.44 - 1.36 (m, 1H), 1.24 - 1.11 (m, 3H)
43	168b	m/z = 944.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.83 (s, 1H), 8.20 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.49 - 7.43 (m, 2H), 7.42 - 7.38 (m, 1H), 7.37 - 7.32 (m, 2H), 7.19 - 7.13 (m, 1H), 6.92 (d, J = 8.8 Hz, 1H), 6.83 - 6.79 (m, 2H), 6.77 - 6.73 (m, 1H), 6.55 (d, J = 8.8 Hz, 1H), 6.34 (s, 1H), 5.15 (s, 2H), 4.96 (s, 2H), 4.24 - 4.20 (m, 1H), 3.89 (t, J = 5.6 Hz, 2H), 3.84 (s, 3H), 3.07 - 3.03 (m, 2H), 3.01 - 2.95 (m, 4H), 2.66 - 2.55 (m, 4H), 2.39 (d, J = 5.6 Hz, 2H), 2.34 - 2.21 (m, 2H), 2.20 - 2.11 (m, 2H), 2.06 - 1.98 (m, 2H), 1.79 - 1.68 (m, 4H), 1.68 - 1.59 (m, 2H)
44	168a	m/z = 944.7 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.83 (s, 1H), 8.13 (s, 1H), 8.03 (d, J = 7.2 Hz, 1H), 7.78 (dd, J = 3.6, 8.4 Hz, 2H), 7.61 (d, J = 7.2 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.44 - 7.40 (m, 1H), 7.38 - 7.32 (m, 2H), 7.19 (t, J = 8.0 Hz, 1H), 7.02 (d, J = 8.8 Hz, 1H), 6.85 - 6.80 (m, 2H), 6.79 - 6.74 (m, 1H), 6.56 (dd, J = 1.6, 8.8 Hz, 1H), 6.35 (s, 1H), 5.19 (s, 2H), 4.98 (s, 2H), 4.23 (dd, J = 5.2, 8.4 Hz, 1H), 3.91 (t, J = 5.6 Hz, 2H), 3.84 (s, 3H), 3.62 - 3.55 (m, 2H), 3.22 - 3.18 (m, 2H), 3.10 - 3.05 (m, 2H), 3.00 (t, J = 6.0 Hz, 3H), 2.60 (d, J = 6.4 Hz, 3H), 2.31 - 2.21 (m, 3H), 2.21 - 2.11 (m, 3H), 1.86 - 1.64 (m, 6H)

45	172b	m/z = 944.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.15 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.77 (dd, J = 8.0, 13.6 Hz, 2H), 7.60 (d, J = 7.2 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.43 - 7.40 (m, 1H), 7.37 - 7.32 (m, 3H), 7.16 (t, J = 8.0 Hz, 1H), 7.04 - 6.97 (m, 3H), 6.84 - 6.77 (m, 2H), 6.76 - 6.71 (m, 1H), 5.16 (s, 2H), 4.97 (s, 2H), 4.33 (dd, J = 5.2, 9.6 Hz, 1H), 4.20 - 4.17 (m, 3H), 3.90 (t, J = 5.6 Hz, 2H), 3.29 (d, J = 6.0 Hz, 1H), 3.18 - 3.12 (m, 2H), 3.11 - 3.07 (m, 2H), 3.02 - 2.96 (m, 4H), 2.68 - 2.58 (m, 4H), 2.32 (dd, J = 4.0, 9.6 Hz, 1H), 2.20 - 2.02 (m, 5H), 1.75 - 1.69 (m, 2H), 1.68 - 1.55 (m, 3H)
46	172a	m/z = 944.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.89 (s, 1H), 8.03 (d, J = 7.2 Hz, 1H), 7.82 - 7.73 (m, 2H), 7.60 (d, J = 6.8 Hz, 1H), 7.50 - 7.44 (m, 1H), 7.44 - 7.40 (m, 1H), 7.38 - 7.32 (m, 3H), 7.20 - 7.13 (m, 1H), 7.06 - 6.97 (m, 3H), 6.84 - 6.78 (m, 2H), 6.77 - 6.71 (m, 1H), 5.17 (s, 2H), 4.97 (s, 2H), 4.33 (dd, J = 5.2, 9.6 Hz, 1H), 4.19 (s, 3H), 3.94 - 3.87 (m, 2H), 3.19 - 3.08 (m, 4H), 3.07 - 2.91 (m, 6H), 2.67 - 2.60 (m, 3H), 2.39 - 2.27 (m, 2H), 2.22 - 2.06 (m, 4H), 1.77 - 1.70 (m, 2H), 1.70 - 1.58 (m, 3H)
47	169a	m/z = 473.0 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.83 (s, 1H), 8.16 - 8.15 (m, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.47 (d, J = 3.2 Hz, 1H), 7.46 - 7.43 (m, 1H), 7.43 - 7.39 (m, 1H), 7.37 - 7.32 (m, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 8.8 Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 6.58 - 6.52 (m, 1H), 6.34 (s, 1H), 5.15 (s, 2H), 4.96 (s, 2H), 4.22 (d, J = 8.8, 4.8 Hz, 1H), 3.90 (t, J = 5.6 Hz, 2H), 3.84 (s, 3H), 3.10 - 3.02 (m, 3H), 3.02 - 2.93 (m, 4H), 2.59 (d, J = 5.6 Hz, 4H), 2.29 - 2.23 (m, 2H), 2.19 - 2.08 (m, 3H), 2.07 - 2.00 (m, 2H), 1.78 - 1.67 (m, 4H), 1.63 (d, J = 2.8 Hz, 2H).
48	169b	m/z = 944.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.38 - 12.09 (m, 1H), 10.83 (s, 1H), 8.14 (s, 1H), 8.03 (d, J = 7.8 Hz, 1H), 7.77 (dd, J = 17.6, 8.4 Hz, 2H), 7.60 (d, J = 3.6 Hz, 1H), 7.52 - 7.29 (m, 5H), 7.13 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 1H), 6.85 (d, J = 8.8 Hz, 2H), 6.60 - 6.49 (m, 1H), 6.34 (s, 1H), 5.16 (s, 2H), 4.97 (s, 2H), 4.22 (dd, J = 8.8, 5.2 Hz, 1H), 3.90 (t, J = 6.0 Hz, 2H), 3.84 (s, 3H), 3.48 - 3.44 (m, 2H), 3.10 - 3.03 (m, 2H), 2.99 (t, J = 6.0 Hz, 3H), 2.69 - 2.57 (m, 3H), 2.43 (s, 4H), 2.34 - 2.24 (m, 1H), 2.21 - 1.99 (m, 4H), 1.80 - 1.55 (m, 5H).
49	173a	m/z = 944.7 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.07 - 12.59 (m, 1H), 10.90 (s, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.83 - 7.71 (m, 2H), 7.61 (d, J = 7.2 Hz, 1H), 7.53 - 7.30 (m, 5H), 7.14 (d, J = 8.8 Hz, 2H), 7.09 - 6.98 (m, 3H), 6.91 (d, J = 8.8 Hz, 2H), 5.19 (s, 2H), 4.97 (s, 2H), 4.35 (dd, J = 5.2, 9.6 Hz, 1H), 4.21 (s, 3H), 3.91 (t, J = 5.6 Hz, 2H), 3.72 - 3.56 (m, 2H), 3.42 - 3.35 (m, 1H), 3.27 (d, J = 5.6 Hz, 2H), 3.21 - 3.03 (m, 4H), 3.00 (t, J = 5.6 Hz, 2H), 2.96 - 2.80 (m, 2H), 2.80 - 2.60 (m, 3H), 2.39 - 2.22 (m, 2H), 2.21 - 2.11 (m, 1H), 2.01 - 1.70 (m, 5H)
50	174a	m/z = 1000.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 7.2 Hz, 1H), 7.52 (t, J = 7.2 Hz, 2H), 7.46 (t, J = 8.0 Hz, 1H), 7.43 - 7.32 (m, 4H), 7.07 - 6.99 (m, 3H), 6.88 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.91 (s, 2H), 4.34 (dd, J = 5.2, 10.0 Hz, 1H), 4.22 - 4.08 (m, 5H), 3.87 (d, J = 9.2 Hz, 2H), 2.96 (s, 2H), 2.90 - 2.81 (m, 3H), 2.79 - 2.72 (m, 3H), 2.70 - 2.60 (m, 5H), 2.36 - 2.31 (m, 2H), 2.18 - 1.98 (m, 4H), 1.96 - 1.79 (m, 4H), 1.76 - 1.59 (m, 1H), 1.56 - 1.37 (m, 4H), 1.33 - 1.07 (m, 4H)
51	174b	m/z = 501.1 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.2 Hz, 1H), 7.55 - 7.45 (m, 3H), 7.44 - 7.32 (m, 4H), 7.07 - 6.98 (m, 3H), 6.86 - 6.76 (m, 3H), 4.90 (s, 2H), 4.34 (dd, J = 5.2, 10.0 Hz,

			1H), 4.21 - 4.19 (m, 3H), 4.13 - 4.07 (m, 2H), 3.86 (d, J = 3.2 Hz, 2H), 2.96 (s, 2H), 2.92 - 2.81 (m, 4H), 2.77 - 2.72 (m, 3H), 2.71 - 2.60 (m, 5H), 2.35 - 2.30 (m, 2H), 2.23 - 1.98 (m, 4H), 1.96 - 1.83 (m, 3H), 1.74 - 1.60 (m, 1H), 1.55 - 1.38 (m, 4H), 1.35 - 1.08 (m, 4H)
52	173b	m/z = 944.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.09 - 12.60 (m, 1H), 10.89 (s, 1H), 10.18 - 9.93 (m, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.78 (t, J = 9.6 Hz, 2H), 7.64 - 7.58 (m, 1H), 7.50 - 7.33 (m, 5H), 7.14 (d, J = 8.0 Hz, 2H), 7.08 - 7.00 (m, 3H), 6.90 (d, J = 8.4 Hz, 2H), 5.23 - 5.13 (m, 2H), 5.00 - 4.92 (m, 2H), 4.34 (dd, J = 4.4, 9.6 Hz, 1H), 4.21 (s, 3H), 3.90 (t, J = 5.2 Hz, 2H), 3.24 (s, 3H), 3.12 (s, 2H), 3.06 - 2.95 (m, 5H), 2.88 (d, J = 6.0 Hz, 1H), 2.79 - 2.60 (m, 4H), 2.36 - 2.26 (m, 2H), 2.17 (dd, J = 5.6, 13.2 Hz, 1H), 2.10 - 2.01 (m, 3H), 1.96 - 1.87 (m, 2H), 1.82 - 1.75 (m, 1H)
53	105	m/z = 946.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.87 (s, 1H), 9.88 (s, 1H), 8.15 (s, 1H), 8.08 - 8.01 (m, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.49 - 7.44 (m, 1H), 7.43 - 7.39 (m, 1H), 7.38 - 7.31 (m, 2H), 7.24 (dd, J = 1.6, 8.8 Hz, 1H), 7.15 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.6 Hz, 1H), 6.83 (d, J = 8.8 Hz, 2H), 4.92 (s, 2H), 4.33 (dd, J = 5.2, 9.6 Hz, 1H), 3.93 (s, 3H), 3.91 - 3.84 (m, 4H), 3.19 (s, 2H), 3.00 - 2.94 (m, 4H), 2.82 - 2.77 (m, 2H), 2.68 - 2.60 (m, 4H), 2.34 - 2.24 (m, 3H), 1.97 - 1.88 (m, 2H), 1.79 - 1.68 (m, 4H)
54	119	m/z = 1015.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.27 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.55 - 7.49 (m, 1H), 7.49 - 7.42 (m, 2H), 7.41 - 7.36 (m, 1H), 7.35 - 7.31 (m, 2H), 7.10 (d, J = 8.4 Hz, 1H), 6.98 - 6.77 (m, 5H), 4.90 (s, 2H), 4.28 - 4.23 (m, 1H), 3.91 - 3.82 (m, 7H), 3.79 - 3.75 (m, 2H), 3.64 - 3.62 (m, 2H), 3.33 - 3.31 (m, 2H), 3.30 - 3.28 (m, 2H), 3.21 (s, 2H), 2.99 - 2.90 (m, 4H), 2.76 - 2.70 (m, 2H), 2.63 - 2.58 (m, 2H), 2.45 - 2.36 (m, 2H), 2.21 - 2.05 (m, 3H), 1.96 - 1.87 (m, 2H), 1.77 - 1.65 (m, 2H), 1.64 - 1.49 (m, 2H)
55	108	m/z = 508.8 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.92 - 10.84 (m, 1H), 8.19 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.64 - 7.56 (m, 1H), 7.54 - 7.44 (m, 2H), 7.43 - 7.38 (m, 2H), 7.38 - 7.29 (m, 3H), 7.15 - 7.08 (m, 1H), 7.05 - 6.98 (m, 2H), 6.89 (d, J = 8.8 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 8.8 Hz, 1H), 4.97 - 4.84 (m, 2H), 4.56 - 4.40 (m, 1H), 4.39 - 4.15 (m, 5H), 3.94 - 3.87 (m, 2H), 3.87 - 3.82 (m, 2H), 3.03 - 2.86 (m, 6H), 2.83 - 2.71 (m, 4H), 2.70 - 2.61 (m, 4H), 2.24 - 2.05 (m, 3H), 2.03 - 1.82 (m, 3H), 1.80 - 1.36 (m, 4H), 1.31 - 1.19 (m, 2H)
56	104	m/z = 946.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.85 (s, 1H), 12.71 (s, 1H), 10.90 (s, 1H), 9.83 - 9.70 (m, 1H), 8.06 - 7.98 (m, 2H), 7.79 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.62 - 7.54 (m, 2H), 7.50 - 7.44 (m, 1H), 7.44 - 7.40 (m, 1H), 7.38 - 7.33 (m, 2H), 7.24 (t, J = 8.0 Hz, 1H), 7.14 (dd, J = 1.2, 8.8 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H), 6.83 - 6.77 (m, 3H), 4.93 (s, 2H), 4.35 (dd, J = 5.2, 9.6 Hz, 1H), 4.22 (s, 2H), 3.94 (s, 5H), 3.87 (t, J = 5.6 Hz, 2H), 3.65 (d, J = 10.4 Hz, 2H), 2.99 (t, J = 5.6 Hz, 2H), 2.88 - 2.75 (m, 4H), 2.66 - 2.60 (m, 2H), 2.18 (dd, J = 5.2, 13.2 Hz, 2H), 2.03 - 1.93 (m, 6H)
57	113	m/z = 508.5 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.25 (s, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.52 (d, J = 9.2 Hz, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.41 - 7.37 (m, 1H), 7.36 - 7.31 (m, 2H), 7.15 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.90 (s, 1H), 6.85 - 6.80 (m, 1H),

			6.78 - 6.69 (m, 3H), 4.90 (s, 2H), 4.26 (dd, J = 5.2, 9.2 Hz, 1H), 3.89 (s, 5H), 3.84 (t, J = 5.6 Hz, 2H), 3.76 (d, J = 1.6 Hz, 2H), 3.63 (s, 2H), 3.21 (s, 6H), 2.97 - 2.91 (m, 4H), 2.74 (t, J = 7.2 Hz, 2H), 2.61 (d, J = 6.0 Hz, 1H), 2.34 - 2.25 (m, 2H), 2.18 - 2.00 (m, 4H), 1.95 - 1.89 (m, 2H), 1.76 - 1.70 (m, 2H), 1.67 - 1.59 (m, 2H)
58	107	m/z = 1015.8 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.84 (s, 1H), 10.89 (s, 1H), 8.14 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.49 - 7.45 (m, 1H), 7.43 - 7.40 (m, 2H), 7.37 - 7.33 (m, 2H), 7.17 (t, J = 7.6 Hz, 1H), 7.04 (s, 2H), 6.95 (d, J = 8.4 Hz, 1H), 6.82 - 6.9 (m, 3H), 4.92 (s, 2H), 4.34 (dd, J = 5.2, 9.6 Hz, 1H), 4.28 (s, 3H), 4.18 - 4.03 (m, 2H), 3.91 (t, J = 6.4 Hz, 2H), 3.86 (t, J = 5.6 Hz, 2H), 3.15 - 3.03 (m, 4H), 2.98 (t, J = 5.6 Hz, 4H), 2.80 (t, J = 7.6 Hz, 4H), 2.72 - 2.60 (m, 4H), 2.58 (s, 2H), 2.37 - 2.22 (m, 2H), 2.20 - 2.14 (m, 1H), 1.95 - 1.91 (m, 2H), 1.78 (s, 4H)
59	111	m/z = 960.4 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.62 - 12.28 (m, 1H), 10.89 (s, 1H), 10.23 - 9.95 (m, 1H), 8.06 - 8.00 (m, 2H), 7.79 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.42 - 7.38 (m, 1H), 7.38 - 7.31 (m, 2H), 7.20 - 7.13 (m, 2H), 6.95 (d, J = 8.8 Hz, 1H), 6.74 - 6.69 (m, 3H), 4.92 (s, 2H), 4.33 (dd, J = 5.2, 9.6 Hz, 1H), 3.93 - 3.89 (m, 5H), 3.87 - 3.84 (m, 2H), 3.25 - 3.15 (m, 4H), 2.97 (t, J = 5.6 Hz, 2H), 2.80 (t, J = 7.2 Hz, 2H), 2.68 - 2.61 (m, 2H), 2.49 - 2.45 (m, 2H), 2.39 - 2.29 (m, 2H), 2.31 - 2.06 (m, 2H), 1.98 - 1.89 (m, 2H), 1.62 - 1.59 (m, 2H), 1.42 - 1.32 (m, 2H), 1.30 - 1.20 (m, 1H)
60	112	m/z = 1029.7 [M-H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.86 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 7.3 Hz, 1H), 7.55 - 7.45 (m, 3H), 7.44 - 7.39 (m, 1H), 7.38 - 7.32 (m, 2H), 7.17 - 7.09 (m, 1H), 6.98 - 6.87 (m, 3H), 6.74 - 6.65 (m, 3H), 4.92 (s, 2H), 4.27 (dd, J = 4.8, 8.8 Hz, 1H), 3.92 - 3.84 (m, 7H), 3.75 - 3.69 (m, 2H), 3.60 (d, J = 3.6 Hz, 2H), 3.15 (d, J = 13.2 Hz, 4H), 3.00 - 2.96 (m, 2H), 2.82 - 2.75 (m, 4H), 2.68 (s, 1H), 2.64 - 2.60 (m, 2H), 2.43 (s, 2H), 2.35 - 2.28 (m, 2H), 2.19 - 2.13 (m, 1H), 1.97 - 1.87 (m, 4H), 1.55 - 1.41 (m, 3H), 1.22 - 1.10 (m, 2H)
61	114	m/z = 1029.7 [M-H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.89 (s, 1H), 8.14 (s, 1H), 8.06 - 8.01 (m, 1H), 7.81 - 7.76 (m, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.50 - 7.44 (m, 1H), 7.44 - 7.39 (m, 2H), 7.37 - 7.32 (m, 2H), 7.17 - 7.11 (m, 1H), 7.04 - 7.00 (m, 2H), 6.94 (d, J = 8.8 Hz, 1H), 6.71 - 6.67 (m, 3H), 4.95 - 4.89 (m, 2H), 4.34 (dd, J = 5.1, 9.6 Hz, 1H), 4.27 (s, 3H), 4.22 - 4.13 (m, 1H), 3.94 - 3.82 (m, 5H), 2.98 (t, J = 5.6 Hz, 3H), 2.92 - 2.76 (m, 6H), 2.68 - 2.60 (m, 4H), 2.43 (d, J = 6.4 Hz, 4H), 2.35 - 2.27 (m, 2H), 2.19 - 2.14 (m, 1H), 2.07 - 1.87 (m, 4H), 1.57 - 1.44 (m, 3H), 1.26 - 1.16 (m, 2H)
62	120	m/z = 932.3 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.86 (s, 1H), 10.90 (s, 1H), 10.79 - 10.70 (m, 1H), 8.08 - 8.01 (m, 1H), 7.98 (s, 1H), 7.79 (dd, J = 6.0, 8.4 Hz, 2H), 7.73 - 7.67 (m, 1H), 7.62 (d, J = 7.2 Hz, 1H), 7.51 - 7.41 (m, 2H), 7.40 - 7.33 (m, 2H), 7.16 - 7.06 (m, 3H), 7.03 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 8.8 Hz, 2H), 5.18 (s, 2H), 4.98 (s, 2H), 4.35 (dd, J = 5.2, 9.6 Hz, 1H), 4.13 (d, J = 0.8 Hz, 2H), 3.94 (s, 3H), 3.93 - 3.88 (m, 2H), 3.57 - 3.50 (m, 2H), 3.01 (t, J = 6.0 Hz, 4H), 2.70 - 2.62 (m, 2H), 2.56 - 2.52 (m, 2H), 2.47 - 2.34 (m, 2H), 2.23 - 2.14 (m, 1H), 1.79 - 1.72 (m, 2H), 1.59 - 1.46 (m, 2H)
63	118	m/z = 932.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 12.87 (d, J = 2.0 Hz, 1H), 10.87 (s, 1H), 9.88 - 9.77 (m, 1H), 8.12 (s, 1H), 8.05 (s, 2H), 7.81 - 7.74 (m, 2H), 7.61 (s, 2H), 7.46 (s, 1H), 7.42 - 7.37 (m,

			1H), 7.37 - 7.32 (m, 2H), 7.21 - 7.14 (m, 2H), 7.00 (d, J = 8.8 Hz, 1H), 6.77 - 6.71 (m, 3H), 5.18 (s, 2H), 4.96 (s, 2H), 4.32 (d, J = 4.4 Hz, 1H), 3.91 (s, 3H), 3.89 (s, 2H), 3.16 (d, J = 4.0 Hz, 2H), 3.12 (d, J = 7.6 Hz, 2H), 2.98 (t, J = 6.0 Hz, 2H), 2.93 - 2.81 (m, 2H), 2.62 (s, 2H), 2.17 (s, 4H), 1.52 (s, 3H), 1.30 (d, J = 12.8 Hz, 2H)
64	121	m/z = 1028.3 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.86 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.48 - 7.44 (m, 1H), 7.41 - 7.39 (m, 1H), 7.36 - 7.32 (m, 3H), 7.04 - 6.99 (m, 4H), 6.94 - 6.92 (m, 1H), 6.80 - 6.78 (m, 2H), 4.91 (s, 2H), 4.39 - 4.30 (m, 2H), 4.22 (s, 3H), 3.89 - 3.84 (m, 4H), 3.20 - 3.18 (m, 2H), 2.99 - 2.96 (m, 2H), 2.80 - 2.76 (m, 2H), 2.67 - 2.60 (m, 4H), 2.45 - 2.39 (m, 3H), 2.31 - 2.29 (m, 2H), 2.20 - 2.11 (m, 2H), 1.93 - 1.87 (m, 2H), 1.81 - 1.76 (m, 2H), 1.71 - 1.65 (m, 1H), 1.60 - 1.40 (m, 2H), 1.46 - 1.40 (m, 2H), 1.31 (s, 1H), 1.25 - 1.19 (m, 2H), 1.08 - 1.01 (m, 1H), 0.95 - 0.89 (m, 1H).
65	126	m/z = 1015.4 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.19 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.2 Hz, 1H), 7.53 - 7.43 (m, 3H), 7.42 - 7.31 (m, 3H), 7.01 (d, J = 8.4 Hz, 2H), 6.89 (t, J = 9.2 Hz, 2H), 6.83 - 6.76 (m, 3H), 4.90 (s, 2H), 4.25 (dd, J = 5.2, 4.0 Hz, 1H), 3.90 - 3.83 (m, 7H), 3.19 (s, 4H), 3.00 - 2.94 (m, 4H), 2.75 (t, J = 7.6 Hz, 2H), 2.69 - 2.52 (m, 9H), 2.40 (d, J = 6.8 Hz, 2H), 2.35 - 2.24 (m, 2H), 2.19 - 2.11 (m, 1H), 2.09 - 2.00 (m, 2H), 1.96 - 1.87 (m, 2H), 1.57 - 1.38 (m, 3H), 1.25 - 1.13 (m, 2H).
66	127	m/z = 1028.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.15 (d, J = 2.0 Hz, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.62 (dd, J = 8.4, 11.2 Hz, 2H), 7.54 (d, J = 8.8 Hz, 1H), 7.51 - 7.45 (m, 1H), 7.44 - 7.38 (m, 2H), 7.40 - 7.32 (m, 2H), 7.03 (d, J = 8.0 Hz, 3H), 6.94 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.92 (s, 2H), 4.56 - 4.47 (m, 1H), 4.33 (dd, J = 5.2, 9.6 Hz, 1H), 4.14 (dd, J = 3.2, 4.0 Hz, 1H), 3.97 (s, 3H), 3.95 - 3.80 (m, 5H), 3.11 (d, J = 12.8 Hz, 2H), 2.98 (t, J = 5.8 Hz, 3H), 2.92 (d, J = 11.2 Hz, 2H), 2.79 (t, J = 7.2 Hz, 3H), 2.71 - 2.56 (m, 4H), 2.41 (d, J = 6.8 Hz, 3H), 2.35 - 2.31 (m, 1H), 2.16 (d, J = 5.6, 7.8 Hz, 1H), 1.94 - 1.89 (m, 2H), 1.85 (s, 1H), 1.72 - 1.65 (m, 1H), 1.62 - 1.51 (m, 3H), 1.48 - 1.41 (m, 1H), 1.26 - 1.17 (m, 2H)
67	123	m/z = 1028.4 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 13.08 - 12.51 (m, 1H), 10.93 - 10.86 (m, 1H), 8.06 - 8.02 (m, 1H), 7.82 - 7.77 (m, 1H), 7.61 - 7.53 (m, 3H), 7.47 (t, J = 7.2 Hz, 1H), 7.43 - 7.32 (m, 3H), 7.22 - 7.16 (m, 1H), 7.11 - 7.01 (m, 3H), 6.95 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.92 (s, 2H), 4.58 - 4.49 (m, 1H), 4.35 (dd, J = 4.4, 10.0 Hz, 1H), 4.25 (s, 3H), 3.91 - 3.83 (m, 4H), 3.68 - 3.60 (m, 1H), 3.28 - 3.15 (m, 4H), 2.98 (t, J = 5.6 Hz, 2H), 2.88 - 2.72 (m, 4H), 2.70 - 2.60 (m, 2H), 2.44 - 2.32 (m, 4H), 2.23 - 2.08 (m, 2H), 1.96 - 1.89 (m, 4H), 1.77 - 1.41 (m, 6H), 1.29 - 1.14 (m, 2H)
68	130	m/z = 1015.4 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.85 (s, 1H), 8.22 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.52 - 7.44 (m, 3H), 7.41 - 7.31 (m, 3H), 7.00 (d, J = 7.2 Hz, 2H), 6.93 - 6.76 (m, 5H), 4.90 (s, 2H), 4.26-4.23 (m, 1H), 3.88 (s, 5H), 3.75 - 3.73 (m, 2H), 2.95 (s, 2H), 2.73 (d, J = 8.4 Hz, 4H), 2.69 - 2.58 (m, 6H), 2.40 (d, J = 3.6 Hz, 2H), 2.35 - 2.23 (m, 2H), 2.15 (dd, J = 5.6, 13.2 Hz, 1H), 2.09 - 2.00 (m, 2H), 1.97 - 1.88 (m, 2H), 1.74 (d, J = 12.0 Hz, 2H), 1.64 - 1.37 (m, 7H), 1.33 - 1.15 (m, 4H).

69	131	m/z = 1028.4 [M+H] ⁺	¹ H NMR (400 MHz, CDCl ₃ -d) δ = 9.73 - 9.35 (m, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 7.6 Hz, 3H), 7.19 (s, 2H), 7.02 (dd, J = 8.0, 14.8 Hz, 4H), 6.93 (d, J = 8.4 Hz, 1H), 6.77 (dd, J = 3.6, 8.4 Hz, 2H), 5.13 - 5.05 (m, 2H), 4.58 - 4.55 (m, 1H), 4.32 - 4.28 (m, 1H), 4.10 - 4.04 (m, 1H), 4.00 (s, 3H), 3.92 - 3.91 (m, 2H), 3.85 - 3.83 (m, 2H), 3.40 - 3.25 (m, 2H), 3.22 - 3.18 (m, 2H), 3.07 - 3.04 (m, 4H), 2.98 - 2.87 (m, 2H), 2.72 - 2.66 (m, 2H), 2.58 - 2.50 (m, 4H), 2.45 - 2.33 (m, 4H), 2.16 - 2.01 (m, 4H), 1.90 - 1.87 (m, 4H), 1.18 - 1.11 (m, 2H).
70	133	m/z = 1000.3 [M+H] ⁺	¹ H NMR (400 MHz, DMSO-d ₆) δ = 10.84 (s, 1H), 8.17 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.49 - 7.44 (m, 2H), 7.43 - 7.38 (m, 1H), 7.34 (t, J = 3.2, 7.5 Hz, 2H), 7.02 (d, J = 8.4 Hz, 2H), 6.90 (t, J = 10.2 Hz, 2H), 6.81 - 6.77 (m, 3H), 4.91 (s, 2H), 4.24 (dd, J = 5.2, 9.0 Hz, 1H), 3.87 (s, 5H), 3.75 (d, J = 12.0 Hz, 4H), 2.97 (t, J = 5.6 Hz, 2H), 2.84 (d, J = 11.2 Hz, 2H), 2.80 - 2.76 (m, 2H), 2.70 (t, J = 12.0 Hz, 2H), 2.64 - 2.58 (m, 2H), 2.41 (d, J = 6.4 Hz, 2H), 2.34 - 2.26 (m, 1H), 2.20 - 2.12 (m, 3H), 1.95 - 1.84 (m, 4H), 1.80 - 1.74 (m, 2H), 1.68 (s, 1H), 1.52 (d, J = 11.2 Hz, 2H), 1.42 (s, 1H), 1.26 - 1.15 (m, 4H).
71	132	m/z = 1001.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO-d ₆) δ = 10.88 (s, 1H), 8.19 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.48 (t, J = 7.6 Hz, 1H), 7.44 - 7.29 (m, 4H), 7.05 - 6.97 (m, 4H), 6.92 (s, 1H), 6.80 (d, J = 7.6 Hz, 2H), 4.92 (s, 2H), 4.35 - 4.31 (m, 1H), 4.23 (s, 3H), 3.92 - 3.84 (m, 4H), 3.03 - 2.96 (m, 2H), 2.91 - 2.75 (m, 5H), 2.69 - 2.59 (m, 4H), 2.41 (d, J = 6.0 Hz, 2H), 2.36 - 2.30 (m, 1H), 2.27 - 2.13 (m, 3H), 2.02 - 1.79 (m, 7H), 1.71 - 1.61 (m, 1H), 1.58 - 1.47 (m, 2H), 1.46 - 1.29 (m, 3H), 1.26 - 1.16 (m, 2H).
72	134	m/z = 972.4 [M+H] ⁺	¹ H NMR (400 MHz, DMSO-d ₆) δ = 10.85 (s, 1H), 8.18 (s, 1H), 8.06 - 8.01 (m, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.51 - 7.45 (m, 2H), 7.44 - 7.40 (m, 1H), 7.39 - 7.32 (m, 2H), 7.04 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 9.2 Hz, 1H), 6.92 - 6.79 (m, 4H), 5.14 (s, 2H), 4.97 (s, 2H), 4.25 (dd, J = 4.8, 9.2 Hz, 1H), 3.96 - 3.69 (m, 7H), 3.02 - 2.97 (m, 2H), 2.89 - 2.81 (m, 2H), 2.75 - 2.65 (m, 2H), 2.64 - 2.59 (m, 1H), 2.41 (d, J = 6.4 Hz, 2H), 2.35 - 2.25 (m, 2H), 2.23 - 2.12 (m, 3H), 1.94 - 1.84 (m, 2H), 1.81 - 1.64 (m, 3H), 1.52 (dd, J = 0.8, 12.4 Hz, 2H), 1.47 - 1.38 (m, 1H), 1.27 - 1.12 (m, 4H).
73	125	m/z = 972.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO-d ₆) δ = 10.84 (s, 1H), 8.04 - 7.98 (m, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.63 - 7.58 (m, 1H), 7.49 - 7.44 (m, 2H), 7.41 - 7.38 (m, 1H), 7.36 - 7.32 (m, 2H), 7.14 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.87 (dd, J = 8.8, 1.6 Hz, 1H), 6.79 (d, J = 1.2 Hz, 1H), 6.73 (t, J = 8.4 Hz, 3H), 5.17 (s, 2H), 4.98 - 4.94 (m, 2H), 4.24 (dd, J = 9.2, 5.2 Hz, 1H), 3.92 - 3.88 (m, 2H), 3.87 (s, 3H), 3.75 - 3.72 (m, 2H), 2.98 (t, J = 5.2 Hz, 2H), 2.84 (d, J = 10.8 Hz, 2H), 2.71 - 2.65 (m, 2H), 2.64 - 2.58 (m, 2H), 2.43 (d, J = 5.6 Hz, 2H), 2.32 - 2.26 (m, 1H), 2.18 (d, J = 6.8 Hz, 2H), 2.16 - 2.11 (m, 1H), 1.93 - 1.85 (m, 2H), 1.81 - 1.57 (m, 4H), 1.52 - 1.47 (m, 2H), 1.25 - 1.17 (m, 4H).
74	135	m/z = 487.1 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO-d ₆) δ = 10.87 (s, 1H), 8.17 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.43 - 7.38 (m, 1H), 7.38 - 7.31 (m, 3H), 7.14 (t, J = 7.6 Hz, 1H), 7.03 - 6.90 (m, 3H), 6.77 - 6.67 (m, 3H), 5.16 (s, 2H), 4.96 (s, 2H), 4.32 (d, J = 5.2, 9.6 Hz, 1H), 4.22 (s, 3H), 3.90 (t, J =

			6.0 Hz, 2H), 3.21 (d, J = 2.8 Hz, 2H), 2.98 (t, J = 5.6 Hz, 2H), 2.82 (d, J = 10.4 Hz, 2H), 2.69 - 2.59 (m, 4H), 2.43 (d, J = 6.4 Hz, 2H), 2.35 - 2.25 (m, 2H), 2.22 - 2.12 (m, 3H), 1.90 - 1.77 (m, 4H), 1.69 - 1.60 (m, 1H), 1.49 (d, J = 12.4 Hz, 2H), 1.38 - 1.26 (m, 2H), 1.16 (d, J = 10.4 Hz, 2H)
75	122	m/z = 958.7 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.17 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 9.2 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.50 - 7.44 (m, 2H), 7.43 - 7.39 (m, 1H), 7.37 - 7.32 (m, 2H), 7.12 (d, J = 8.8 Hz, 2H), 6.96 - 6.87 (m, 2H), 6.87 - 6.80 (m, 3H), 5.14 (s, 2H), 4.96 (s, 2H), 4.28 - 4.21 (m, 1H), 3.88 (s, 3H), 3.80 - 3.75 (m, 2H), 3.01 - 2.91 (m, 6H), 2.74 - 2.66 (m, 3H), 2.62 - 2.58 (m, 2H), 2.41 (d, J = 3.2 Hz, 2H), 2.33 (dd, J = 2.0, 3.6 Hz, 2H), 2.22 - 2.18 (m, 2H), 2.01 - 1.94 (m, 2H), 1.84 - 1.79 (m, 2H), 1.73 - 1.66 (m, 3H), 1.65 - 1.57 (m, 2H)
76	129	m/z = 958.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.05 - 8.01 (m, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 9.2 Hz, 1H), 7.59 (d, J = 1.2 Hz, 1H), 7.50 - 7.45 (m, 1H), 7.44 - 7.40 (m, 1H), 7.38 - 7.32 (m, 3H), 7.14 - 7.10 (m, 2H), 7.02 - 6.95 (m, 3H), 6.85 (d, J = 8.8 Hz, 2H), 5.15 (s, 2H), 4.96 (s, 2H), 4.33 (dd, J = 5.2, 9.8 Hz, 1H), 4.24 (s, 3H), 3.93 - 3.86 (m, 2H), 3.01 - 2.95 (m, 4H), 2.70 - 2.60 (m, 4H), 2.49 - 2.46 (m, 4H), 2.35 - 2.24 (m, 4H), 2.19 - 2.13 (m, 1H), 2.05 - 1.97 (m, 2H), 1.91 - 1.84 (m, 2H), 1.75 - 1.67 (m, 3H), 1.66 - 1.57 (m, 2H)
77	124	m/z = 958.7 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.89 (s, 1H), 8.14 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.78 (t, J = 8.0 Hz, 2H), 7.60 (d, J = 7.2 Hz, 1H), 7.49 - 7.44 (m, 1H), 7.43 - 7.40 (m, 1H), 7.38 - 7.32 (m, 3H), 7.20 - 7.14 (m, 1H), 7.00 (d, J = 6.4 Hz, 3H), 6.84 - 6.79 (m, 2H), 6.77 - 6.73 (m, 1H), 5.17 (s, 2H), 4.97 (s, 2H), 4.33 (dd, J = 5.2, 9.6 Hz, 1H), 4.24 (s, 3H), 3.91 (t, J = 6.0 Hz, 2H), 3.07 - 2.94 (m, 6H), 2.70 - 2.60 (m, 4H), 2.37 - 2.27 (m, 4H), 2.22 - 2.03 (m, 4H), 1.87 (d, J = 13.2 Hz, 2H), 1.76 - 1.66 (m, 4H), 1.45 - 1.33 (m, 2H)
78	128	m/z = 958.4 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.15 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.77 (dd, J = 8.4, 13.2 Hz, 2H), 7.63 - 7.58 (m, 1H), 7.50 - 7.44 (m, 2H), 7.44 - 7.40 (m, 1H), 7.38 - 7.32 (m, 2H), 7.20 - 7.14 (m, 1H), 6.98 (d, J = 9.2 Hz, 1H), 6.93 - 6.88 (m, 1H), 6.84 - 6.79 (m, 3H), 6.75 (d, J = 7.6 Hz, 1H), 5.17 (s, 2H), 4.97 (s, 2H), 4.24 (dd, J = 5.2, 9.2 Hz, 1H), 3.93 - 3.89 (m, 2H), 3.88 (s, 3H), 3.78 (d, J = 11.2 Hz, 2H), 3.00 - 2.95 (m, 4H), 2.79 - 2.63 (m, 4H), 2.63 - 2.57 (m, 2H), 2.34 - 2.32 (m, 1H), 2.25 - 2.21 (m, 2H), 2.18 - 2.13 (m, 1H), 2.05 - 1.97 (m, 2H), 1.85 - 1.79 (m, 2H), 1.74 - 1.71 (m, 2H), 1.67 - 1.58 (m, 2H), 1.30 - 1.21 (m, 2H)
79	137	m/z = 1015.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.87 (s, 1H), 8.03 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.53 - 7.44 (m, 2H), 7.41 - 7.32 (m, 4H), 7.01 (d, J = 6.0 Hz, 4H), 6.89 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.91 (s, 2H), 4.33 (dd, J = 4.8, 9.6 Hz, 1H), 4.22 (s, 3H), 3.91 - 3.83 (m, 4H), 2.99 - 2.90 (m, 7H), 2.79 - 2.73 (m, 3H), 2.68 - 2.59 (m, 3H), 2.40 (d, J = 6.8 Hz, 4H), 2.34 - 2.29 (m, 2H), 2.21 - 2.10 (m, 2H), 2.03 - 1.85 (m, 5H), 1.57 - 1.35 (m, 4H), 1.25 - 1.13 (m, 3H)
80	138	m/z = 1014.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.53 - 7.44 (m, 2H), 7.42 - 7.37 (m, 2H), 7.37 - 7.31 (m, 2H), 7.04 - 6.98 (m, 3H), 6.87 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.90 (s, 2H), 4.34 - 4.29 (m, 1H), 3.95 (s, 3H), 3.90 - 3.83 (m, 4H), 3.05 - 3.01 (m, 2H), 2.98 - 2.93 (m, 4H), 2.78 - 2.72 (m, 2H), 2.68 - 2.58 (m, 3H), 2.56 - 2.52 (m, 4H), 2.40 (d,

			J = 6.8 Hz, 2H), 2.21 - 1.97 (m, 6H), 1.95 - 1.89 (m, 2H), 1.80 - 1.71 (m, 4H), 1.55 - 1.49 (m, 2H), 1.47 - 1.40 (m, 1H), 1.24 - 1.14 (m, 2H)
81	139	m/z = 1014.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.56 - 7.43 (m, 3H), 7.41 - 7.30 (m, 3H), 7.22 (d, J = 7.2 Hz, 1H), 7.05 (t, J = 8.0 Hz, 1H), 7.00 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.90 (s, 2H), 4.37 - 4.31 (m, 1H), 4.19 (s, 3H), 3.90 - 3.87 (m, 2H), 3.86 - 3.83 (m, 2H), 3.05 (d, J = 10.4 Hz, 2H), 2.99 - 2.93 (m, 4H), 2.75 (t, J = 7.6 Hz, 2H), 2.68 - 2.61 (m, 2H), 2.60 - 2.53 (m, 4H), 2.39 (d, J = 6.4 Hz, 2H), 2.37 - 2.27 (m, 2H), 2.24 - 2.13 (m, 3H), 2.08 - 2.00 (m, 2H), 1.96 - 1.89 (m, 2H), 1.88 - 1.73 (m, 4H), 1.56 - 1.48 (m, 2H), 1.47 - 1.40 (m, 1H), 1.24 - 1.14 (m, 2H)
82	140	m/z = 1014.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.87 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.59 (d, J = 7.6 Hz, 1H), 7.51 - 7.43 (m, 2H), 7.41 - 7.32 (m, 4H), 7.04 - 6.98 (m, 4H), 6.88 - 6.83 (m, 1H), 6.79 (d, J = 8.4 Hz, 2H), 4.90 (s, 2H), 4.32 (d, J = 5.2, 9.6 Hz, 1H), 4.22 (s, 3H), 3.90 - 3.82 (m, 4H), 2.96 (s, 2H), 2.90 (d, J = 1.2 Hz, 2H), 2.76 - 2.73 (m, 2H), 2.67 (s, 2H), 2.64 - 2.61 (m, 2H), 2.43 - 2.39 (m, 5H), 2.33 (d, J = 1.2 Hz, 2H), 1.94 - 1.87 (m, 4H), 1.81 - 1.76 (m, 2H), 1.55 - 1.50 (m, 2H), 1.47 - 1.38 (m, 6H), 1.24 - 1.17 (m, 3H).
83	136	m/z = 1028.6 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.88 (s, 1H), 8.04 (d, J = 7.6 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 6.4 Hz, 1H), 7.54 (t, J = 8.4 Hz, 2H), 7.50 - 7.45 (m, 1H), 7.43 - 7.39 (m, 1H), 7.38 - 7.32 (m, 2H), 7.24 (d, J = 7.2 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 7.04 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 8.8 Hz, 1H), 6.80 (d, J = 8.4 Hz, 2H), 4.92 (s, 2H), 4.37 - 4.29 (m, 2H), 4.20 (s, 3H), 4.03 - 3.95 (m, 1H), 3.86 (t, J = 6.0 Hz, 4H), 3.14 - 3.02 (m, 2H), 2.98 (t, J = 5.6 Hz, 2H), 2.95 - 2.81 (m, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.68 - 2.61 (m, 2H), 2.44 (d, J = 4.0 Hz, 4H), 2.37 - 2.27 (m, 2H), 2.21 - 1.97 (m, 2H), 1.89 (d, J = 5.6 Hz, 4H), 1.79 - 1.67 (m, 2H), 1.63 - 1.54 (m, 2H), 1.31 - 1.14 (m, 2H), 1.11 - 0.80 (m, 2H)
84	142	m/z = 1028.5 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.84 (s, 1H), 8.19 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.52 - 7.46 (m, 3H), 7.41 (d, J = 7.2, 1H), 7.37 - 7.33 (m, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 9.2 Hz, 2H), 6.82 - 6.80 (m, 3H), 4.91 (s, 2H), 4.42 - 4.43 (m, 1H), 4.26 - 4.23 (m, 1H), 3.91 - 3.81 (m, 9H), 3.77 - 3.71 (m, 2H), 2.98 (t, J = 5.2 Hz, 2H), 2.92 - 2.87 (m, 1H), 2.79 - 2.71 (m, 3H), 2.64 - 2.58 (m, 2H), 2.44 - 2.42 (m, 2H), 2.28 - 2.23 (m, 3H), 2.18 - 2.13 (m, 1H), 1.96 - 1.89 (m, 2H), 1.87 - 1.81 (m, 1H), 1.79 - 1.73 (m, 2H), 1.70 - 1.65 (m, 1H), 1.59 - 1.52 (m, 2H), 1.34 - 1.29 (m, 2H), 1.24 (s, 1H), 1.06 - 1.00 (m, 1H), 0.97 - 0.91 (m, 1H)
85	141	m/z = 487.1 [M/2+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ = 10.87 (s, 1H), 8.20 (s, 1H), 8.02 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.60 (d, J = 7.3 Hz, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.42 - 7.30 (m, 4H), 7.05 - 6.94 (m, 4H), 6.93 - 6.79 (m, 3H), 5.12 (s, 1H), 4.96 (s, 1H), 4.32 (d, J = 5.1, 9.5 Hz, 1H), 4.25 - 4.19 (m, 3H), 3.88 (t, J = 5.4 Hz, 2H), 3.23 (s, 2H), 2.97 (d, J = 5.3 Hz, 2H), 2.81 (d, J = 9.9 Hz, 2H), 2.71 - 2.59 (m, 4H), 2.40 (d, J = 6.1 Hz, 2H), 2.36 - 2.25 (m, 2H), 2.22 - 2.11 (m, 3H), 1.81 (d, J = 10.5 Hz, 4H), 1.71 - 1.59 (m, 1H), 1.51 (d, J = 11.8 Hz, 2H), 1.43 - 1.26 (m, 3H), 1.26 - 1.03 (m, 3H).

Example B1

HiBiT based degradation assay

Human BCL-X_L protein coding open reading frame fused with N-terminal HiBiT coding sequence (N-HiBiT-BCL-X_L) was synthesized from Integrated DNA Technologies (IDT). Next, N-HiBiT-BCL-X_L sequence was cloned into pLV-UBC-PGK-Puro, a lentivirus plasmid purchased from Vectorbuilder, to generate pLV-UBC-N-HiBiT-BCL-X_L-PGK-puro. Lentiviral particles were generated from Lenti-X™ 293T cells (Clontech) by co-transfection of pLV-UBC-N-HiBiT-BCL-X_L-PGK-puro plasmids and lentiviral packaging plasmid mix (Cellecta). HT-1080 [HT1080] (ATCC CCL-121™) cells were infected with the lentivirus, and HT1080 cells stably integrated with the lentiviral vector were established by incubation with 1 µg/mL puromycin (Thermofisher).

HT1080 cells expressing N-terminal HiBiT tagged BCL-X_L were dispensed into 384-well plates pre-spotted with compounds at varying concentrations. Three thousand cells were seeded into each well in 40 µL of RPMI 1640 media. After 24 hours of incubation at 37°C with 5% CO₂, 30 µL of the NANO-GLO® HiBiT Lytic Detection System working solution (Promega) was added to each well and incubated at room temperature for 30 min. After incubation, luminescence was read on a PHERAstar FSX Plate Reader (BMG). BCL-X_L degradation at each indicated concentration was normalized with DMSO control. The BCL-X_L degradation curves were plotted using a four-parameter logistic model. Curve fitting was performed using bottom point of hook curves (i.e., the point of Y_{min}) as bottom plateau to calculate EC₅₀. For compounds with multiple data points, the geometric mean is presented. Y_{min} and EC₅₀ values for certain compounds are shown in **Table B1**.

Table B1

Compound No.	EC ₅₀ (24 h)	Y _{min} (24 h)
101	++++	B
102	++	B
104	+++	B
105	++++	B
107	+++	B
108	+++	B
109	+++	C
111	+++	B
112	+++	B
113	+++	B

Compound No.	EC ₅₀ (24 h)	Y _{min} (24 h)
114	+++	B
115	+++	B
116	++++	A
117	+++	B
118	+++	B
119	++++	A
120	+++	C
121	+++	B
122	++++	A
123	++++	B
124	+++	B
125	++++	A
126	++++	A
127	++++	A
128	++++	A
129	++++	B
130	++++	A
131	++++	A
132	++++	A
133	++++	A
134	++++	A
135	+++	A
136	++++	B
137	+++	A
138	++++	A
139	++++	A
140	+++	A
141	+++	B
142	++++	B
143	++++	C
144	+++	A
145	++++	A
146	++++	A
147	++++	B
148	++++	A
149	++++	B
150	++++	A
151	++++	A
152	++++	A
153	++++	A
154	++++	A
155	+++	A
156	++++	A

Compound No.	EC ₅₀ (24 h)	Y _{min} (24 h)
157	++++	A
158	++++	A
159	+++	A
160	++++	A
161	+++	A
162	++++	A
163	++++	A
164	++++	A
165	++++	A
166	++++	A
167	++++	A
168a	+++	B
168b	+++	B
169a	++++	A
169b	++++	A
170a	++++	A
170b	++++	A
171a	++++	A
171b	++++	A
172a	+++	B
172b	+++	C
173a	+++	A
173b	++++	B
174a	++++	A
174b	+++	A
175a	++++	A
175b	++++	A
176a	++++	A
176b	++++	A
177a	++++	A
177b	++++	A

Notes:

(1) “A”: Y_{min} < 30%; “B”: 30% ≤ Y_{min} < 50%; “C”: 50% ≤ Y_{min} < 70%; "D": Y_{min} ≥ 70%

(2) "++++": EC₅₀ < 10 nM; “+++”: 10 nM ≤ EC₅₀ < 100 nM; “++”: 100 nM ≤ EC₅₀ < 1000

5 nM; “+”: 1000 nM ≤ EC₅₀ < 10,000 nM

Example B2

Western Blotting based degradation assay

BCL-X_L degradation in human cancer cell lines is measured using traditional Western blotting methods as well as with the automated “Jess” instrument from ProteinSimple. Cells are seeded at 0.5-1 million cells per well in 2 ml of growth media (RPMI + 10% FBS) in 6-well plates. The plates are treated with compounds at varying concentrations for up to 5 days. Cells are harvested and lysed using RIPA Buffer (#9806S, Cell Signaling Technology) with Halt Protease & Phosphatase Inhibitor Cocktail (#78441, Thermo Fisher). Protein concentrations of each sample are quantified using Pierce™ BCA Protein Assay Kit (#23225, Thermo Fisher). For the Jess instrument the standard protocol provided by the manufacturer using the Jess Separation Module SM-W004 is followed. For traditional Western blotting, samples resolved on a 4-20% Criterion TGX gel (#5671094, BioRad) and transferred to a PVDF membrane using the Trans-Blot Turbo Transfer system (#1704157, BioRad). Chemiluminescent detection of BCL-X_L is performed using a BCL-X_L antibody (#2764, Cell Signaling Technology) according to the manufacturer’s instructions.

Example B3

MOLT-4 proliferation assay

MOLT-4 (ATCC CRL-1582™) cells are seeded at 4,000 cells per well in 50 µL RPMI 1640 media in 384-well plates. The plates are pre-spotted with compounds at varying concentrations. After 3 days of incubation at 37 °C with 5% CO₂, cell viability is assessed using CELLTITER-GLO® Cell Viability Assay kit according to manufacturer’s instructions (Promega). Relative cell proliferation at each concentration is normalized against DMSO control.

Example B4

Platelet viability assay


Human platelet-rich plasma (PRP, SER-PRP-SDS) is obtained from Zenbio. Sodium citrate is used as anticoagulant. To remove any contaminating blood cells, the samples are spun at 200 x g at room temperature for 20 minutes in 50 mL falcon tubes, and supernatant is transferred to a new tube. One hundred microliter PRP are added to each well of a 96-well plate spotted with compounds at varying concentrations. Plates are incubated at 37 °C with 5% CO₂ for 24 hours, and platelet viability are assessed with CELLTITER-GLO® Cell Viability Assay

kit according to manufacturer's instructions (Promega). Relative viability at each concentration is normalized against DMSO control.

EMBODIMENTS

5 Exemplary P01 Embodiments

Embodiment 1. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of:

- (a) C(O)OH,
- (b) C(O)NR^dR^e, and
- (c) C(O)OC₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 **R^c**;

each **R²**, **R³**, **R⁴**, and **R⁵** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, OH, and NR^dR^e;

m2 is 0, 1, or 2;

m3 and **m4** are independently 0, 1, 2, or 3;

m5 is 0, 1, 2, 3, or 4;

each **R⁶** is independently selected from the group consisting of: **R^a**, -(C₀₋₃ alkylene)-C₃₋₆ cycloalkyl, and -(C₀₋₃ alkylene)-(4-6 membered heterocyclyl);

m6 is 0, 1, 2, 3, or 4;

L¹ is -(L^A)_{n1}-, wherein **n1** is an integer from 2 to 12, and each **L^A** is selected from the group consisting of **L^{A1}**, **L^{A3}**, and **L^{A4}**, wherein 1-3 occurrence of **L^A** is **L^{A4}**;

L^2 is $-(L^B)_{n2}-$, wherein $n2$ is an integer from 1 to 5, and each L^B is selected from the group consisting of L^{B1} and L^{B3} ;

each L^{A1} and L^{B1} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;

each L^{A3} and L^{B3} is independently selected from the group consisting of: $-N(R^d)-$, $-N(R^b)-$, $-O-$, $-S(O)_{0-2}-$, and $C(=O)-$;


each L^{A4} is independently selected from the group consisting of:

(a) C_{3-15} cycloalkylene or 3-15 membered heterocyclylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ; and

(b) C_{6-15} arylene or 5-15 membered heteroarylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ;

wherein each R^L is independently selected from the group consisting of: halo, cyano, $-OH$, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NR^dR^e$, $C(=O)N(R^f)_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), $S(O)_{0-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(R^f)_2$, $-R^b$, and C_{1-6} alkyl optionally substituted with 1-6 R^c ;

20



$c1$ is 0, 1, 2, or 3;

each R^Y is independently selected from the group consisting of: R^a and R^b ;

R^{aN} is H or C_{1-6} alkyl optionally substituted with 1-3 R^c ;

Y^1 and Y^2 are independently N, CH, or CR^Y ;

yy represents the point of attachment to L^1 ;

25

X is CH, C, or N;

the --- is a single bond or a double bond;

L^c is selected from the group consisting of: a bond, -CH₂-, -CH**R^a**-, -C(**R^a**)₂-, -N(**R^d**)-, and O;

5 each **R^a** is independently selected from the group consisting of:

- (a) halo;
- (b) cyano;
- (c) -OH;
- (d) oxo;
- 10 (e) -C₁₋₆ alkoxy;
- (f) -C₁₋₆ haloalkoxy;
- (g) -N**R^d****R^e**;
- (h) C(=O)C₁₋₆ alkyl;
- (i) C(=O)C₁₋₆ haloalkyl;
- 15 (j) C(=O)OH;
- (k) C(=O)OC₁₋₆ alkyl;
- (l) C(=O)OC₁₋₆ haloalkyl;
- (m) C(=O)N(**R^f**)₂;
- (n) S(O)₀₋₂(C₁₋₆ alkyl);
- 20 (o) S(O)₀₋₂(C₁₋₆ haloalkyl);
- (p) S(O)₁₋₂N(**R^f**)₂; and
- (q) C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl, each optionally substituted with 1-6 **R^e**;

25 each **R^b** is independently selected from the group consisting of: -(**L^b**)_{**b**}-**R^{b1}** and -**R^{b1}**, wherein:

each **b** is independently 1, 2, or 3;

each -**L^b** is independently selected from the group consisting of: -O-, -N(H)-, -N(C₁₋₃ alkyl)-, -S(O)₀₋₂-, C(=O)-, and C₁₋₃ alkylene; and

30 each **R^{b1}** is independently selected from the group consisting of: C₃₋₁₀ cycloalkyl, 4-10 membered heterocyclyl, C₆₋₁₀ aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 **R^g**;

each R^c is independently selected from the group consisting of: halo, cyano, -OH, -C₁₋₆ alkoxy, -C₁₋₆ haloalkoxy, -NR^dR^e, C(=O)C₁₋₆ alkyl, C(=O)C₁₋₆ haloalkyl, C(=O)OC₁₋₆ alkyl, C(=O)OC₁₋₆ haloalkyl, C(=O)OH, C(=O)N(R^f)₂, S(O)₀₋₂(C₁₋₆ alkyl), S(O)₀₋₂(C₁₋₆ haloalkyl), and S(O)₁₋₂N(R^f)₂;

5 each R^d and R^e is independently selected from the group consisting of: H, C(=O)C₁₋₆ alkyl, C(=O)C₁₋₆ haloalkyl, C(=O)OC₁₋₆ alkyl, C(=O)OC₁₋₆ haloalkyl, C(=O)N(R^f)₂, S(O)₁₋₂(C₁₋₆ alkyl), S(O)₁₋₂(C₁₋₆ haloalkyl), S(O)₁₋₂N(R^f)₂, and C₁₋₆ alkyl optionally substituted with 1-3 R^h ;

each R^f is independently selected from the group consisting of: H and C₁₋₆ alkyl optionally substituted with 1-3 R^h ;

each R^g is independently selected from the group consisting of: R^h , C₁₋₃ alkyl, and C₁₋₃ haloalkyl; and

each R^h is independently selected from the group consisting of: halo, cyano, -OH, -C₁₋₆ alkoxy, -C₁₋₆ haloalkoxy, -NH₂, -N(H)(C₁₋₃ alkyl), and -N(C₁₋₃ alkyl)₂;

15 provided that the compound does not contain any N-O, N-N, N-S(O)₀, or O-S(O)₀₋₂ bonds.

Embodiment 2. The compound of Embodiment 1, wherein R^1 is C(O)OH.

20 **Embodiment 3.** The compound of Embodiment 1, wherein R^1 is C(O)NHR^e.

Embodiment 4. The compound of any one of Embodiments 1-3, wherein m_2 is 0.

25 **Embodiment 5.** The compound of any one of Embodiments 1-4, wherein m_3 is 0.


Embodiment 6. The compound of any one of Embodiments 1-5, wherein m_4 is 0.

30 **Embodiment 7.** The compound of any one of Embodiments 1-6, wherein m_5 is 0.


Embodiment 8. The compound of Embodiment 1, wherein R^1 is $C(O)OH$ or $C(O)NHR^e$; and 3-4 of **m2**, **m3**, **m4**, and **m5** are 0.

Embodiment 9. The compound of Embodiments 1 or 8, wherein R^1 is $C(O)OH$; and 3-4 of **m2**, **m3**, **m4**, and **m5** are 0.


Embodiment 10. The compound any one of Embodiments 1-9, wherein **Ring C** is




Embodiment 11. The compound of any one of Embodiments 1-10, wherein **Ring**




Embodiment 12. The compound of any one of Embodiments 1-10, wherein **Ring**




Embodiment 13. The compound of any one of Embodiments 1-10, wherein **Ring**



Embodiment 14. The compound of any one of Embodiments 1-9, wherein **Ring**



Embodiment 15. The compound of any one of Embodiments 1-9 or 14, wherein



Ring C is

Embodiment 16. The compound of any one of Embodiments 1-13, wherein R^{aN} is C_{1-3} alkyl.

Embodiment 17. The compound of any one of Embodiments 1-13 or 16, wherein R^{aN} is methyl.


Embodiment 18. The compound of any one of Embodiments 1-17, wherein $c1$ is 0.

Embodiment 19. The compound of any one of Embodiments 1-17, wherein $c1$ is 1; and R^Y is -F.


Embodiment 20. The compound of any one of Embodiments 1-19, wherein X is CH.

Embodiment 21. The compound of any one of Embodiments 1-20, wherein L^C is a bond.


Embodiment 22. The compound of any one of Embodiments 1-9, wherein the



Embodiment 23. The compound of any one of Embodiments 1-9, wherein the



Embodiment 24. The compound of any one of Embodiments 1-9, wherein the



Embodiment 25. The compound of any one of Embodiments 1-24, wherein **n1** + **n2** is 4 to 12.

Embodiment 26. The compound of any one of Embodiments 1-25, wherein **n1** + **n2** is 5 to 10.

Embodiment 27. The compound of any one of Embodiments 1-26, wherein **n2** is an integer from 2 to 5.

Embodiment 28. The compound of any one of Embodiments 1-27, wherein **n2** is an integer from 2 to 4.

Embodiment 29. The compound of any one of Embodiments 1-28, wherein **L²** is $-(L^{B1})_{1-3}-L^{B3-aa}$, wherein **aa** represents the point of attachment to **Ring A**.

Embodiment 30. The compound of any one of Embodiments 1-29, wherein **L²** is $-(L^{B1})_{1-3}-O-aa$, wherein **aa** represents the point of attachment to **Ring A**.

Embodiment 31. The compound of Embodiments 29 or 30, wherein each **L^{B1}** is **CH₂**.

Embodiment 32. The compound of any one of Embodiments 1-31, wherein **L²** is $-\text{CH}_2-\text{O}-aa$ or $-\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-aa$, wherein **aa** represents the point of attachment to **Ring A**.

Embodiment 33. The compound of any one of Embodiments 1-32, wherein **m6** is 0.

Embodiment 34. The compound of any one of Embodiments 1-32, wherein **m6** is 1.

Embodiment 35. The compound of any one of Embodiments 1-34, wherein L^1 is *para* to L^2 .

5 **Embodiment 36.** The compound of any one of Embodiments 1-34, wherein L^1 is *meta* to L^2 .

Embodiment 37. The compound of any one of Embodiments 1-36, wherein $n1$ is an integer from 3 to 10.

10 **Embodiment 38.** The compound of any one of Embodiments 1-37, wherein $n1$ is an integer from 4 to 7.

Embodiment 39. The compound of any one of Embodiments 1-36, wherein L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-(L^{A3})_{1-2}-bb$, wherein *bb* represents the point of attachment to **Ring C**.

15 **Embodiment 40.** The compound of any one of Embodiments 1-36 or 39, wherein L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)NH-bb$, wherein *bb* represents the point of attachment to **Ring C**.

20 **Embodiment 41.** The compound of Embodiments 39 or 40, wherein L^{A4} is C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

25 **Embodiment 42.** The compound of any one of Embodiments 39-41, wherein L^{A4} is a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a .

Embodiment 43. The compound of any one of Embodiments 39-42, wherein L^{A4} is a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

30 **Embodiment 44.** The compound of any one of Embodiments 39-43, wherein L^{A4} is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

35 **Embodiment 45.** The compound of Embodiments 43 or 44, wherein L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.


Embodiment 46. The compound of any one of Embodiments 39-45, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

5 **Embodiment 47.** The compound of any one of Embodiments 39-46, wherein each L^{A1} is CH_2 .

Embodiment 48. The compound of any one of Embodiments 1-40, wherein L^1 is

selected from the group consisting of:

10 wherein bb represents the point of attachment to **Ring C**.



Embodiment 49. The compound of any one of Embodiments 1-36, wherein L^1 is selected from the group consisting of:

15 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-L^{A3}-L^{A4}-bb$; and

$-(L^{A1})_{0-2}-L^{A4}-L^{A3}-(L^{A1})_{0-2}-L^{A4}-bb$,

wherein bb represents the point of attachment to **Ring C**.

Embodiment 50. The compound of any one of Embodiments 1-36, wherein L^1 is selected from the group consisting of:

20 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$;

$-(L^{A1})_{0-2}-L^{A4}-C(=O)-(L^{A1})_{0-2}-L^{A4}-bb$; and

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-2}-L^{A4}-bb$,

wherein bb represents the point of attachment to **Ring C**.

25 **Embodiment 51.** The compound of Embodiments 49 or 50, wherein each L^{A4} is independently C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

30 **Embodiment 52.** The compound of any one of Embodiments 49-51, wherein each L^{A4} is independently a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a .

Embodiment 53. The compound of any one of Embodiments 49-52, wherein each L^{A4} is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

Embodiment 54. The compound of any one of Embodiments 49-53, wherein each L^{A4} is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

5



Embodiment 55. The compound of Embodiments 53 or 54, wherein each L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

Embodiment 56. The compound of any one of Embodiments 49-55, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

15


Embodiment 57. The compound of any one of Embodiments 49-56, wherein each L^{A1} is CH_2 .

Embodiment 58. The compound of any one of Embodiments 1-38 or 49-50,

wherein L^1 is selected from the group consisting of:  and , wherein *bb* represents the point of attachment to **Ring C**.

20

Embodiment 59. The compound of Embodiment 1, wherein the compound of Formula (I) is a compound of Formula (I-a):



Formula (I-a)

or a pharmaceutically acceptable salt thereof, wherein:

25

m_6 is 0, 1, or 2;

each **R**⁶ is independently selected from the group consisting of: halo, CN, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl optionally substituted with 1-3 F;

L² is -(**L**^{B1})₁₋₃-O-*aa*, wherein *aa* represents the point of attachment to **Ring A**;

5 $\mathbf{L}^1$ is $-(\mathbf{L}^{\mathbf{A}1})_{0-2}-\mathbf{L}^{\mathbf{A}4}-(\mathbf{L}^{\mathbf{A}1})_{0-2}-\text{C}(=\text{O})\text{NH-}$ *bb*, wherein *bb* represents the point of attachment to **Ring C**; and

L^{A4} is C₃₋₁₀ cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 **R^a**.

Embodiment 60. The compound of Embodiment 59, wherein L^{A4} is a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

Embodiment 61. The compound of Embodiments 59 or 60, wherein **L^{A4}** is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.


15 **Embodiment 62.** The compound of Embodiments 60 or 61, wherein **L^{A4}** contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

Embodiment 63. The compound of any one of Embodiments 59-62, wherein each **R^a** present on **L^{A4}** is independently selected from the group consisting of: -F, CN, C₁₋₃ alkoxy, OH, and C₁₋₃ alkyl optionally substituted with 1-3 F.

Embodiment 64. The compound of any one of Embodiments 59-63, wherein each L^{A1} is CH_2 .

25

Embodiment 65. The compound of Embodiment 1, wherein the compound of Formula **(I)** is a compound of Formula **(I-b)**:



Formula (I-b)

30 or a pharmaceutically acceptable salt thereof, wherein:

m6 is 0, 1, or 2;

each **R⁶** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl optionally substituted with 1-3 F;

5 **L²** is **-(L^{B1})₁₋₃-O-*aa***, wherein ***aa*** represents the point of attachment to **Ring A**;

L^{A1} is selected from the group consisting of:

-(L^{A1})₀₋₂-L^{A4}-(L^{A1})₀₋₂-C(=O)-L^{A4}-*bb*; and

-(L^{A1})₀₋₂-L^{A4}-(L^{A1})₁₋₂-L^{A4}-*bb* wherein ***bb*** represents the point of attachment to **Ring C**;

and

10 each **L^{A4}** is independently C₃₋₁₀ cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 **R^a**.

15 **Embodiment 66.** The compound of Embodiment 65, wherein each **L^{A4}** is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.


20 **Embodiment 67.** The compound of Embodiments 65-66, wherein each **L^{A4}** is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.

25 **Embodiment 68.** The compound of Embodiments 66 or 67, wherein each **L^{A4}** contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.


30 **Embodiment 69.** The compound of any one of Embodiments 65-68, wherein each **R^a** present on **L^{A4}** is independently selected from the group consisting of: -F, CN, C₁₋₃ alkoxy, OH, and C₁₋₃ alkyl optionally substituted with 1-3 F.

35 **Embodiment 70.** The compound of any one of Embodiments 65-69, wherein each **L^{A1}** is CH₂.

Embodiment 71. The compound of any one of Embodiments 59-70, wherein **Ring**



Embodiment 72. The compound of any one of Embodiments 59-70, wherein **Ring**



Embodiment 73. The compound of any one of Embodiments 59-72, wherein **m6** is 0.

10 **Embodiment 74.** The compound of any one of Embodiments 59-73, wherein each **L^{B1}** is CH₂.

Embodiment 75. The compound of Embodiment 1, wherein the compound of Formula **(I)** is selected from the group consisting of the compounds in **Table C1**, or a pharmaceutically acceptable salt thereof.

Embodiment 76. A pharmaceutical composition comprising a compound of any one of Embodiments 1-75, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

20

Embodiment 77. A BCL-X_L protein non-covalently bound with a compound of any one of Embodiments 1-75, or a pharmaceutically acceptable salt thereof.

25 **Embodiment 78.** A ternary complex comprising a BCL-X_L protein, a compound of any one of Embodiments 1-75, or a pharmaceutically acceptable salt thereof, and a CRBN protein.

Embodiment 79. A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a

compound of any one of Embodiments 1-75, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to Embodiment 76.

5 **Embodiment 80.** The method of Embodiment 79, further comprising administering an additional therapy or therapeutic agent.

10 **Embodiment 81.** The method of Embodiment 80, wherein the additional therapy or therapeutic agent is an ALK inhibitor, a BCL-2 inhibitor, a BCR-Abl inhibitor, a BRaf inhibitor, a CDK2 inhibitor, CDK 4/6 inhibitor, a CDK7 inhibitor, a CDK9 inhibitor, an EGFR inhibitor, an anti-EGFR antibody, an ERK inhibitor, a FGFR1 inhibitor, a FGFR2 inhibitor, a FGFR3 inhibitor, a FGFR4 inhibitor, a HER2 inhibitor, a JAK2 inhibitor, a KRas inhibitor, a MEK inhibitor, a MET inhibitor, a PARP inhibitor, an LSD1 inhibitor, a BET inhibitor, a telomerase inhibitor, a TORC1/2 inhibitor, chemotherapy, radiotherapy, or a combination thereof.

15 **Embodiment 82.** The method of any one of Embodiments 79-81, wherein the cancer is breast cancer, colorectal cancer, bile duct cancer, colorectal cancer, gastrointestinal stromal tumor, pancreatic cancer, bladder cancer, kidney cancer, cervical cancer, ovarian cancer, uterine cancer, head and neck cancer, hematological cancer, lung cancer, skin cancer, or a combination thereof

20 **Embodiment 83.** The method of Embodiment 82, wherein the hematological cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), essential thrombocythemia, polycythemia vera, myelofibrosis, or a combination thereof.

25 **Embodiment 84.** A method for inducing degradation of a BCL-X_L protein in a mammalian cell, the method comprising contacting the mammalian cell with an effective amount of a compound of any one of Embodiments 1-75, or a pharmaceutically acceptable salt thereof.

30 **Embodiment 85.** The method of Embodiment 84, wherein the contacting occurs in vivo.

35 **Embodiment 86.** The method of Embodiment 84, wherein the contacting occurs


in vitro.

Embodiment 87. The method of any one of Embodiments 84-86, wherein the mammalian cell is a mammalian cancer cell.

5

Exemplary P02 Embodiments

Embodiment 1. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof, wherein:

10

R¹ is selected from the group consisting of:

- (a) C(O)OH,
- (b) C(O)NR^dR^e, and
- (c) C(O)OC₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 **R^c**;

15

each **R²**, **R³**, **R⁴**, and **R⁵** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, OH, and NR^dR^e;

m2 is 0, 1, or 2;

m3 and **m4** are independently 0, 1, 2, or 3;

m5 is 0, 1, 2, 3, or 4;

20

each **R⁶** is independently selected from the group consisting of: **R^a**, -(C₀₋₃ alkylene)-C₃₋₆ cycloalkyl, and -(C₀₋₃ alkylene)-(4-6 membered heterocyclyl);

m6 is 0, 1, 2, 3, or 4;

L^1 is $-(L^A)_{n1}-$, wherein $n1$ is an integer from 2 to 12, and each L^A is selected from the group consisting of L^{A1} , L^{A3} , and L^{A4} , wherein 1-3 occurrence of L^A is L^{A4} ;

L^2 is $-(L^B)_{n2}-$, wherein $n2$ is an integer from 1 to 5, and each L^B is selected from the group consisting of L^{B1} and L^{B3} ;

5

each L^{A1} and L^{B1} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;

each L^{A3} and L^{B3} is independently selected from the group consisting of: $-N(R^d)-$, $-N(R^b)-$, $-O-$, $-S(O)_{0-2}-$, and $C(=O)-$;

10

each L^{A4} is independently selected from the group consisting of:

(a) C_{3-15} cycloalkylene or 3-15 membered heterocyclylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ; and


15

(b) C_{6-15} arylene or 5-15 membered heteroarylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ;

wherein each R^L is independently selected from the group consisting of: halo, cyano, $-OH$, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NR^dR^e$, $C(=O)N(R^f)_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), $S(O)_{0-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(R^f)_2$, $-R^b$, and C_{1-6} alkyl optionally substituted with 1-6 R^c ;

20

Ring C is selected from the group consisting of:



25

$c1$ is 0, 1, 2, or 3;

each R^Y is independently selected from the group consisting of: R^a and R^b ;

R^{aN} is H or C_{1-6} alkyl optionally substituted with 1-3 R^c ;

Y^1 and Y^2 are independently N, CH, or CR^Y ;

yy represents the point of attachment to L^1 ;

L^c is selected from the group consisting of: a bond, $-CH_2-$, $-CHR^a-$, $-C(R^a)_2-$, $-N(R^d)-$, and O;

5 each R^a is independently selected from the group consisting of:

- (a) halo;
- (b) cyano;
- (c) $-OH$;
- (d) oxo;
- 10 (e) $-C_{1-6}$ alkoxy;
- (f) $-C_{1-6}$ haloalkoxy;
- (g) $-NR^dR^e$;
- (h) $C(=O)C_{1-6}$ alkyl;
- (i) $C(=O)C_{1-6}$ haloalkyl;
- 15 (j) $C(=O)OH$;
- (k) $C(=O)OC_{1-6}$ alkyl;
- (l) $C(=O)OC_{1-6}$ haloalkyl;
- (m) $C(=O)N(R^f)_2$;
- (n) $S(O)_{0-2}(C_{1-6}$ alkyl);
- 20 (o) $S(O)_{0-2}(C_{1-6}$ haloalkyl);
- (p) $S(O)_{1-2}N(R^f)_2$; and
- (q) C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl, each optionally substituted with 1-6 R^c ;

25 each R^b is independently selected from the group consisting of: $-(L^b)_b-R^{b1}$ and $-R^{b1}$, wherein:

each b is independently 1, 2, or 3;

each $-L^b$ is independently selected from the group consisting of: $-O-$, $-N(H)-$, $-N(C_{1-3}$ alkyl)-, $-S(O)_{0-2}-$, $C(=O)$, and C_{1-3} alkylene; and

30 each R^{b1} is independently selected from the group consisting of: C_{3-10} cycloalkyl, 4-10 membered heterocyclyl, C_{6-10} aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 R^g ;

each R^c is independently selected from the group consisting of: halo, cyano, -OH, -C₁₋₆ alkoxy, -C₁₋₆ haloalkoxy, -NR^dR^e, C(=O)C₁₋₆ alkyl, C(=O)C₁₋₆ haloalkyl, C(=O)OC₁₋₆ alkyl, C(=O)OC₁₋₆ haloalkyl, C(=O)OH, C(=O)N(R^f)₂, S(O)₀₋₂(C₁₋₆ alkyl), S(O)₀₋₂(C₁₋₆ haloalkyl), and S(O)₁₋₂N(R^f)₂;

5 each R^d and R^e is independently selected from the group consisting of: H, C(=O)C₁₋₆ alkyl, C(=O)C₁₋₆ haloalkyl, C(=O)OC₁₋₆ alkyl, C(=O)OC₁₋₆ haloalkyl, C(=O)N(R^f)₂, S(O)₁₋₂(C₁₋₆ alkyl), S(O)₁₋₂(C₁₋₆ haloalkyl), S(O)₁₋₂N(R^f)₂, and C₁₋₆ alkyl optionally substituted with 1-3 R^h ;

each R^f is independently selected from the group consisting of: H and C₁₋₆ alkyl optionally substituted with 1-3 R^h ;

each R^g is independently selected from the group consisting of: R^h , C₁₋₃ alkyl, and C₁₋₃ haloalkyl; and

each R^h is independently selected from the group consisting of: halo, cyano, -OH, -C₁₋₆ alkoxy, -C₁₋₆ haloalkoxy, -NH₂, -N(H)(C₁₋₃ alkyl), and -N(C₁₋₃ alkyl)₂;


15 provided that the compound does not contain any N-O, N-N, N-S(O)₀, or O-S(O)₀₋₂ bonds.

- 20 **Embodiment 2.** The compound of Embodiment 1, wherein R^1 is C(O)OH.
- Embodiment 3.** The compound of Embodiment 1, wherein R^1 is C(O)NHR^e.
- Embodiment 4.** The compound of any one of Embodiments 1-3, wherein m_2 is 0.
- 25 **Embodiment 5.** The compound of any one of Embodiments 1-4, wherein m_3 is 0.
- Embodiment 6.** The compound of any one of Embodiments 1-5, wherein m_4 is 0.
- 30 **Embodiment 7.** The compound of any one of Embodiments 1-6, wherein m_5 is 0.


Embodiment 8. The compound of Embodiment 1, wherein R^1 is $C(O)OH$ or $C(O)NHR^e$; and 3-4 of **m2**, **m3**, **m4**, and **m5** are 0.

Embodiment 9. The compound of Embodiment 1 or 8, wherein R^1 is $C(O)OH$; and 3-4 of **m2**, **m3**, **m4**, and **m5** are 0.


Embodiment 10. The compound any one of Embodiments 1-9, wherein **Ring C** is




Embodiment 11. The compound of any one of Embodiments 1-10, wherein **Ring**




Embodiment 12. The compound of any one of Embodiments 1-10, wherein **Ring**




Embodiment 13. The compound of any one of Embodiments 1-10, wherein **Ring**



Embodiment 14. The compound of any one of Embodiments 1-9, wherein **Ring**



Embodiment 15. The compound of any one of Embodiments 1-9 or 14, wherein



Ring C is

Embodiment 16. The compound of any one of Embodiments 1-13, wherein R^{aN} is C_{1-3} alkyl.


Embodiment 17. The compound of any one of Embodiments 1-13 or 16, wherein R^{aN} is methyl.

Embodiment 18. The compound of any one of Embodiments 1-17, wherein $c1$ is 0.


Embodiment 19. The compound of any one of Embodiments 1-17, wherein $c1$ is 1; and R^Y is -F.

Embodiment 20. The compound of any one of Embodiments 1-19, wherein L^C is a bond.


Embodiment 21. The compound of any one of Embodiments 1-9, wherein the



Embodiment 22. The compound of any one of Embodiments 1-9, wherein the



Embodiment 23. The compound of any one of Embodiments 1-9, wherein the



Embodiment 24. The compound of any one of Embodiments 1-23, wherein **n1** + **n2** is 4 to 12.

Embodiment 25. The compound of any one of Embodiments 1-23, wherein **n1** + **n2** is 5 to 10.

Embodiment 26. The compound of any one of Embodiments 1-25, wherein **n2** is an integer from 2 to 5.

Embodiment 27. The compound of any one of Embodiments 1-26, wherein **n2** is an integer from 2 to 4.

Embodiment 28. The compound of any one of Embodiments 1-27, wherein **L²** is $-(\mathbf{L}^{\mathbf{B1}})_{1-3}-\mathbf{L}^{\mathbf{B3}}_{-aa}$, wherein **aa** represents the point of attachment to **Ring A**.

Embodiment 29. The compound of any one of Embodiments 1-28, wherein **L²** is $-(\mathbf{L}^{\mathbf{B1}})_{1-3}-\mathbf{O}_{-aa}$, wherein **aa** represents the point of attachment to **Ring A**.

Embodiment 30. The compound of Embodiment 28 or 29, wherein each **L^{B1}** is **CH₂**.

Embodiment 31. The compound of any one of Embodiments 1-30, wherein **L²** is $-\text{CH}_2-\text{O}_{-aa}$ or $-\text{CH}_2\text{CH}_2\text{CH}_2\text{O}_{-aa}$, wherein **aa** represents the point of attachment to **Ring A**.

Embodiment 32. The compound of any one of Embodiments 1-31, wherein **m6** is 0.



Embodiment 33. The compound of any one of Embodiments 1-31, wherein **m6** is 1.

- Embodiment 34.** The compound of any one of Embodiments 1-33, wherein L^1 is *para* to L^2 .
- Embodiment 35.** The compound of any one of Embodiments 1-33, wherein L^1 is *meta* to L^2 .
- Embodiment 36.** The compound of any one of Embodiments 28-35, wherein $n1$ is an integer from 3 to 10.
- Embodiment 37.** The compound of any one of Embodiments 28-36, wherein $n1$ is an integer from 4 to 7.
- Embodiment 38.** The compound of any one of Embodiments 1-23, wherein L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-(L^{A3})_{1-2}-bb$, wherein *bb* represents the point of attachment to **Ring C**.
- Embodiment 39.** The compound of any one of Embodiments 1-23 or 38, wherein L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)NH-bb$, wherein *bb* represents the point of attachment to **Ring C**.
- Embodiment 40.** The compound of Embodiment 38 or 39, wherein L^{A4} is C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .
- Embodiment 41.** The compound of any one of Embodiments 38-40, wherein L^{A4} is a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a .
- Embodiment 42.** The compound of any one of Embodiments 38-41, wherein L^{A4} is a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .
- Embodiment 43.** The compound of any one of Embodiments 38-42, wherein L^{A4} is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .
- Embodiment 44.** The compound of Embodiment 42 or 43, wherein L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

Embodiment 45. The compound of any one of Embodiments 38-44, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

5 **Embodiment 46.** The compound of any one of Embodiments 38-45, wherein each L^{A1} is CH_2 .

Embodiment 47. The compound of any one of Embodiments 1-39, wherein L^1 is

selected from the group consisting of:  and ,
10 wherein *bb* represents the point of attachment to **Ring C**.

Embodiment 48. The compound of any one of Embodiments 1-23, wherein L^1 is selected from the group consisting of:

15 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-L^{A3}-L^{A4}-bb$;
 $-(L^{A1})_{0-2}-L^{A4}-L^{A3}-(L^{A1})_{0-2}-L^{A4}-bb$; and
 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-3}-L^{A4}-bb$;
wherein *bb* represents the point of attachment to **Ring C**.

20 **Embodiment 49.** The compound of any one of Embodiments 1-23 or 48, wherein L^1 is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$;
 $-(L^{A1})_{0-2}-L^{A4}-C(=O)-(L^{A1})_{0-2}-L^{A4}-bb$; and
 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-3}-L^{A4}-bb$,
25 wherein *bb* represents the point of attachment to **Ring C**.

Embodiment 50. The compound of any one of Embodiments 1-35 or 48-49, wherein L^1 is selected from the group consisting of:

30 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$;
 $-(L^{A1})_{0-2}-L^{A4}-C(=O)-(L^{A1})_{0-2}-L^{A4}-bb$; and
 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-2}-L^{A4}-bb$,
wherein *bb* represents the point of attachment to **Ring C**.

Embodiment 51. The compound of any one of Embodiments 48-50, wherein each L^{A4} is independently C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

5 **Embodiment 52.** The compound of any one of Embodiments 48-51, wherein each L^{A4} is independently a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a .

Embodiment 53. The compound of any one of Embodiments 48-52, wherein each L^{A4} is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .



Embodiment 54. The compound of any one of Embodiments 48-53, wherein each L^{A4} is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

15 **Embodiment 55.** The compound of Embodiment 53 or 54, wherein each L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.


Embodiment 56. The compound of any one of Embodiments 48-55, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

Embodiment 57. The compound of any one of Embodiments 48-56, wherein each L^{A1} is CH_2 .

25 **Embodiment 58.** The compound of any one of Embodiments 1-37 or 48-50,

wherein L^1 is selected from the group consisting of:  and , wherein *bb* represents the point of attachment to **Ring C**.

30 **Embodiment 59.** The compound of Embodiment 1, wherein the compound of Formula (I) is a compound of Formula (I-a):



Formula (I-a)

or a pharmaceutically acceptable salt thereof, wherein:

m6 is 0, 1, or 2;

5 each **R⁶** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl optionally substituted with 1-3 F;

L² is $-(L^{B1})_{1-3}-O_{-aa}$, wherein **aa** represents the point of attachment to **Ring A**;

L¹ is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)NH_{-bb}$, wherein **bb** represents the point of attachment
10 to **Ring C**; and

L^{A4} is C₃₋₁₀ cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 **R^a**.

Embodiment 60. The compound of Embodiment 59, wherein **L^{A4}** is a 4-10
15 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.


Embodiment 61. The compound of Embodiment 59 or 60, wherein **L^{A4}** is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.

20 **Embodiment 62.** The compound of any one of Embodiments 59-61, wherein **L^{A4}** contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

Embodiment 63. The compound of any one of Embodiments 59-62, wherein each **R^a** present on **L^{A4}** is independently selected from the group consisting of: -F, CN, C₁₋₃ alkoxy, OH, and C₁₋₃ alkyl optionally substituted with 1-3 F.
25

Embodiment 64. The compound of any one of Embodiments 59-63, wherein each **L^{A1}** is CH₂.

Embodiment 65. The compound of Embodiment 1, wherein the compound of Formula (I) is a compound of Formula (I-b):



Formula (I-b)

5 or a pharmaceutically acceptable salt thereof, wherein:

m6 is 0, 1, or 2;

each **R⁶** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl optionally substituted with 1-3 F;

10 **L²** is **-(L^{B1})₁₋₃-O-*aa***, wherein ***aa*** represents the point of attachment to **Ring A**;

L^{A1} is selected from the group consisting of:

-(L^{A1})₀₋₂-L^{A4}-(L^{A1})₀₋₂-C(=O)-L^{A4}-*bb*; and

-(L^{A1})₀₋₂-L^{A4}-(L^{A1})₁₋₃-L^{A4}-*bb* wherein ***bb*** represents the point of attachment to **Ring C**;

and

15 each **L^{A4}** is independently C₃₋₁₀ cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 **R^a**.

Embodiment 66. The compound of Embodiment 65, wherein each **L^{A4}** is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.


Embodiment 67. The compound of Embodiment 65 or 66, wherein each **L^{A4}** is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.

25 **Embodiment 68.** The compound of Embodiment 66 or 67, wherein each **L^{A4}** contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

Embodiment 69. The compound of any one of Embodiments 65-68, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.


5 **Embodiment 70.** The compound of any one of Embodiments 65-69, wherein each L^{A1} is CH_2 .

Embodiment 71. The compound of any one of Embodiments 59-70, wherein **Ring**



10

Embodiment 72. The compound of any one of Embodiments 59-70, wherein **Ring**




15

Embodiment 73. The compound of any one of Embodiments 59-72, wherein **m6** is 0.


Embodiment 74. The compound of any one of Embodiments 59-73, wherein each L^{B1} is CH_2 .

20


Embodiment 75. The compound of Embodiment 1 or 65, wherein the compound of Formula (I) is a compound of Formula (I-b1), (I-b2), (I-b3), or (I-b4):




Formula (I-b1)



Formula (I-b2)



Formula (I-b3)



Formula (I-b4)

or a pharmaceutically acceptable salt thereof, wherein:

10


Ring C is selected from the group consisting of:

, wherein:

c1 is 0, 1, or 2;

each **R^Y** is independently -F, C₁₋₃ alkoxy, or C₁₋₃ alkyl optionally substituted with 1-3

F; and



R^{aN} is C_{1-3} alkyl optionally substituted with 1-3 F;

5 L^{A4a} and L^{A4b} are independently selected 4-10 membered nitrogen-containing heterocyclene optionally substituted with 1-3 substituents each independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F;

each L^{A1a} , L^{A1b} , and L^{A1c} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;
10 $a1a$ is 0, 1, or 2;
 $a1b$ is 1, 2, or 3;
 $a1c$ is 1 or 2;

each L^{B1} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;
15 $b1$ is 1, 2, or 3;

each R^L is independently selected from the group consisting of: -F and C_{1-3} alkyl optionally substituted with 1-3 F;

20 $m6$ is 0 or 1; and
each R^6 is independently selected from the group consisting of: halo, CN, C_{1-3} alkoxy, C_{1-3} haloalkoxy, and C_{1-3} alkyl optionally substituted with 1-3 F.

25 **Embodiment 76.** The compound of Embodiment 75, wherein each L^{A1a} , L^{A1b} , and L^{A1c} is CH_2 .

Embodiment 77. The compound of Embodiment 75 or 76, wherein each L^{B1} is CH_2 .

30 **Embodiment 78.** The compound of any one of Embodiments 75-77, wherein L^{A4a} and L^{A4b} are each an independently selected 4-6 membered nitrogen-containing heterocyclene optionally substituted with 1-3 substituents each independently selected from

the group consisting of: -F, CN, C₁₋₃ alkoxy, OH, and C₁₋₃ alkyl optionally substituted with 1-3 F, wherein:

L^{A4a} and **L^{A4b}** independently contain 1-2 ring nitrogen atoms and no additional ring heteroatoms.

5

Embodiment 79. The compound of any one of Embodiments 75-78, wherein **L^{A4a}** and **L^{A4b}** are each an independently selected 4-6 (e.g., 5-6) membered nitrogen-containing heterocyclene, wherein:

L^{A4a} and **L^{A4b}** independently contain 1-2 ring nitrogen atoms and no additional ring heteroatoms.

10

Embodiment 80. The compound of any one of Embodiments 75-79, wherein **m6** is 0.

Embodiment 81. The compound of any one of Embodiments 75-80, wherein **c1** is 0; and **R^{aN}** is methyl.

15

Embodiment 82. The compound of Embodiment 1, wherein the compound of Formula **(I)** is selected from the group consisting of the compounds in **Table C1**, or a pharmaceutically acceptable salt thereof.

20

Embodiment 83. A pharmaceutical composition comprising a compound of any one of Embodiments 1-82, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

25

Embodiment 84. A BCL-X_L protein non-covalently bound with a compound of any one of Embodiments 1-82, or a pharmaceutically acceptable salt thereof.

Embodiment 85. A ternary complex comprising a BCL-X_L protein, a compound of any one of Embodiments 1-82, or a pharmaceutically acceptable salt thereof, and a CRBN protein.

30

Embodiment 86. A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a

compound of any one of Embodiments 1-82, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to Embodiment 83.

5 **Embodiment 87.** The method of Embodiment 86, further comprising administering an additional therapy or therapeutic agent.

Embodiment 88. The method of Embodiment 87, wherein the additional therapy or therapeutic agent is an ALK inhibitor, a BCL-2 inhibitor, a BCR-Abl inhibitor, a BRaf inhibitor, a CDK2 inhibitor, CDK 4/6 inhibitor, a CDK7 inhibitor, a CDK9 inhibitor, an EGFR
10 inhibitor, an anti-EGFR antibody, an ERK inhibitor, a FGFR1 inhibitor, a FGFR2 inhibitor, a FGFR3 inhibitor, a FGFR4 inhibitor, a HER2 inhibitor, a JAK2 inhibitor, a KRas inhibitor, a MEK inhibitor, a MET inhibitor, a PARP inhibitor, an LSD1 inhibitor, a BET inhibitor, a telomerase inhibitor, a TORC1/2 inhibitor, a TpoR agonist, chemotherapy, radiotherapy, or a combination thereof.

15 **Embodiment 89.** The method of any one of Embodiments 86-88, wherein the cancer is breast cancer, colorectal cancer, bile duct cancer, colorectal cancer, gastrointestinal stromal tumor, pancreatic cancer, bladder cancer, kidney cancer, cervical cancer, ovarian cancer, uterine cancer, head and neck cancer, hematological cancer, lung cancer, skin cancer,
20 or a combination thereof

Embodiment 90. The method of Embodiment 89, wherein the hematological cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL),
25 essential thrombocythemia, polycythemia vera, myelofibrosis, or a combination thereof.

Embodiment 91. The method of Embodiment 89, wherein the cancer is lung cancer.

30 **Embodiment 92.** The method of Embodiment 91, wherein the lung cancer is small cell lung cancer (SCLC).

Embodiment 93. The method of Embodiment 92, comprising administering an additional therapy or therapeutic agent.

35

Embodiment 94. The method of Embodiment 93, wherein the additional therapy or therapeutic agent is a BCL-2 inhibitor.

5 **Embodiment 95.** The method of Embodiment 94, wherein the BCL-2 inhibitor is selected from the group consisting of flisastoclax, navitoclax, obatoclax, venetoclax, oblimersen (e.g., oblimersen sodium), beclanorsen, AZD-0466, BGB-11417, UBX-1325 (or a phosphate prodrug thereof), UBX-1967 (or a phosphate prodrug thereof), ZN-d5, or a combination thereof.

10 **Embodiment 96.** The method of Embodiment 95, wherein the BCL-2 inhibitor is venetoclax.

Embodiment 97. A method for inducing degradation of a BCL-X_L protein in a mammalian cell, the method comprising contacting the mammalian cell with an effective
15 amount of a compound of any one of Embodiments 1-82, or a pharmaceutically acceptable salt thereof.


Embodiment 98. The method of Embodiment 97, wherein the contacting occurs
in vivo.

20 **Embodiment 99.** The method of Embodiment 97, wherein the contacting occurs in vitro.

Embodiment 100. The method of any one of Embodiments 97-99, wherein the
25 mammalian cell is a mammalian cancer cell.

WHAT IS CLAIMED IS:

1. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof, wherein:

$\mathbf{R}^1$ is selected from the group consisting of:

- (a) C(O)OH,
 (b) C(O)NR^dR^e, and
 (c) C(O)OC₁₋₆ alkyl, wherein the C₁₋₆ alkyl is optionally substituted with 1-3 R^c;

each **R**², **R**³, **R**⁴, and **R**⁵ is independently selected from the group consisting of: halo, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, OH, and **NR**^d**R**^e;

m2 is 0, 1, or 2;

m3 and **m4** are independently 0, 1, 2, or 3;

m5 is 0, 1, 2, 3, or 4;

each **R**⁶ is independently selected from the group consisting of: **R**^a, -(C₀₋₃ alkylene)-C₃-alkyl, and -(C₀₋₃ alkylene)-(4-6 membered heterocyclyl);

m6 is 0, 1, 2, 3, or 4;

$\mathbf{L}^1$ is $-(\mathbf{L}^A)_{\mathbf{n}1}$, wherein $\mathbf{n}1$ is an integer from 2 to 12, and each $\mathbf{L}^A$ is selected from the group consisting of $\mathbf{L}^{A1}$, $\mathbf{L}^{A3}$, and $\mathbf{L}^{A4}$, wherein 1-3 occurrence of $\mathbf{L}^A$ is $\mathbf{L}^{A4}$;

$\mathbf{L}^2$ is $-(\mathbf{L}^{\mathbf{B}})_{\mathbf{n}2}$, wherein $\mathbf{n}2$ is an integer from 1 to 5, and each $\mathbf{L}^{\mathbf{B}}$ is selected from the group consisting of $\mathbf{L}^{\mathbf{B}1}$ and $\mathbf{L}^{\mathbf{B}3}$;

each L^{A1} and L^{B1} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;

each L^{A3} and L^{B3} is independently selected from the group consisting of: $-N(R^d)-$, $-N(R^b)-$, $-O-$, $-S(O)_{0-2}-$, and $C(=O)-$;

5

each L^{A4} is independently selected from the group consisting of:


(a) C_{3-15} cycloalkylene or 3-15 membered heterocyclylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ; and

10 (b) C_{6-15} arylene or 5-15 membered heteroarylene, each of which is optionally substituted with 1-6 substituents independently selected from the group consisting of: R^a and R^b ;

wherein each R^L is independently selected from the group consisting of: halo, cyano, $-OH$, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NR^dR^e$, $C(=O)N(R^f)_2$, $S(O)_{0-2}(C_{1-6}$ alkyl), $S(O)_{0-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(R^f)_2$, $-R^b$, and C_{1-6} alkyl optionally substituted with 1-6 R^c ;

15

Ring C is selected from the group consisting of:



20

$c1$ is 0, 1, 2, or 3;

each R^Y is independently selected from the group consisting of: R^a and R^b ;

R^{aN} is H or C_{1-6} alkyl optionally substituted with 1-3 R^c ;

Y^1 and Y^2 are independently N, CH, or CR^Y ;

yy represents the point of attachment to L^1 ;

25

L^C is selected from the group consisting of: a bond, $-CH_2-$, $-CHR^a-$, $-C(R^a)_2-$, $-N(R^d)-$, and O;

each R^a is independently selected from the group consisting of:

- (a) halo;
- (b) cyano;
- (c) -OH;
- (d) oxo;
- 5 (e) -C₁₋₆ alkoxy;
- (f) -C₁₋₆ haloalkoxy;
- (g) -NR^dR^e;
- (h) C(=O)C₁₋₆ alkyl;
- (i) C(=O)C₁₋₆ haloalkyl;
- 10 (j) C(=O)OH;
- (k) C(=O)OC₁₋₆ alkyl;
- (l) C(=O)OC₁₋₆ haloalkyl;
- (m) C(=O)N(R^f)₂;
- (n) S(O)₀₋₂(C₁₋₆ alkyl);
- 15 (o) S(O)₀₋₂(C₁₋₆ haloalkyl);
- (p) S(O)₁₋₂N(R^f)₂; and
- (q) C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl, each optionally substituted with 1-6 R^c;

each R^b is independently selected from the group consisting of: -(L^b)_b-R^{b1} and -R^{b1},

20 wherein:

each b is independently 1, 2, or 3;

each -L^b is independently selected from the group consisting of: -O-, -N(H)-, -N(C₁₋₃ alkyl)-, -S(O)₀₋₂-, C(=O), and C₁₋₃ alkylene; and

each R^{b1} is independently selected from the group consisting of: C₃₋₁₀ cycloalkyl, 4-10 membered heterocyclyl, C₆₋₁₀ aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 R^g;

25

each R^c is independently selected from the group consisting of: halo, cyano, -OH, -C₁₋₆ alkoxy, -C₁₋₆ haloalkoxy, -NR^dR^e, C(=O)C₁₋₆ alkyl, C(=O)C₁₋₆ haloalkyl, C(=O)OC₁₋₆ alkyl, C(=O)OC₁₋₆ haloalkyl, C(=O)OH, C(=O)N(R^f)₂, S(O)₀₋₂(C₁₋₆ alkyl), S(O)₀₋₂(C₁₋₆ haloalkyl), and S(O)₁₋₂N(R^f)₂;

30

each R^d and R^e is independently selected from the group consisting of: H, C(=O)C₁₋₆ alkyl, C(=O)C₁₋₆ haloalkyl, C(=O)OC₁₋₆ alkyl, C(=O)OC₁₋₆ haloalkyl, C(=O)N(R^f)₂, S(O)₁₋

$2(C_{1-6}$ alkyl), $S(O)_{1-2}(C_{1-6}$ haloalkyl), $S(O)_{1-2}N(R^f)_2$, and C_{1-6} alkyl optionally substituted with 1-3 R^h ;

each R^f is independently selected from the group consisting of: H and C_{1-6} alkyl optionally substituted with 1-3 R^h ;

5 each R^g is independently selected from the group consisting of: R^h , C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each R^h is independently selected from the group consisting of: halo, cyano, -OH, $-C_{1-6}$ alkoxy, $-C_{1-6}$ haloalkoxy, $-NH_2$, $-N(H)(C_{1-3}$ alkyl), and $-N(C_{1-3}$ alkyl) $_2$;

10 provided that the compound does not contain any N-O, N-N, N-S(O) $_0$, or O-S(O) $_{0-2}$ bonds.

2. The compound of claim 1, wherein R^1 is $C(O)OH$.

15 3. The compound of claim 1, wherein R^1 is $C(O)NHR^e$.

4. The compound of any one of claims 1-3, wherein m_2 is 0.

5. The compound of any one of claims 1-4, wherein m_3 is 0.

20 6. The compound of any one of claims 1-5, wherein m_4 is 0.


7. The compound of any one of claims 1-6, wherein m_5 is 0.


25 8. The compound of claim 1, wherein R^1 is $C(O)OH$ or $C(O)NHR^e$; and 3-4 of m_2 , m_3 , m_4 , and m_5 are 0.

9. The compound of claim 1 or 8, wherein R^1 is $C(O)OH$; and 3-4 of m_2 , m_3 , m_4 , and m_5 are 0.


30

10. The compound any one of claims 1-9, wherein **Ring C** is







11. The compound of any one of claims 1-10, wherein **Ring C** is




12. The compound of any one of claims 1-10, wherein **Ring C** is




13. The compound of any one of claims 1-10, wherein **Ring C** is



14. The compound of any one of claims 1-9, wherein **Ring C** is



15. The compound of any one of claims 1-9 or 14, wherein **Ring C** is



16. The compound of any one of claims 1-13, wherein **R^{aN}** is C₁₋₃ alkyl.


17. The compound of any one of claims 1-13 or 16, wherein **R^{aN}** is methyl.

18. The compound of any one of claims 1-17, wherein **c1** is 0.


19. The compound of any one of claims 1-17, wherein **c1** is 1; and **R^Y** is -F.

20. The compound of any one of claims 1-19, wherein L^C is a bond.


21. The compound of any one of claims 1-9, wherein the




5 moiety is



22. The compound of any one of claims 1-9, wherein the




moiety is




10

23. The compound of any one of claims 1-9, wherein the



moiety is



24. The compound of any one of claims 1-23, wherein $n1 + n2$ is 4 to 12.

15

25. The compound of any one of claims 1-23, wherein $n1 + n2$ is 5 to 10.

26. The compound of any one of claims 1-25, wherein $n2$ is an integer from 2 to 5.

20

27. The compound of any one of claims 1-26, wherein $n2$ is an integer from 2 to 4.

28. The compound of any one of claims 1-27, wherein L^2 is $-(L^{B1})_{1-3}-L^{B3}-aa$, wherein *aa* represents the point of attachment to **Ring A**.

29. The compound of any one of claims 1-28, wherein L^2 is $-(L^{B1})_{1-3}-O-aa$, wherein
5 *aa* represents the point of attachment to **Ring A**.

30. The compound of claim 28 or 29, wherein each L^{B1} is CH_2 .

31. The compound of any one of claims 1-30, wherein L^2 is $-CH_2-O-aa$ or $-CH_2CH_2CH_2O-aa$, wherein *aa* represents the point of attachment to **Ring A**.
10

32. The compound of any one of claims 1-31, wherein **m6** is 0.

33. The compound of any one of claims 1-31, wherein **m6** is 1.
15

34. The compound of any one of claims 1-33, wherein L^1 is *para* to L^2 .

35. The compound of any one of claims 1-33, wherein L^1 is *meta* to L^2 .

36. The compound of any one of claims 28-35, wherein **n1** is an integer from 3 to
20 10.

37. The compound of any one of claims 28-36, wherein **n1** is an integer from 4 to
7.

25 38. The compound of any one of claims 1-23, wherein L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-(L^{A3})_{1-2}-bb$, wherein *bb* represents the point of attachment to **Ring C**.

39. The compound of any one of claims 1-23 or 38, wherein L^1 is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)NH-bb$, wherein *bb* represents the point of attachment to **Ring C**.
30

40. The compound of claim 38 or 39, wherein L^{A4} is C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

35 41. The compound of any one of claims 38-40, wherein L^{A4} is a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a .

42. The compound of any one of claims 38-41, wherein L^{A4} is a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .



43. The compound of any one of claims 38-42, wherein L^{A4} is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

44. The compound of claim 42 or 43, wherein L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

45. The compound of any one of claims 38-44, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

46. The compound of any one of claims 38-45, wherein each L^{A1} is CH_2 .

47. The compound of any one of claims 1-39, wherein L^1 is selected from the group

consisting of:  and , wherein *bb* represents the point of attachment to **Ring C**.

48. The compound of any one of claims 1-23, wherein L^1 is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-L^{A3}-L^{A4}-bb$;
 $-(L^{A1})_{0-2}-L^{A4}-L^{A3}-(L^{A1})_{0-2}-L^{A4}-bb$; and
 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-3}-L^{A4}-bb$;




wherein *bb* represents the point of attachment to **Ring C**.

49. The compound of any one of claims 1-23 or 48, wherein L^1 is selected from the group consisting of:

$-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)-L^{A4}-bb$;
 $-(L^{A1})_{0-2}-L^{A4}-C(=O)-(L^{A1})_{0-2}-L^{A4}-bb$; and
 $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{1-3}-L^{A4}-bb$;

wherein *bb* represents the point of attachment to **Ring C**.

50. The compound of any one of claims 1-35 or 48-49, wherein L^1 is selected from the group consisting of:



wherein *bb* represents the point of attachment to **Ring C**.

51. The compound of any one of claims 48-50, wherein each L^{A4} is independently C_{3-10} cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 R^a .

52. The compound of any one of claims 48-51, wherein each L^{A4} is independently a 4-12 membered heterocyclylene optionally substituted with 1-3 R^a .

53. The compound of any one of claims 48-52, wherein each L^{A4} is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .


54. The compound of any one of claims 48-53, wherein each L^{A4} is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 R^a .

55. The compound of claim 53 or 54, wherein each L^{A4} contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.


56. The compound of any one of claims 48-55, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

57. The compound of any one of claims 48-56, wherein each L^{A1} is CH_2 .

58. The compound of any one of claims 1-37 or 48-50, wherein L^1 is selected from



59. The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-a):



Formula (I-a)

or a pharmaceutically acceptable salt thereof, wherein:

m6 is 0, 1, or 2;

each **R⁶** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl optionally substituted with 1-3 F;

L² is $-(L^{B1})_{1-3}-O-aa$, wherein **aa** represents the point of attachment to **Ring A**;

L¹ is $-(L^{A1})_{0-2}-L^{A4}-(L^{A1})_{0-2}-C(=O)NH-bb$, wherein **bb** represents the point of attachment to **Ring C**; and

L^{A4} is C₃₋₁₀ cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 **R^a**.

60. The compound of claim 59, wherein **L^{A4}** is a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.


61. The compound of claim 59 or 60, wherein **L^{A4}** is a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.

62. The compound of any one of claims 59-61, wherein **L^{A4}** contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

63. The compound of any one of claims 59-62, wherein each **R^a** present on **L^{A4}** is independently selected from the group consisting of: -F, CN, C₁₋₃ alkoxy, OH, and C₁₋₃ alkyl optionally substituted with 1-3 F.

64. The compound of any one of claims 59-63, wherein each **L^{A1}** is CH₂.

65. The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (I-b):



Formula (I-b)

or a pharmaceutically acceptable salt thereof, wherein:

m6 is 0, 1, or 2;

each **R⁶** is independently selected from the group consisting of: halo, CN, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, and C₁₋₃ alkyl optionally substituted with 1-3 F;

L² is **-(L^{B1})₁₋₃-O-*aa***, wherein ***aa*** represents the point of attachment to **Ring A**;

L^{A1} is selected from the group consisting of:

-(L^{A1})₀₋₂-L^{A4}-(L^{A1})₀₋₂-C(=O)-L^{A4}-*bb*; and

-(L^{A1})₀₋₂-L^{A4}-(L^{A1})₁₋₃-L^{A4}-*bb* wherein ***bb*** represents the point of attachment to **Ring C**;

and

each **L^{A4}** is independently C₃₋₁₀ cycloalkylene or 4-12 membered heterocyclylene, each of which is optionally substituted with 1-6 **R^a**.


66. The compound of claim 65, wherein each **L^{A4}** is independently a 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.

67. The compound of claim 65 or 66, wherein each **L^{A4}** is independently a 4-6 membered monocyclic nitrogen-containing heterocyclylene optionally substituted with 1-3 **R^a**.


68. The compound of claim 66 or 67, wherein each **L^{A4}** contains 1-2 ring nitrogen atoms and no additional ring heteroatoms.

69. The compound of any one of claims 65-68, wherein each R^a present on L^{A4} is independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F.

70. The compound of any one of claims 65-69, wherein each L^{A1} is CH_2 .




72. The compound of any one of claims 59-70, wherein **Ring C** is




73. The compound of any one of claims 59-72, wherein m_6 is 0.

74. The compound of any one of claims 59-73, wherein each L^{B1} is CH_2 .


75. The compound of claim 1 or 65, wherein the compound of Formula (I) is a compound of Formula (I-b1), (I-b2), (I-b3), or (I-b4):



Formula (I-b1)




Formula (I-b2)




Formula (I-b3)

5



Formula (I-b4)

or a pharmaceutically acceptable salt thereof, wherein:



10

Ring C is selected from the group consisting of:

, wherein:

c1 is 0, 1, or 2;

each **R^Y** is independently -F, C₁₋₃ alkoxy, or C₁₋₃ alkyl optionally substituted with 1-3

F; and

R^{aN} is C_{1-3} alkyl optionally substituted with 1-3 F;

5 L^{A4a} and L^{A4b} are independently selected 4-10 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 substituents each independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F;

each L^{A1a} , L^{A1b} , and L^{A1c} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;

10 $a1a$ is 0, 1, or 2;

$a1b$ is 1, 2, or 3;

$a1c$ is 1 or 2;

15 each L^{B1} is independently selected from the group consisting of: $-CH_2-$, $-CHR^L-$, and $-C(R^L)_2-$;

$b1$ is 1, 2, or 3;

each R^L is independently selected from the group consisting of: -F and C_{1-3} alkyl optionally substituted with 1-3 F;

20

$m6$ is 0 or 1; and

each R^6 is independently selected from the group consisting of: halo, CN, C_{1-3} alkoxy, C_{1-3} haloalkoxy, and C_{1-3} alkyl optionally substituted with 1-3 F.

25 **76.** The compound of claim 75, wherein each L^{A1a} , L^{A1b} , and L^{A1c} is CH_2 .

77. The compound of claim 75 or 76, wherein each L^{B1} is CH_2 .

30 **78.** The compound of any one of claims 75-77, wherein L^{A4a} and L^{A4b} are each an independently selected 4-6 membered nitrogen-containing heterocyclylene optionally substituted with 1-3 substituents each independently selected from the group consisting of: -F, CN, C_{1-3} alkoxy, OH, and C_{1-3} alkyl optionally substituted with 1-3 F, wherein:

L^{A4a} and L^{A4b} independently contain 1-2 ring nitrogen atoms and no additional ring heteroatoms.

79. The compound of any one of claims 75-78, wherein L^{A4a} and L^{A4b} are each an independently selected 4-6 (e.g., 5-6) membered nitrogen-containing heterocyclene, wherein:

L^{A4a} and L^{A4b} independently contain 1-2 ring nitrogen atoms and no additional ring heteroatoms.

80. The compound of any one of claims 75-79, wherein $m6$ is 0.

81. The compound of any one of claims 75-80, wherein $c1$ is 0; and R^{aN} is methyl.

82. The compound of claim 1, wherein the compound of Formula (I) is selected from the group consisting of the compounds in Table C1, or a pharmaceutically acceptable salt thereof.

83. A pharmaceutical composition comprising a compound of any one of claims 1-82, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

84. A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-82, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 83.

85. The method of claim 86, further comprising administering an additional therapy or therapeutic agent.

86. The method of claim 87, wherein the additional therapy or therapeutic agent is an ALK inhibitor, a BCL-2 inhibitor, a BCR-Abl inhibitor, a BRaf inhibitor, a CDK2 inhibitor, CDK 4/6 inhibitor, a CDK7 inhibitor, a CDK9 inhibitor, an EGFR inhibitor, an anti-EGFR antibody, an ERK inhibitor, a FGFR1 inhibitor, a FGFR2 inhibitor, a FGFR3 inhibitor, a FGFR4 inhibitor, a HER2 inhibitor, a JAK2 inhibitor, a KRas inhibitor, a MEK inhibitor, a MET inhibitor, a PARP inhibitor, an LSD1 inhibitor, a BET inhibitor, a telomerase inhibitor, a TORC1/2 inhibitor, chemotherapy, radiotherapy, or a combination thereof.

87. The method of any one of claims 86-88, wherein the cancer is breast cancer,

colorectal cancer, bile duct cancer, colorectal cancer, gastrointestinal stromal tumor, pancreatic cancer, bladder cancer, kidney cancer, cervical cancer, ovarian cancer, uterine cancer, head and neck cancer, hematological cancer, lung cancer, skin cancer, or a combination thereof.

5 **88.** The method of claim 89, wherein the hematological cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), essential thrombocythemia, polycythemia vera, myelofibrosis, or a combination thereof.

10 **89.** The method of claim 89, wherein the cancer is lung cancer.